The Diagnosis and Management of Heart Failure across Primary and Secondary Care by Ahmet Fuat,
Durham E-Theses
The Diagnosis and Management of Heart Failure
across Primary and Secondary Care
Ahmet Fuat,
How to cite:
Ahmet Fuat, (2006) The Diagnosis and Management of Heart Failure across Primary and Secondary Care,
Durham theses, Durham University. Available at Durham E-Theses Online: http://etheses.dur.ac.uk/2358/
Use policy
The full-text may be used and/or reproduced, and given to third parties in any format or medium, without prior permission or
charge, for personal research or study, educational, or not-for-profit purposes provided that:
• a full bibliographic reference is made to the original source
• a link is made to the metadata record in Durham E-Theses
• the full-text is not changed in any way
The full-text must not be sold in any format or medium without the formal permission of the copyright holders.
Please consult the full Durham E-Theses policy for further details.
Academic Support Office, Durham University, University Office, Old Elvet, Durham DH1 3HP
e-mail: e-theses.admin@dur.ac.uk Tel: +44 0191 334 6107
http://etheses.dur.ac.uk
University of Durham 
The Diagnosis and Management of Heart Failure across 
Primary and Secondary Care 
Ahmet Fuat 
MBChB FRCGP DRCOG DFFP PG Dip (Cardiology) 
A thesis submitted for the degree of 
The copyright of this thesis rests with the Doctor of Philosophy author or the university to which it was 
submitted. No quotation from it, or 
information derived from it may be 
published without the prior written 
consent of the author or university, and 
any information derived from it should be 
. ~cknowledged. 
Carmel Medical Practice 
Nunnery Lane, Darlington 
County Durham DL3 7RD 
2006 
11 JUN 2007 
For Karen, Ay§e and Tamer 
Table of Contents 
Abstract .......................................................................................................... 1 
Acknowledgements ....................................................................................... 3 
Publications ................................................................................................... 4 
Authorship notes ........................................................................................... 7 
Declaration ..................................................................................................... 8 
Sta.tement of Copyright ................................................................................. 8 
Abbreviations ................................................................................................. 9 
Chapter 1. A resume of the literature ......................................................... 12 
1.1 The definition of heart failure and descriptive terms ........................ 12 
1.2 Epidemiology of heart failure ........................................................... 15 
1.2.1 Introduction - Heart failure, a problem that will not go away ..... 15 
1.2.2 How are epidemiological data obtained? ................................. 16 
1.2.3 Prevalence of heart failure ....................................................... 16 
1.2.3.1 Surveys from general practice .......................................... 17 
1.2.3.2 Cross sectional surveys using echocardiography ............. 18 
1.2.3.3 Why such variation in prevalence of heart failure? ............ 19 
1.2.4 Incidence of Heart Failure ........................................................ 19 
1.2.5 A summary of prevalence and incidence of heart failure .......... 21 
1.2.6 Prognosis and quality of life ..................................................... 21 
1.2. 7 Health service workload and health economic issues .............. 22 
1.3 Aetiology and pathophysiology of heart failure ................................ 24 
1.3.1 Aetiology of heart failure .......................................................... 24 
1.3.2 Pathophysiology of heart failure ............................................... 25 
1.4 The diagnosis of heart failure .......................................................... 26 
1.4.1 Introduction .............................................................................. 26 
1.4.2 Past medical history and the diagnosis of heart failure ............ 26 
1.4.3 Symptoms in the diagnosis of heart failure .............................. 27 
1.4.4 Clinical signs in the diagnosis of heart failure .......................... 28 
1.4.5 Clinical scoring systems in the diagnosis of heart failure ......... 32 
1.4.6 Symptoms and severity of heart failure .................................... 33 
1.4.7 The electrocardiogram in the diagnosis of heart failure ............ 34 
1.4.8 The chest X-ray in the diagnosis of heart failure ...................... 37 
1.4.9 Haematology and biochemistry in the diagnosis of heart failure .. 
································································································· 38 
1.4.1 0 Natriuretic peptides in the diagnosis of heart failure ................ 38 
1.4.11 Echocardiography and heart failure ......................................... 38 
1.4.12 Other non-invasive tests in heart failure diagnosis and 
assessment .............................................................................. 39 
1.4.13 Systolic versus diastolic heart failure ....................................... 40 
1.5 What is the reality in investigation and management of heart failure in 
primary and secondary care? .......................................................... 41 
1.5.1 The use of diagnostic tests for suspected heart failure ............ 41 
1.5.2 Surveys of primary and secondary care diagnosis and 
management of heart failure across Europe ............................ 43 
1.5.3 Questionnaire studies of heart failure in UK primary care settings 
................................................................................................. 44 
1.5.4 Qualitative studies of heart failure in primary care ................... 46 
1.5.5 Summary of studies ................................................................. 48 
1.6 Availability and use of Echocardiography and diagnostic services for 
heart failure ..................................................................................... 48 
ii 
1.6.1 Introduction .............................................................................. 48 
1.6.2 Open access echocardiography ............................................... 49 
1.6.2.1 Definition of open access echocardiography .................... 49 
1.6.2.2 Open access echocardiography studies in the UK ............ 49 
1.6.2.3 Discussion of open access echocardiography services .... 51 
1.6.3 Specialist heart failure clinics ................................................... 52 
1.6.3.1 An introduction .................................................................. 52 
1.6.3.2 Secondary care heart failure clinic models ....................... 53 
1.6.3.3 Primary care heart failure clinics ....................................... 54 
1.6.3.4 Nurse-led heart failure clinics ............................................ 55 
1.6.4 Multidisciplinary heart failure management programs .............. 56 
1.6.4.1 An introduction .................................................................. 56 
1.6.4.2 Some examples of multidisciplinary programs for heart 
failure ................................................................................ 57 
1.6.4.3 Systematic reviews of multidisciplinary programs for heart 
failure ................................................................................ 58 
1.6.4.4 Summary and future research suggestions ...................... 59 
1.7 Treatment of heart failure ................................................................ 60 
1. 7.1 Aims of treatment for heart failure ............................................ 60 
1.7.2 Prevention of heart failure ........................................................ 61 
1.7.2.1 Improving the outlook for heart failure ............................... 61 
1.7.2.2 ACE inhibitor use can reduce the risk of heart failure ....... 62 
1.7.2.3 Summary of prevention of heart failure ............................. 63 
1.7.3 Non-Pharmacological treatments for heart failure .................... 64 
1. 7 .3.1 Do lifestyle changes improve heart failure? ...................... 64 
1.7.3.2 Exercise training and cardiac rehabilitation ....................... 64 
iii 
1.7.4 Avoidance of detrimental drugs and polypharmacy in patients 
with heart failure ....................................................................... 64 
1.7.5 Pharmacological therapies for heart failure .............................. 65 
1. 7 .5.1 Diuretics ............................................................................ 65 
1. 7 .5.2 Angiotensin converting enzyme (ACE) inhibitors .............. 65 
1.7.5.2.1 Introduction .................................................................... 65 
1.7.5.2.2 Major trials of ACE inhibitors in heart failure .................. 66 
1.7.5.2.3 Optimising ACE inhibitor dosage ................................... 68 
1.7.5.2.4 Current state of management in primary and secondary 
care ................................................................................ 68 
1.7.5.2.5 Summary of ACE inhibitor therapy for heart failure ........ 71 
1.7.5.3 Beta-blockers for heart failure ........................................... 71 
1.7.5.3.1 Introduction .................................................................... 71 
1.7.5.3.2 Landmark beta blocker studies ...................................... 71 
1.7.5.3.2.1 A critical appraisal of the CIBIS 11 trial ..................... 72 
1.7.5.3.2.2 The MERIT-HF trial ................................................. 74 
1.7.5.3.2.3 The US Carvedilol program (USCP) ....................... 74 
1.7.5.3.3 More recent beta blocker studies ................................... 75 
1.7.5.3.4 Systematic review of effect of beta blockers on heart 
failure mortality .............................................................. 76 
1.7.5.3.5 Systematic review of effects of beta blockers on left 
ventricular function ......................................................... 76 
1. 7 .5.3.6 Traditional contraindications and cautions to the use of 
beta blockers- are they justified? ................................. 77 
1.7.5.3.6.1 Beta blockers in chronic obstructive pulmonary 
disease .................................................................... 77 
1.7.5.3.6.2 Beta blockers in peripheral arterial disease ............. 78 
iv 
1. 7.5.3.6.3 Beta blockers in diabetes ........................................ 78 
1.7.5.3.6.4 Beta blockers in older people .................................. 79 
1.7.5.3.7 Outpatient initiation of beta-blockers for heart failure ..... 80 
1.7.5.3.8 Ongoing Research with beta blockers for heart failure .. 81 
1.7.5.4 
1.7.5.5 
1.7.5.6 
Aldosterone receptor antagonists for heart failure ............ 82 
Angiotensin 11 receptor blockers (ARB) for heart failure .... 83 
Digoxin and heart failure ................................................... 85 
1. 7 .5.6.1 A historical perspective .................................................. 85 
1.7.5.6.2 Early studies of digoxin in heart failure .......................... 85 
1.7.5.6.3 The Digitalis Investigators Group (DIG) study- a critical 
review ............................................................................ 85 
1.7.5.6.4 How should we use and monitor digoxin in heart failure? .. 
1.7.5.7 
1.7.5.8 
1.7.5.9 
······················································································· 86 
Summary of main treatments for HF due to LVSD ............ 87 
Antithrombotic agents and heart failure ............................ 87 
Lipid lowering agents-should all patients with heart failure 
be on a statin? .................................................................. 88 
1. 7 .5.1 0 Anti-arrhythmic agents and heart failure ........................... 88 
1. 7 .5.11 Calcium channel blockers and heart failure ...................... 89 
1.7.6 Monitoring of patients with heart failure .................................... 89 
1.7.7 Device therapies for heart failure ............................................. 90 
1.7.8 The treatment of heart failure with preserved left ventricular 
ejection fraction or diastolic dysfunction ................................... 90 
1.8 Guidelines for diagnosis and management of heart failure ............. 91 
1.8.1 Introduction .............................................................................. 91 
1.8.2 The National Service Framework for Coronary Heart Disease -
what are the implications for primary and secondary care? ..... 92 
V 
1.8.3 National Institute for Clinical Excellence guidelines for CHF .... 93 
1.8.4 Implementation strategies in heart failure ................................ 95 
1.8.4.1 Isolated provider interventions and academic detailing ..... 95 
1.8.4.2 Disease management systems for heart failure ................ 97 
1.8.4.3 Who should provide care for patients with heart failure? .. 97 
Chapter 2. Barriers to accurate diagnosis and effective management of 
heart failure in general practice - a qualitative study .............................. 99 
Abstract. ................................................................................................... 1 00 
2.1 Introduction ................................................................................... 102 
2.1.1 Choice of methodology .......................................................... 103 
2.1.1.1 
2.1.1.2 
2.1.1.3 
Research methodology ................................................... 1 03 
Sampling strategy ........................................................... 1 06 
Sample Size .................................................................... 1 07 
2.2 Method .......................................................................................... 108 
2.2.1 Subjects, Setting and sampling strategy ................................ 108 
2.2.2 Analysis .................................................................................. 113 
2.2.3 Respondent validation ............................................................ 117 
2.3 Results .......................................................................................... 118 
2.3.1 Clinical practice uncertainty ................................................... 118 
2.3.1.1 The diagnostic process ................................................... 118 
2.3.1.2 Availability and use of echocardiography services .......... 120 
2.3.1.3 Treatment issues ............................................................ 121 
2.3.2 Lack of Awareness of Relevant Research Evidence .............. 125 
2.3.3 Influences of personal preference and local organisational 
factors .................................................................................... 125 
2.4 Discussion ..................................................................................... 127 
vi 
2.4.1 Summary of main findings ...................................................... 127 
2.4.2 Study Strengths and Limitations ............................................ 129 
2.5 Conclusions ................................................................................... 130 
Chapter 3. The diagnosis and management of heart failure across 
primary-secondary care: a qualitative study of specialists' views and 
attitudes ..................................................................................................... 131 
Abstract .................................................................................................... 132 
3.1 Introduction ................................................................................... 134 
3.2 Methodology .................................................................................. 134 
3.2.1 Justification for the choice of methodology ............................ 134 
3.2.2 Subjects, setting and sampling strategy ................................. 136 
3.2.3 Analysis .................................................................................. 138 
3.3 Results .......................................................................................... 140 
3.3.1 Diagnosis ............................................................................... 141 
3.3.1.1 Need for an accurate diagnosis ...................................... 141 
3.3.1.2 Presenting picture ........................................................... 143 
3.3.1.3 Transient Heart Failure ................................................... 143 
3.3.2 Treatment. .............................................................................. 144 
3.3.2.1 An accurate diagnosis as a pre-requisite ........................ 144 
3.3.2.2 Use of therapies .............................................................. 145 
3.3.2.3 Elderly patients ............................................................... 146 
3.3.2.4 Constraints on the use of evidence-based drugs ............ 146 
3.3.2.5 Palliative care .................................................................. 148 
3.3.3 Influences on Service Delivery ............................................... 149 
3.3.3.1 Gaps between evidence and practice ............................. 149 
3.3.3.2 Who should manage heart failure? ................................. 150 
vii 
3.4 Discussion ..................................................................................... 153 
3.4.1 Methodological considerations and limitations ....................... 153 
3.4.2 Potential solutions .................................................................. 153 
Chapter 4. One stop diagnostic clinic for suspected heart failure and the 
Darlington integrated heart failure service - a descriptive study .......... 156 
Abstract. ................................................................................................... 157 
4.1 Background ................................................................................... 158 
4.2 Aims of the service ........................................................................ 159 
4.3 Clinic structure .............................................................................. 160 
4.3.1 Service outline and funding .................................................... 160 
4.3.2 Referral criteria ...................................................................... 161 
4.3.3 Staffing of clinic ...................................................................... 162 
4.3.3.1 Role of the GP specialist in cardiology ............................ 162 
4.3.3.2 Role of the specialist heart failure and auxiliary nurse .... 163 
4.3.3.3 Role of the consultant cardiologist .................................. 163 
4.3.4 Heart failure review clinic ....................................................... 163 
4.4 Summary of services and referral pathways ................................. 164 
4.5 Facts and figures ........................................................................... 165 
4.5.1 Referrals ................................................................................ 165 
4.5.2 Diagnoses .............................................................................. 165 
4.5.3 Initiation of evidence-based therapy ....................................... 166 
4.5.4 Admission data ...................................................................... 167 
4.5.5 Patient follow-up ..................................................................... 169 
4.6 Service evaluation ......................................................................... 170 
4.7 Changing GP contractual obligations ............................................ 170 
4. 7.1 The new General Medical Services (GMS) contract .............. 170 
viii 
4.7.1.1 New GMS contract LVD data .......................................... 171 
4.7.2 Potential hospital influences on new GMS contract ............... 171 
4.7.2.2 Myocardial Infarct National Audit Program (MINAP) data172 
4.8 Discussion ..................................................................................... 172 
4.8.1 Strengths of the service ......................................................... 172 
4.8.2 GP satisfaction survey ........................................................... 174 
4.8.3 Weaknesses of the service .................................................... 178 
4.9 Future service developments ........................................................ 179 
4.10 Conclusions ................................................................................... 179 
Chapter 5. Natriuretic Peptides- a resume of the literature ................. 181 
5.1 Introduction ................................................................................... 182 
5.2 Methods ........................................................................................ 182 
5.2.1 Search Strategy ..................................................................... 182 
5.2.2 Describing diagnostic tests .................................................... 182 
5.2.3 Receiver operating characteristic (ROC) curves .................... 183 
5.3 Physiological perspectives ............................................................ 184 
5.3.1 Natriuretic peptides subtypes and physiology ........................ 184 
5.3.2 Factors other than heart failure affecting natriuretic peptide 
levels ...................................................................................... 185 
5.3.3 Cardiac natriuretic peptide assay methodology ..................... 186 
5.3.4 Stability of natriuretic peptides in blood .................................. 187 
5.3.5 Available commercial assays ................................................. 187 
5.4 The role of cardiac peptides in clinical practice ............................. 188 
5.4.1 Diagnosis of Heart Failure ...................................................... 188 
5.4.1.1 "Positive" studies ............................................................. 194 
5.4.1.2 "Negative" studies ........................................................... 195 
ix 
5.4.1.3 
5.4.1.4 
5.4.1.5 
Possible reasons for variations in diagnostic accuracy ... 196 
Potential diagnostic utility of natriuretic peptides in primary 
care ................................................................................. 197 
Possible impact of B-type natriuretic peptide (BNP) test 
introduction and future research ..................................... 198 
5.4.2 Prognosis and Risk Stratification in HF .................................. 198 
5.4.3 Treatment. .............................................................................. 199 
5.4.4 Monitoring the efficacy of therapy .......................................... 199 
5.4.5 Screening for cardiac dysfunction in an asymptomatic 
population .............................................................................. 200 
5.5 Summary and Future Research .................................................... 200 
5.5.1 The current situation .............................................................. 200 
5.5.2 Potential future developments using natriuretic peptides ....... 201 
5.5.3 Future research ...................................................................... 201 
Chapter 6. The diagnostic accuracy and utility of natriuretic peptides in a 
community population of patients with suspected heart failure, using 
near patient and laboratory assay methods ............................................ 203 
Abstract. ................................................................................................... 204 
6.1 Introduction ................................................................................... 206 
6.2 Methods ........................................................................................ 207 
6.2.1 Sampling for BNP and N-Terminal proBNP ........................... 208 
6.2.2 Statistical Analysis ................................................................. 208 
6.2.3 Echocardiography and Electrocardiography .......................... 209 
6.3 Results .......................................................................................... 210 
6.4 Discussion ..................................................................................... 216 
6.4.1 Summary of main findings ...................................................... 216 
6.4.2 Comparison with existing literature ........................................ 216 
X 
6.4.3 Study Strengths and Limitations ............................................ 219 
6.4.4 Implications for future clinical practice and future research .... 219 
Chapter 7. N-terminal pro B-type natriuretic (NT proBNP) to screen for 
heart failure referral: a pragmatic primary care study ........................... 221 
Abstract. ................................................................................................... 222 
7.1 Introduction ................................................................................... 223 
7.2 Methods ........................................................................................ 225 
7.2.1 Setting and subjects ............................................................... 225 
7 .2.2 Exploratory Cost Analysis Methodology ................................. 225 
7.2.3 Sampling for NT proBNP ........................................................ 226 
7.2.4 Statistical Analysis ................................................................. 226 
7.2.5 Echocardiography and Electrocardiography .......................... 227 
7.3 Results .......................................................................................... 227 
7.3.1 The impact on secondary care referrals ................................. 227 
7.3.2 Exploratory cost analysis results ............................................ 232 
7.4 Discussion ..................................................................................... 234 
7 .4.1 The impact on secondary care referrals ................................. 235 
7 .4.2 Referral thresholds for NT proBNP ........................................ 237 
7.4.3 Electrocardiography in screening for left ventricular systolic 
dysfunction ............................................................................. 238 
7.4.4 Exploratory Cost Analysis ...................................................... 239 
7.5 Strengths and limitations of this study ........................................... 240 
7.6 Conclusions and future research implications ............................... 241 
Chapter 8. Discussion and Conclusions ................................................. 243 
8.1 Background ................................................................................... 244 
8.2 Summary of the studies ................................................................. 244 
xi 
8.2.1 Study 1 ................................................................................... 244 
8.2.2 Study 2 ................................................................................... 246 
8.2.3 Study 3 ................................................................................... 247 
8.2.4 Study 4 ................................................................................... 248 
8.2.5 Study 5 ................................................................................... 249 
8.3 Conclusions ................................................................................... 251 
8.4 Implications of this research .......................................................... 252 
8.5 Future research ............................................................................. 254 
References ................................................................................................. 256 
Appendices ................................................................................................................ 319 
xii 
Abstract 
NAME: Dr Ahmet Fuat 
TITLE OF THESIS: The Diagnosis and Management of Heart Failure across 
Primary and Secondary Care 
HIGHER DEGREE FOR WHICH SUBMITTED: Doctor of Philosophy (PhD) 
YEAR OF SUBMISSION: 2006 
This thesis is centred on the complex arena of heart failure diagnosis and 
management across the primary-secondary care interface, including service 
delivery models and the utility of natriuretic peptides in triage of patients. The 
thesis combines qualitative and quantitative methodologies to identify barriers 
to heart failure care and to test strategies for overcoming these. 
The findings were: 
1. GPs found heart failure difficult to diagnose and treat due to clinical 
uncertainty, lack of awareness of the relevant research evidence and 
organisational issues including lack of access to diagnostics. 
2. With regard to specialists variable opinions and practice in diagnosis 
and management of heart failure in hospitals and across primary-
secondary care were confirmed, these centred on diagnostic 
difficulties, treatment issues and service delivery problems. 
3. A GP-specialist led one-stop diagnostic clinic facilitated expedient, 
accurate diagnosis of left ventricular systolic dysfunction. 
4. An integrated heart failure service across primary and secondary care 
delivered evidence based therapy, patient and carer education and 
access to social and palliative care for patients with heart failure. 
5. Natriuretic peptide measurement had high negative predictive value for 
excluding heart failure in a consecutive GP referred cohort. 
6. Electrocardiography was not as accurate at excluding heart failure as 
suggested by national guidelines. 
1 
7. Use of N-terminal pro B-type natriuretic peptide as a pre-screening test 
for secondary care referral may have reduced potential referrals, but 
the low specificity of the test and high prevalence of confounding 
factors in the screened population increased demand on diagnostic 
services and did not lead to cost savings. 
Conclusions 
The diagnostic and treatment difficulties identified by GPs and hospital 
specialists are dependent on a complex interplay of patient, clinician and 
organisational factors. Barriers need to be overcome in locality specific and 
multi-faceted implementation strategies across primary-secondary care. This 
thesis described an integrated heart failure diagnosis and management 
system that overcame these barriers and delivered accurate diagnosis and 
modern evidence based treatment. 
The relatively poor positive predictive value and low specificity of natriuretic 
peptides in real life practice meant that large numbers of patients with raised 
BNP/NT proBNP did not have heart failure due to left ventricular systolic 
dysfunction. 
This thesis demonstrated that the prognostic power of BNP/NT proBNP 
extended beyond LVSD to most cardiac conditions. Ideally, all patients with 
raised natriuretic peptides deserve a full cardiac assessment including 
echocardiography, followed by optimal use of evidenced based 
pharmacotherapy and health professional support. We need to find ways of 
providing expedient diagnostic and treatment services to these patients 
especially in rationed health care systems such as the NHS. Until this issue is 
addressed widespread natriuretic peptide use is unlikely within the UK. 
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Chapter 1. 
A resume of the literature 
This literature review has been, by necessity, an iterative process over a six 
year period, with several additions made during that time. This has been 
necessary in order to keep up to date, both clinically and as a researcher, with 
the rapidly changing and expansive arena that heart failure research has 
become worldwide. 
"Heart failure fulfils the three simple criteria for identifying diseases that should 
have a high priority and be the focus of healthcare programmes; it is common, 
it can be detected, and treatment is effective"1. 
1.1 The definition of heart failure and descriptive terms 
Before general practitioners can accurately diagnose and optimally treat heart 
failure they need to be clear about how it is defined. Research and clinical 
management of heart failure (HF) has been handicapped by the absence of a 
generally accepted practical definition24. Dargie (1998) argues that we need 
an acceptable definition not only for diagnosis but also for "budgeting within 
health services, for regulatory reasons and for research purposes"5. The much 
quoted textbook definition of heart failure; "a state in which an abnormality of 
cardiac function is responsible for failure of the heart to pump blood at a rate 
commensurate with the requirements of the metabolising tissues or, to do so, 
only from an elevated filling pressure"6, gives useful pathophysiological insight 
but does not address the practical definition required by clinicians. 
The difficulty in clinically defining heart failure stems from the fact that it is not 
a clear-cut diagnosis or disease per se, but a complex clinical syndrome7. 
Unlike renal or pulmonary failure there is no easily measured organ function 
parameter (e.g. serum creatinine or pulmonary function tests) to help us in 
diagnosis. Although left ventricular ejection fraction (LVEF) is often used as a 
descriptor of left ventricular function, different methods of measurement give 
different results in the same patient. One problem clinicians face in 
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establishing a diagnosis of heart failure is that there is no clearly defined 
LVEF below which HF or LVSD is confirmed5. The European Society of 
Cardiology (1995)8 and American College of Cardiology/American Heart 
Association guidelines9·10 suggest that LVSD should be diagnosed if LVEF is 
less than 40%; in some studies 35% was used as the cut off, and in 
significant mitral regurgitation an ejection fraction of less than 60% is 
considered abnormal. Furthermore it is not always possible to measure LVEF 
especially in patients who are obese or have significant chronic obstructive 
pulmonary disease (COPD), mainly due to the inability to identify an adequate 
echocardiographic window for trans-thoracic assessment. These difficulties 
are compounded by the fact that major clinical trials use different L VEF cut-
points for patient enrolment and "definition" of HF or LVSD. (See table 1.1 
below) 
Table 1.1 LVEF cut-points in major HF clinical trials 
Major HF clinical trial LVEF cut-point for LVSD 
diagnosis 
SOL VD T11 S35% 
CAPRICORN 1;l S40% 
CHARM1~ S40% 
CIBIS W4 S35% 
COMET10 S35% 
DIG16 S45% 
ELITE 11 1 ' S40% 
MERIT HFHj S40% 
RALES19 S35% 
SAVE;lu S40% 
Vai-HeFT"1 S45% 
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Historically, matters have been confounded by a multitude of descriptive terms 
such as; acute and chronic, right and left, high and low-output, forward and 
backward, overt, treated, congestive and undulating heart failure. 
The Task Force on Heart Failure of the European Society of Cardiology did 
address this in their "Guidelines for the diagnosis of heart failure"8 by 
suggesting that heart failure could be described in acute or chronic terms. 
They suggested the terms of acute (cardiogenic) pulmonary oedema and 
cardiogenic shock (a syndrome characterised by a low arterial pressure, 
oliguria and a cool periphery). Chronic heart failure can be classified as either 
systolic or diastolic left ventricular dysfunction. These do seem to be 
acceptable, practical descriptive terms, which also point to the correct 
management strategy, which differs for each entity22. 
The clinical definition of heart failure agreed by the Task Force (1995)8 guides 
diagnosis and encapsulates subjective, objective and retrospective criteria4; 
Definition of Heart Failure. 
(Criteria 1 and 2 should be fulfilled in all cases). 
1. Symptoms of heart failure ( at rest or during exercise ) and 
2. Objective evidence of cardiac dysfunction (at rest) and 
3. Response to treatment directed towards heart failure (in cases 
where the diagnosis is in doubt). 
Symptoms of heart failure are typically breathlessness or fatigue, either at rest 
or during exertion, or ankle swelling. A clinical response to treatment directed 
at heart failure alone is not sufficient for diagnosis. 
Tan and colleagues reviewed hitherto proposed representative definitions of 
heart failure. lt would seem reasonable to have the practical definition 
proposed by the Task Force and preface this with a statement that reflects the 
recent developments in our understanding of the pathophysiological basis of 
heart failure. Professor Philip Poole-Wilson proposed the definition "a 
syndrome which develops as a consequence of cardiac disease, and is 
recognised clinically by a constellation of symptoms and signs produced by 
complex circulatory and neurohormonal responses to cardiac dysfunction"23. 
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1.2 Epidemiology of heart failure 
1.2.1 Introduction - Heart failure, a problem that will not go away. 
Despite growing public awareness of the risk factors for heart failure, chronic 
heart failure (CHF) as a result of coronary heart disease continues to inflict a 
terrible toll on the people of this country. The current estimate that 900,000 
people in the UK have CHF is predicted to increase by about 10% each 
year-24 . 
The resulting cost to society is impossible to assess fully. Approximately, 
6,000 deaths occur annually in the UK due to CHF - nearly 40% of patients 
will die within 1 year of CHF diagnosis25. However, the pain and suffering 
caused by the symptoms of CHF affect even more people and their families. 
The shortness of breath associated with CHF can severely restrict mobility in 
all but those experiencing mild CHF6 , and the effects on quality of life are far 
reaching with emotional worries and social limitations a frequent occurrence 
56
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. Many of these symptoms result in hospitalisation of patients; an 
estimated 5% of all emergency medical admissions to hospital are for CHF 
and up to 50% of severe cases require readmission within 3 months24•26. 
Inevitably, such a health burden is associated with an economic burden and 
CHF is thought to cost the NHS around £625 million per year-27. 
The risk of CHF increases with age- around 1 in 35 people aged 65-74 years 
has heart failure, increasing to about 1 in 15 of those aged between 75 and 
84, and to >1 in 7 in those aged 85 years and older- and as the average age 
of the UK population is increasing, this alone points towards an increasing 
number of people at risk24. There is a clear association between the risk of 
CHF and the presence of other cardiovascular defects such as previous 
myocardial infarction (MI), hypertension, atrial fibrillation, cardiomyopathy and 
cerebrovascular disease (e.g. strokes) 23. Other conditions that are known to 
contribute to cardiovascular disease (CVD) in general increase the risk of 
CHF. For example, patients with CHF are four-times more likely than the 
general population to have diabetes (1 in 5 patients with CHF have diabetes 
compared with 1 in 20 of the general population). 
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There have been comprehensive reviews of epidemiology and the associated 
burden of heart failure published by McMurray and colleagues28•29, and Cowie 
et af0•31 • These describe prevalence and incidence data as well as 
addressing aetiology, prognosis, quality of life (QOL) and health economic 
issues. 
1.2.2 How are epidemiological data obtained? 
Data relating to the epidemiology of heart failure are available from five types 
of studies29: 
1. Cross sectional and longitudinal follow up of well defined populations. 
These tend to focus on individuals with clinical signs and symptoms 
indicative of heart failure. Examples include the American Framingham 
Heart Study and the Swedish Study of Men born in 191332·33. 
2. Cross sectional surveys of individuals who have been medically treated 
for signs and symptoms of heart failure within a well defined region. An 
example is prevalence data based on prescription data from the county 
of Nottinghamshire34 
3. Echocardiographic surveys of individuals within a well defined 
population to determine the presence of LVSD. The first population 
based study was provided by McDonagh and colleagues from 
Glasgow35 . Subsequently studies from Southampton and the Midlands 
have followed36·37. 
4. Nationwide studies of annual trends in heart failure related 
hospitalisations. The British Heart Foundation collates such data from 
National Statistics24. 
5. Comprehensive clinical registries collected in conjunction with major 
clinical trials. 
1.2.3 Prevalence of heart failure 
There are many studies from across the western world that are outlined in the 
above mentioned reviews, but I propose only to mention those studies that 
are particularly relevant to primary and secondary care in the UK. 
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1.2.3.1 Surveys from general practice 
Parameshwar and colleagues38 surveyed the clinical records of diuretic-
treated patients in three general practices in northwest London in 1992 to 
identify possible cases of heart failure. From a total of 30,204 patients, 117 
cases (71 female and 46 male) of heart failure were identified, giving an 
overall prevalence of 3.9 cases per 1000. The prevalence of heart failure 
increased significantly with increasing age - from 0.6 cases/1 000 in those 
under 65 to 28 cases/1 000 in those aged 65 or over. A methodological 
weakness of this study was that objective investigation of left ventricular 
function was only undertaken in about a third of cases. 
Wheeldon and colleagues39 reviewed the GP notes of 12012 patients in 
Carnoustie, Scotland. The estimated prevalence of LVSD was 0.84%, 
whereas 1.6% of the population received loop diuretics for this indication. 
However, just under a half of patients invited did not attend for 
echocardiography and this non-responder bias suggests that the calculated 
prevalence figure is probably too low. 
In 1996 Mair et al40 used similar methodology to identify 266 cases of heart 
failure from 17,400 patients within two general practices in Liverpool. The 
overall prevalence was 15 cases/1 000 in individuals aged under 65, rising to 
80 cases/1 000 in those aged 65 or over. Both the above studies could be 
subject to selection and location bias which may limit generalisabilty of results 
to a wider population. 
Clarke and colleagues41 conducted a larger survey based on similar methods 
by analysing loop diuretic prescriptions for all residents in Nottinghamshire. lt 
was estimated that between 13,017 and 26,214 patients had been prescribed 
frusemide. Random case record review found that 56% were being treated for 
heart failure. Overall prevalence was estimated at 8-16 cases/1000 for those 
less than 70 years of age. Prevalence increased to 40-60/1 000 among those 
aged 70 years and over. 
UK national data from RCGP surveys of research practices42•43 shows an 
increase in overall prevalence from 3/1000 in 1985 to 9/1000 in 1995 (patients 
aged 25 to 74). There was no data for older patients from 1985 but a 
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prevalence of 7 4/1 000 was recorded for those aged 65-7 4 years of age in 
1995. 
Toal and Walker44 audited the notes of 3 north Cumbria general practices with 
a total population of 23210. Prevalence rate for HF was 1.1% (n = 258) 
A limitation of all retrospective analyses of notes is that they are open to bias 
and error due to variable legibility and completeness of medical records and 
difficulty of data interpretation by a detached clinician not present at the 
moment of the doctor-patient consultation. Computerisation of data may 
reduce some of these errors but analyses are still dependent on accuracy and 
completeness of data entry. 
1.2.3.2 Cross sectional surveys using echocardiography 
McDonagh and colleagues35 studies a representative cohort of 2000 people 
aged 25-74 years living in North Glasgow. Of these 1640 (83%) underwent 
echocardiographic assessment of cardiac function. LVSD was defined as 
LVEF s 30%. The overall prevalence of LVSD was 2.9%. Interestingly only 
1.5% had symptoms of heart failure with the other 1.4% being asymptomatic. 
Prevalence was both greater in men and increased with age. The use of a 
strict criterion (LVEF s 30%) was designed to identify those with significant 
LVSD but may have excluded those with mild or moderate L VSD who are also 
at risk of early death, poor morbidity and hospitalisation. This suggests that 
the prevalence data may be an underestimate especially in an area with 
recognised high CHD rates. 
Morgan and colleagues36 carried out a cross sectional survey in four general 
practices in Poole, Dorset. 870 elderly patients aged 70 to 84 had left 
ventricular function assessed by echocardiography. Measurement of ejection 
fraction was possible in 82% of patients. The overall prevalence for LVSD was 
7.5% (95% Cl 5.8% to 9.5%). At all ages prevalence is much higher in men 
than in woman (odds ratio 5.1, 95% Cl 2.6 to 10.1). 52% of patients with left 
ventricular dysfunction had not previously been diagnosed. A conclusion from 
this is that unrecognized left ventricular dysfunction is a common problem in 
elderly patients in a general practice setting and diagnosis should not be 
based on clinical history and examination alone. Whilst this raises the 
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feasibility and desirability of screening patients in general practice, it should 
not be implemented until the optimum method of identifying left ventricular 
dysfunction is clarified and the cost effectiveness of screening has been 
shown. 
Davies and colleagues37 randomly selected 6286 patients aged over 45 years 
from 16 practices in the West Midlands. 3960 (63%) were assessed clinically, 
and by ECG and echocardiography. LVSD (LVEF < 40%) was diagnosed in 
72 (1.8%; 95% Cl 1.4-2.3) with a mean age of 69 years and 54 subjects 
(1.4%) had definite HF (by ESC diagnostic criteria) from other causes apart 
from LVSD, with a mean age of 73 years. Half of the LVSD group were 
asymptomatic. The overall prevalence of significant cardiac dysfunction was 
3.2%. These results are lower than the North Glasgow despite the use of a 
lower LVEF (S35%) in the Glasgow study35 and may be related to a high 
frequency of IHD in that population, a major precursor for LVSD. The 
prevalence rate was also lower than the Poole study36 which used different 
diagnostic methods in an elderly select population. 
1.2.3.3 Why such variation in prevalence of heart failure? 
Different epidemiological surveys show considerable variations in the 
prevalence of chronic heart failure. Whilst some of this may be accounted for 
by true differences in populations including social, demographic and risk 
factor profiles of study cohorts in contrasting geographical locations, the 
greatest cause of variability is most likely to be related to differing definitions, 
research methodologies, methods of measuring and assessing heart failure. 
Most data show progressive increase of prevalence of CHF with age and a 
significant eo-relation with CHD, hypertension and diabetes. Furthermore 
prevalence seems to have increased over the past few decades. Until there is 
a consensus in terms of definition of heart failure for epidemiological studies, 
they are unlikely to achieve a homogeneous figure collection and allow a true 
data comparison. 
1.2.4 Incidence of Heart Failure 
There appears to be much less known about the incidence of heart failure29, 
with only two studies relating to British populations. Cowie and colleagues45 in 
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a population-based study determined the incidence of heart failure in a UK 
population through the surveillance of 151,000 patients registered with 52 
primary care practices in Hillingdon, south London. Using the ESC criteria for 
the diagnosis of heart failure, the overall incidence was found to be 1.3 cases 
per 1 000 population per year. The incidence rate was age related and 
increased steadily from 0.02 cases per 1000 population per year in those 
aged 25 to 34, to 11.6 cases per 1000 population per year in those aged over 
85. The incidence of heart failure was greater in men than in women with an 
age standardised incidence ratio of 1.75 (p < 0.0001). That was maintained 
across all age groups. The median age of onset of heart failure was 76 years, 
considerably higher than the median age of patients involved in clinical trials 
evaluating pharmacological therapy of the disease. 
Johansson and colleagues46 conducted a survey of UK GPs who had 
diagnosed patients with heart failure as part of the general practice research 
database covering three million patients. This revealed an overall incidence 
of 4.4 per thousand population per year in men and 3.9 per thousand 
population per year in woman. Whilst this study suggests a significant 
incidence of heart failure in the UK population, it should be noted that the 
diagnosis criteria may not have been as stringent as in other population based 
studies. 
Studies from Sweden, Finland and the USA give broadly similar incidence 
rates to that estimated by Cowie and colleagues: 
Table 1.2. Heart Failure Incidence 
Study and year Location Incidence rate Incidence rate in 
(total population) older age groups 
Eriksson et al Sweden - 10/1000 
198933 (61-67 years) 
Remes et al Finland 1-4/1000 8/1000 
199247 (45-74 years) (> 65 years) 
Rodeheffer et al Rochester 1/1000 16/1000 
199348 USA (<75 years) (> 65 years) 
Ho et al 1993.,;.! Framing ham 1/1000 12/1000 
USA . (>85 years) 
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As with prevalence data there is an obvious increased incidence in older 
individuals. 
1.2.5 A summary of prevalence and incidence of heart failure 
Heart failure is a major public health problem in industrialised countries with 
ageing populations. Prevalence rates vary between 3 to 35 per 1000 under 
the age of 65, rising to between 28 to 130 per 1000 over 6530. These 
estimates probably vary widely due to differences in methodology and timing30 
and diagnostic heterogeneity in clinical studies49 , rather than reflecting true 
differences between populations. Incidence rates average between 1 to 5 per 
1000, but can rise up to 40 per 1000 in over 75 years of age in some 
studies30. 
1.2.6 Prognosis and quality of life 
Annual mortality exceeds 60% in severe heart failure and 5 year mortality 
approaches 50% even in mild cases32·50"52 . This is worse than many forms of 
cancer53. The commonest cause is now ischaemic heart disease, followed by 
hypertension54 . As populations age, and the management of ischaemic heart 
disease, myocardial infarction and hypertension continues to improve, the 
prevalence and incidence will continue to escalate55. In terms of morbidity it 
impairs quality of life more than any other common chronic condition 
(including hypertension, diabetes, arthritis, chronic lung disease and 
angina)56·57 . There are several disease specific quality of life (QOL) measures 
for HF which are reliable, valid and responsive in measuring changes of 
health, including the left ventricular dysfunction questionnaire (L VD-36) and 
the Minnesota living with HF questionnaire58·59. Unfortunately most studies 
tend to focus on mortality endpoints rather than QOL. In elderly patients in 
particular QOL may be equally or more important than prolongation of life, 
although I could find no studies that addressed this difficult ethical issue. 
Whilst QOL measures are useful research tools they are rarely used in clinical 
practice, largely due to time and workload pressures faced by secondary and 
primary care clinicians and health professionals. 
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1.2.7 Health service workload and health economic issues. 
Heart failure not only imposes a huge burden on the patient and their carers, 
but also is a great drain on NHS resources. The majority of these patients are 
cared for in general practice39 . A GP with a list size of 2000 would expect to 
see 20 patients with heart failure per year (1 0 of these being new cases). 
These patients will generate 45 consultations, 8 outpatient visits and 4 
inpatient episodes per year. Heart failure accounts for 1.68 million GP 
consultations per annum39• 
Hospital care accounts for 59% of the total direct economic costs of NHS 
heart failure expenditure per annum (compared to only 1% for drug costs). 
This total amounted to £359 million in 1990/1991, and represented just over 
1% of the total NHS budget60 . This is similar to the total expenditure on 
asthma and stroke care. More contemporary UK data from coronary heart 
disease statistics shows a sharp rise in NHS costs to around £625 million in 
200027: 
Figure 1.1 Costs of heart failure to the UK (2000) 
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The biggest cost is hospital inpatient care and hospitalisations are increasing 
in the western world,55·61 •62 with heart failure now accounting for 5% of all 
general medical and geriatric admissions to hospital in the UK. Average 
length of inpatient stay is 14-16.5 days61 ·62 and readmission rates are high62. 
Age-adjusted readmission rates for HF represented 23% of all hospitalisations 
for CHF in Scotland during 199663. Scottish data from McMurray and 
colleagues62 documents a mean length of stay for a heart failure related 
admission in 1990 at 11.4 days on acute medical wards and 28.5 days on 
acute elderly care wards. About one third of patients in this study were 
readmitted within 12 months of discharge62 . The trajectory of HF includes 
episodes of relative stability interspersed by episodes of decompensation that 
can lead to readmission to hospital. Identifying factors that lead to repeated 
hospitalisation could help target those patients for intensive follow up in an 
attempt to reduce admissions64•65. 
Khand and colleagues66 analysed a large Scottish database (n = 12640; mean 
age 74 years) who had had a first admission in 1992. 23% of these died on 
their first admission and the remaining 9718 patients had 22747 readmissions 
and 4877 deaths over the subsequent 3 year period. The reasons for first 
readmission were primarily HF (first listed diagnosis) without any obvious 
precipitating event in 37% of cases, renal failure or respiratory infection in 
12%, acute ischaemic events (including Ml) in 19%, Ml alone in 8% and AF in 
11%. 
Opasich and colleagues67 identified concomitant factors contributing to 
decompensation in 161 out of 304 HF patients (mean age 59) followed up 
over a 2 year period. These included arrhythmia in 24%, infection (23%), poor 
treatment compliance (15%), episodic chest pain (14%) and iatrogenic causes 
mostly relating to inadequate treatment in 10%. Along with the above study, 
this study confirms that concomitant factors not directly related to cardiac 
pathology were an important determinant in frequency of decompensation and 
hospital admission. 
These studies suggest that systematic structured review in the community 
with emphasis on holistic care that also focuses on co-morbidities, social 
support and treatment compliance is necessary to prevent costly 
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readmissions to hospital. Multidisciplinary models of care will be discussed in 
detail later in this review. 
1.3 Aetiology and pathophysiology of heart failure 
1.3.1 Aetiology of heart failure 
Heart Failure is the common end-result of many different conditions and 
processes that impair cardiac function, both systolic and diastolic54 . In the 
westernised world coronary artery disease and hypertension are the 
commonest causes of heart failure29. However, it is often impossible to 
determine the primary aetiology as patients may have multiple co-morbidities 
that contribute to the development of heart failure, including coronary artery 
disease, hypertension, diabetes mellitus, atrial fibrillation and valvular heart 
disease. 
Aetiology of heart failure can be inferred from population based studies, 
cohorts attending clinics or from clinical trial databases and registers. Whilst 
earlier Framingham data reported by Kannel and colleagues68 in 1972 
reported hypertension as the sole or contributory cause of heart failure in over 
70% of patients68, more recent data confirms that coronary artery disease is 
now the commonest cause30. One has to remember that the earlier 
Framingham data68 was based on clinical assessment only and more recent 
increases in invasive coronary investigations have undoubtedly increased the 
importance of coronary artery disease. Furthermore, the decline of rheumatic 
fever has also reduced the number of cases with valvular disease in the 
Framingham cohort and the western world in general. Treatment advances in 
anti-hypertensive drugs and more aggressive treatment thresholds have also 
reduced the degree of heart and renal damage that may contribute to the 
development of cardiac impairment. 
McMurray and colleagues29 studied seven large clinical trial registers (number 
of patients from 1663 to 9580 in these studies) between 1991 and 1999. 
Ischaemic heart disease was documented as the main cause of heart failure 
in 54% to 71% of patients. Whilst hypertension was a eo-morbidity in 27% to 
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46%, it was only considered a cause of heart failure in between 4% to 20% of 
these studies29. 
In UK hospital or GP studies ischaemic heart disease appears to be the 
commonest cause. Parameshwar and colleagues28 found 32% of 117 patients 
with heart failure in primary care had IHD, 6% hypertension, 19% VHD and 
4% cor pulmonale. Mair and colleagues40 found that in 266 GP patients, 45% 
had IHD, 18% hypertension, 9% VHD, 2.3% cardiomyopathy and 6.8% cor 
pulmonale. Lip and colleagues69 in a survey in 3 West Birmingham general 
practices found that of 118 heart failure patients 53% had IHD, 36% 
hypertension, 7% VHD, 15% cardiomyopathy, 29% atrial fibrillation and 23% 
diabetes. In a more recent study McCallum and colleagues70 in a Scottish 
primary care setting found in 100 patients with LVSD, 66% had IHD, 11% 
hypertension and 13% VHD. 
In practice one of the most important aspects of the investigation of patients 
with heart failure is the identification of a cause that may need specific 
treatment or optimisation of therapy e.g. revascularisation in CAD, rate or 
rhythm control in AF and aggressive treatment of hypertension, especially if 
associated with LVH. This is a further argument for thorough investigation 
including ECG, CXR and echocardiography. 
1.3.2 Pathophysiology of heart failure 
Heart failure was formerly known as a mainly a haemodynamic problem of 
pump dysfunction but is know considered to be a highly complex clinical 
syndrome encompassing many extra-cardiac features including 
neurohormonal alterations (renin-angiotensin-aldosterone system and the 
sympathetic nervous system), skeletal muscle disturbance and cytokine 
release. 
Cardiac damage and remodelling (e.g. after Ml) leads to reduced cardiac 
output, which in turn activates the sympathetic nervous system 23• The cardiac 
endocrine system tries to compensate by releasing natriuretic peptides that 
increase diuresis, natriuresis and increased vascular dilatation. However, 
increased heart rate and vasoconstriction often ensues and by reducing renal 
perfusion activates the renin-angiotensin-aldosterone system. Production of 
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angiotensin 11 leads to sodium retention (via aldosterone production), fluid 
retention (via posterior pituitary vasopressin production) and further 
vasoconstriction that causes structural arteriolar changes with stiffness of 
blood vessels via increased vascular total peripheral resistance. These 
arteriolar changes contribute to the symptoms of HF by affecting skeletal 
muscle (fatigue) and reducing respiratory function by increased physiological 
dead space and airways obstruction (breathlessness). All of these changes 
may cause further cardiac dilation and remodelling creating a cycle of 
deteriorating symptoms unless therapies directed at reducing sympathetic 
over activation (beta blockers), blocking the renin-angiotensin-aldosterone 
system axis (ACE inhibitors or ARBs), reducing fluid overload (diuretics) 
and/or blocking aldosterone action (spironolactone or eplerenone) are 
initiated. In some instances further reduction in cardiac output can lead to 
electrical instability and thrombus formation which can lead to sudden death 
by inducing fatal arrhythmias or progressive pump failure. 
1.4 The diagnosis of heart failure 
1.4.1 Introduction 
The key to reduction of mortality, morbidity and cost of heart failure is 
accurate and early diagnosis of LVSD. Unfortunately, heart failure is difficult 
to diagnose accurately on clinical grounds71 ·72 . This is mainly due to the non-
specificity of the clinical symptoms and the non-sensitivity of the clinical 
signs73•74, especially in elderly patients who often have multiple co-morbidities 
and are on polypharmacy. This would suggest that to establish positively a 
diagnosis of heart failure in primary care, patients must be referred for cardiac 
imaging. 
1.4.2 Past medical history and the diagnosis of heart failure 
The past medical history may provide useful clues in assessing patients with 
suspected HF. A patient who has IHD and in particular previous Ml is more 
likely to have objective evidence of LVSD than a patient who does noe5•73•75. 
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Hypertension, atrial fibrillation and diabetes mellitus also raise suspicions that 
a patient presenting with breathlessness or oedema may have HF35.4°·76• 
Skaner and colleagues77 report an interesting study on GPs' clinical diagnosis 
of HF. They used a clinical judgement analysis using 45 case vignettes based 
on actual patients. Participants were 27 GPs from 9 health centres in 
Stockholm. The GPs utilisation of clinical information in their judgement 
strategies was measured using clinical variables as independent variables. 
The variation between the GPs' assessments of the probability of HF was 
considerable. An important source of this variation was the difference in how 
they made use of clinical information, with the most important variables being 
lung and heart X-rays and a history of Ml. This shows the need for a better 
understanding of the relationship between cues provided by clinical 
information and a diagnosis of HF by GPs, and is at least one important 
reason behind difficulties GPs face in achieving accurate diagnosis. 
1.4.3 Symptoms in the diagnosis of heart failure 
HF can present with very few symptoms in its early stages or a lot of 
symptoms once well established. Typical symptoms include breathlessness 
(at rest or on exercise), fatigue, reduced exercise tolerance and ankle 
oedema. In elderly patients unexplained confusion and altered mental state 
may also be present. Orthopnoea and paroxysmal nocturnal dyspnoea are 
less common in the general population and may be useful and specific, but 
less sensitive for suggesting the presence of HF due to LVSD78. 
However, breathlessness is a very common symptom in primary and 
secondary care with estimated prevalence of up to 25% in a community 
cohort78. Major medical textbooks document more than 30 possible causes for 
breathlessness 79. 
Interpretation of symptoms such as breathlessness, ankle oedema and 
fatigue can be very difficult in elderly patients, the obese, women and those 
with pre-existing pulmonary disease8. Indeed in elderly patients presenting 
with dyspnoea it is particularly problematic to differentiate between pulmonary 
and cardiac aetiologies80. Other factors including physical deconditioning or 
lack of fitness can cause dyspnoea on exertion. Extra-cardiac causes of 
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peripheral oedema not related to HF are common and include, venous 
insufficiency causing dependent oedema, hypoproteinaemia, renal failure and 
iatrogenic oedema caused by various commonly used drugs (e.g. calcium 
channel blockers, corticosteroids and non-steroidal anti-inflammatory agents). 
Inter-observer reproducibility of eliciting presence or absence of symptoms in 
the diagnosis of HF is low81 •82 . There have been several studies that have 
examined the sensitivity, specificity, and positive and negative predictive 
value of symptoms for the diagnosis of HF. These studies have concentrated 
on dyspnoea on exertion, orthopnoea, paroxysmal nocturnal dyspnoea (PND) 
and ankle oedema. See Table 1.3 below. 
There is considerable variation between results and it is difficult for the 
clinician to draw any conclusion from these studies, except that none of the 
symptoms studied are consistently useful in the diagnosis of HF74. 
Furthermore, reliance on symptoms and signs alone may lead to under or 
over-diagnosis of HF and inappropriate care80•84. 
1.4.4 Clinical signs in the diagnosis of heart failure 
The clinical signs of HF reflect the consequences more than the causes of 
HF74. Cardiomegaly caused by ventricular dilatation may be detected by a 
displaced apex beat, increased area of cardiac dullness and a third heart 
sound; fluid retention is reflected in signs of congestion including ankle 
oedema, a raised jugular venous pressure and pulmonary crepitations or 
crackles; neuroendocrine activation causing increased sympathetic tone leads 
to a resting tachycardia; and low cardiac output causes decreased 
proportional pulse pressure due to poor perfusion. 
Several studies and systematic reviews have determined the value of clinical 
signs and clinical examination in diagnosis of HF by examining sensitivity, 
specificity and predictive values. See Table 1.4 below. 
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Table 1.3: Sensitivity, specificity, positive predictive value (PPV) and 
negative predictive value (NPV) of symptoms for diagnosis of HF (%) 
Harlan83 Chakko84 Stevenson85 Echeverria86 Davie75 
Dyspnoea 
on exertion 
Sensitivity 66 97 100 
Specificity 52 15 17 
PPV 23 63 18 
NPV 75 100 
Orthopnoea 
Sensitivity 21 66 91 73 22 
Specificity 81 47 100 40 74 
PPV 2 61 100 65 14 
NPV 37 64 50 83 
Paroxysmal 
nocturnal 
dyspnoea 
Sensitivity 33 50 39 
Specificity 76 45 80 
PPV 26 58 27 
NPV 38 37 
Ankle 
oedema 
Sensitivity 23 46 23 23 49 
Specificity 80 73 100 70 47 
PPV 22 79 100 54 15 
NPV 37 18 38 83 
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Table 1.4: Sensitivity, specificity, PPV and NPV of signs for the 
diagnosis of HF (%) 
Harlan83 Heckerling87 O'Neill88 Chakko84 Butman89 Stevenson88 Echeverrla88 
Resting 
tachycardia 
Sensitivity 7 
Specificity 99 
PPV 6 
NPV 
Pulmonary 
crackles 
Sensitivity 13 66 24 19 70 
Specificity 91 84 100 100 35 
PPV 27 87 100 100 62 
NPV 61 35 17 44 
Ankle 
Oedema 
Sensitivity 10 46 23 40 
Specificity 93 73 100 70 
PPV 3 79 100 67 
NPV 46 18 44 
Third heart 
sound 
Sensitivity 31 73 68 98 63 
Specificity 95 42 73 14 55 
PPV 62 66 86 88 68 
NPV 85 48 50 50 
Jugular 
venous 
distension 
Sensitivity 10 70 57 58 47 
Specificity 97 79 93 100 65 
PPV 2 85 95 100 67 
NPV 62 47 28 45 
Increased 
percussion 
Davle78 
22 
92 
33 
86 
29 
77 
19 
85 
20 
86 
21 
85 
24 
99 
77 
87 
17 
98 
64 
86 
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Harlan83 Heckerling87 O'Neill88 Chakko84 Butman89 Stevenson811 Echeverrla86 Davie75 
distance 
Sensitivity 94 
Specificity 67 
PPV 
NPV 
Displaced 
apex beat 
Sensitivity 59 60 66 
Specificity 76 50 96 
PPV 59 64 75 
NPV 77 45 94 
Proportional 
pulse 
pressure 
Sensitivity 91 0 
Specificity 8 100 
PPV 91 0 
NPV 87 84 
Wheeze 
Sensitivity 12 
Specificity 82 
PPV 11 
NPV 83 
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Similar to symptoms suggestive of HF, utility of clinical signs show variation 
between studies in terms of specificity, sensitivity, PPV and NPV for detecting 
HF. Systematic reviews78•90 also came up with differing utility of certain signs. 
Mulrow and colleagues78 concluded that the initial assessment was 
approximately 70% accurate in determining cause in patients presenting with 
dyspnoea. Badgett and colleagues90 concluded that abnormal apical impulse 
and a third heart sound were the best clinical indicators of systolic 
dysfunction. Davie and colleagues75 also found in a study of hospitalised 
patients that a displaced apex beat was the best predictor of LVSD with a 
sensitivity of 66% and specificity of 96%. However, patients with HF may not 
have signs such as displaced apex beat, raised JVP85 or a third heart sound91 . 
Furthermore, there is wide variability in the precision and reliability of eliciting 
clinical signs between clinicians92•93. lt would appear that the most useful 
signs are probably the most subtle: third heart sound, increased width of 
cardiac dullness and displaced apex beae4 but are likely to be difficult signs 
for GPs to be able to elicit with confidence. 
In summary, whilst symptoms and signs are important as they alert a clinician 
to the possibility that HF exists, the clinical suspicion must be confirmed by 
more objective tests particularly aimed at assessing cardiac function. 
1.4.5 Clinical scoring systems in the diagnosis of heart failure 
The combinations of symptoms and signs suggestive of HF have been used 
to devise several scoring systems for the diagnosis of HF50•94-98. Mosterd and 
colleagues99 compared the usefulness of six HF scores in non-hospitalised 
subjects. They demonstrated that five of the six scores were broadly similar in 
the detection of manifest HF, but felt that there was generally low sensitivity 
for detecting possible HF. The authors concluded that given the atypical 
presentation and low sensitivity in suspected HF clinical scoring systems were 
unlikely to be useful in clinical practice and suggested that all such patients 
need objective assessment of cardiac function by echocardiography. 
In summary, clinical scoring systems are interesting but of limited use in 
practice99. Clinical evaluation must be combined with objective assessment in 
confirming LVSD8. 
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1.4.6 Symptoms and severity of heart failure 
Once a diagnosis of HF has been established, symptoms can be used to 
classify severity and may be used to monitor progress and the effects of 
therapy. The New York Heart Association (NYHA) classification 100 , initially 
developed for patients with angina, is widely used in practice and in clinical 
trials. See Table 1.5 below. 
Table 1.5: New York Heart Association classification of heart failure100 
Class I 
Class 11 
Class Ill 
Class IV 
No limitation: ordinary physical exercise does not cause 
undue fatigue, dyspnoea, or palpitations 
Slight limitation of physical activity: 
Comfortable at rest but ordinary activity results in fatigue, 
palpitations, or dyspnoea 
Marked limitation of physical activity: 
Comfortable at rest but less than ordinary activity results in 
symptoms 
Unable to carry out any physical activity without 
discomfort: symptoms of heart failure are present even at 
rest with increased discomfort with any physical activity 
However, symptoms are often very subjective and may not correlate 
particularly well with degree of cardiac impairmenf1·82 . In practice it is not 
always easy to apply an NYHA class to all patients, and clinicians often simply 
label patients as having mild (NYHA 11), moderate (NYHA Ill) or severe (NYHA 
IV) HF. Guidelines 101 suggest the use of walking distance or number of stairs 
climbed in a given time as an objective measure of functional capacity and 
hence HF severity. Most GPs are unlikely to be aware of or routinely use such 
measures, although no formal assessment of their knowledge has been 
made. 
A simpler and more practical method of classifying and staging HF has been 
proposed by American College of Cardiology/American Heart Association 
guidelines 10. However, it remains to be seen whether this will be used in 
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everyday clinical practice or indeed in future clinical trial staging and 
assessment of HF (See table 1.6 below). 
Table 1.6 American College of Cardiology/ American Heart Association 
Staging System for Heart Failure 2001 
Stage Patient Description 
High risk for • Coronary artery disease 
A developing heart • Hypertension 
failure (HF) • Diabetes mellitus 
• Family history of cardiomyopathy 
• Previous myocardial infarction 
B Asymptomatic HF • Left ventricular dysfunction 
• Asymptomatic valvular disease 
• Known structural heart disease 
c Symptomatic HF • Shortness of breath and fatigue 
• Reduced exercise tolerance 
• Marked symptoms at rest despite maximal 
D Refractory end- medical therapy (e.g., those who are 
stage HF recurrently hospitalized or cannot be 
safely discharged from hospital without 
specialized interventions) 
1.4.7 The electrocardiogram in the diagnosis of heart failure 
All guidelines8•22•101-104 and NICE guidance 105 for the diagnosis and 
management of heart failure due to LVSD suggest that if a 12 lead ECG is 
normal then LVSD is very unlikely. This has led to suggestions that a normal 
ECG be used to screen out patients with suspected HF prior to referral for 
echocardiography. This advice appears to be largely based on a trial by Davie 
and colleagues 106 suggesting that LVSD is unlikely to be present if an ECG is 
normal, with a sensitivity of 94% and NPV 98%. However, these claims have 
been contradicted by other studies. The following Table 1.7 summarises the 
available studies where ECG has been assessed against an 
echocardiographic diagnosis of LVSD. 
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Table 1.7: Sensitivity and specificity of ECG studies in identifying HF 
Study author/year Sensitivity 95%CI Specificity 95%CI 
Davie 1996106 0.94 0.86-0.97 0.61 0.57-0.66 
Khandekar 1996107 0.78 0.64-0.88 0.20 0.12-0.30 
Gillespie 1997108 0.98 0.88-1.00 0.69 0.48-0.86 
Houghton 1997109 0.89 0.85-0.94 0.46 0.31-0.66 
Lindsay 2000110 0.91 0.82-0.95 0.65 0.60-0.70 
Sandler 2000111 0.73 0.61-0.83 0.53 0.45-0.60 
Nielsen 2000112 0.87 0.60-0.98 0.56 0.46-0.65 
Landray 2000113 0.42 0.26-0.58 0.87 0.78-0.93 
Hutcheon 2002114 0.96 0.83-1.00 0.50 0.44-0.56 
Ng 2003115 0.88 0.64-0.99 0.61 0.58-0.64 
lt is obvious from this table that there is considerable variation between 
sensitivity and specificity of studies. Relying on an abnormal ECG as a screen 
for echocardiography would have failed to detect between 2% to 58% of 
individuals with LVSD in the various study cohorts. In a further study in 
patients randomly selected from those attending a heart failure clinic, Talwar 
and colleagues116 found that using the ECG as a screening tool would have 
led to failure to diagnose significant systolic impairment (left WMI < 1.2) in 
33% (n= 12) of patients with a normal ECG (n = 36), and a further 17% (n =6) 
with mild to moderate systolic impairment (left WMI between 1.3 and 1.9). 
Only four of these studies 106•107•110·111 were broadly representative of patients 
seen by GPs with suspected HF as they were all based on studies of OAE 
services, in a UK setting. Others studies were either patient referred to 
secondary care clinics, acute admissions with dyspnoea or cohorts enrolled in 
research projects in secondary care. Even within these 4 studies there was 
considerable heterogeneity between studies in NPV and PPV, where NPV 
could be used to estimate the utility of ECG in excluding HF. The results were 
Davie et al106, PPV 35%, NPV 98%; Lindsay et al110, PPV 43%, NPV 96%; 
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Khandekar et al107 , PPV 36%, NPV 61%, and Sandler et al111 , PPV 39%, NPV 
82%. One possible explanation of this variation was that in the first two 
studies displaying high NPV both the ECG and echocardiograms were 
reported by cardiologists, who are more likely to have expertise in this area. 
The variation in studies may be explained by several other factors. 
Dependence on case selection (consecutive patients studied in an attempt to 
reduce potential selection bias) and the prevalence of LVSD in the population 
studied; differences in referral criteria; differences in echocardiographic 
reporting criteria (LVEF, WMI or semi-quantitative measures) and ECG 
classification (i.e. what constitutes an abnormal ECG?) and the experience of 
the person reporting these tests. Most studies used very similar ECG 
criteria117 but only the Khandekar et al study107 reported that consecutive 
patients were studied. Very recently Khunti and colleagues118 evaluated the 
accuracy of a 12-lead ECG in screening patients with suspected HF for OAE 
by means of a systematic review and meta-analysis. They concluded that a 12 
lead ECG is an inadequate screening tool for identifying patients with 
suspected HF who require echocardiography118. 
Furthermore, GPs and hospital doctors may not have sufficient skills and 
express lack of confidence in interpretation of ECG changes119•120. Clinicians 
are also doubtful as to the accuracy of interpretive ECG machines 121 . This has 
led to calls for courses on interpreting ECGs to improve GPs' skills 122. 
In summary these findings would suggest that use of a normal ECG to rule out 
HF due to LVSD may miss a significant number of patients with this condition. 
lt is likely that previous studies may not have been representative of patients 
referred by GPs with suspected HF. More research is needed to investigate 
the role of the ECG in triage of patients with suspected HF by GPs. 
Furthermore, studies of GP confidence of interpreting ECGs and educational 
initiatives to improve skills in this area are needed. With developments in 
natriuretic peptides to rule out HF, studies comparing the ECG with natriuretic 
peptides and the incremental value of using both tests are also needed. 
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1.4.8 The chest X-ray in the diagnosis of heart failure 
Patients are often referred by their GP to diagnostic clinics due to 
cardiomegaly (defined as a cardio thoracic ratio of over 50%). However, there 
is considerable doubt as to the usefulness of the chest X-ray as a diagnostic 
tool or as a means of selecting which patients to refer for echocardiography. 
Research shows that there is a poor relationship between heart size on a 
chest X-ray and left ventricular systolic dysfunction 123 and conversely 
significant LVSD may occur in the absence of cardiomegali 24. Furthermore, 
there are significant differences between GPs use of clinical information 
provided by the chest X-ray in their judgement of heart failure diagnosis77. 
Whilst pulmonary oedema with classical bats wing appearance, upper lobe 
venous diversion or redistribution, fluid in the horizontal fissures, Kerley B 
lines in the costophrenic angles with or without effusions, may be helpful signs 
in diagnosing left ventricular failure, this does not always mean the patient has 
LVSD. Furthermore, inter-observer agreement in interpretation of pulmonary 
oedema is only modest125. 
The cardiac silhouette in valvular calcification may point to aetiology, e.g. left 
atrial enlargement in rheumatic mitral disease or a calcified aortic stenotic 
valve126. 
Badgett and colleagues conducted a review of the evidence for the diagnostic 
utility of the chest X-ray for left ventricular dysfunction90. Two independent 
readers reviewed 29 studies. They found that upper lobe venous 
redistribution best diagnosed increased preload with a sensitivity of 65% (95% 
Cl 55 to 75%) and specificity 67% (95% Cl, 53 to 79%). Cardiomegaly best 
diagnosed decreased left ventricular ejection fraction with a sensitivity of 51% 
(95% Cl, 43 to 60%) and specificity of 79% (95% Cl, 71 to 85%). lnter-rater 
reliability was fair to moderate for redistribution and moderate for 
cardiomegaly. They concluded that whilst redistribution and cardiomegaly are 
the best chest radiographic findings for diagnosing increased preload and 
reduced left ventricular ejection fraction, unfortunately neither finding alone 
could adequately exclude or confirm left ventricular dysfunction in a usual 
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clinical setting. 
interpreted90. 
Furthermore redistribution was not always reliably 
In general practice the chest X-ray is useful in excluding pulmonary disease 
as a cause of symptoms and if there is evidence of cardiomegaly or vascular 
redistribution with symptoms suggestive of heart failure, the patient should be 
referred for further investigation. The chest X-ray should not be considered as 
a substitute for echocardiogram or radionuclide ventriculography127. 
1.4.9 Haematology and biochemistry in the diagnosis of heart failure 
Guidelines8•22•104•105 suggest the measurement of urea and electrolytes, 
creatinine, full blood count, thyroid function tests, serum glucose, urinalysis 
and lipids in assessment of patients with suspected or established HF. 
Anaemia may exacerbate HF and is associated with increased risk of 
morbidity and mortality128. Hyperthyroidism and hypothyroidism need to be 
excluded as a cause of HF. HF and renal dysfunction may co-exist especially 
in diabetes or hypertension. Electrolyte balance needs to be assessed and 
reviewed especially once treatment with diuretics and ACE inhibitors or ARBs 
has been started. 
1.4.1 0 Natriuretic peptides in the diagnosis of heart failure 
NICE105 and ESC guidelines 104 suggest the use of natriuretic peptides in the 
diagnostic triage of patients with suspected HF. They recommend that in 
clinical practice BNP or NT proBNP is used as a rule out test to exclude 
significant cardiac disease in primary care and in certain aspects of secondary 
care (e.g. the emergency room and clinics). The role of natriuretic peptides 
will be reviewed in detail in Chapter 5. 
1.4.11 Echocardiography and heart failure 
Echocardiography is the preferred method for the documentation of cardiac 
dysfunction at rest and is encouraged by all guidelines for the diagnosis of 
HF. Transthoracic echocardiography (TOE) is rapid, safe and widely available 
in secondary care. The process of making this test available to primary care 
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physicians has stimulated considerable debate and research and will be 
discussed in detail later in this review. 
TOE is a non-invasive technique that can be used to assess chamber 
dimensions, wall thicknesses and geometry, indices of regional and global 
systolic and diastolic function. lt also provides semi-quantitative assessment 
of valvular function 104•129. 
The most important measurement of ventricular function is the L VEF for 
distinguishing patients with cardiac systolic function from those with preserved 
systolic function. Patients with an ejection fraction less than 40% are generally 
considered to have systolic dysfunction9·10. Diastolic dysfunction is deemed to 
be present if the following three conditions are simultaneously satisfied: (1) 
presence of signs or symptoms of CHF, (2) presence of normal or only mildly 
abnormal left ventricular systolic function (LVEF ~ 45-50%), and (3) evidence 
of abnormal left ventricular relaxation, diastolic distensibility, or diastolic 
stiffness 130. This may be particularly difficult to assess in atrial fibrillation. 
However, reproducibility of LVEF among different observers is poor, even 
when the same techniques are used8·104. 
Willenheimer and colleagues 131 proposed a rapid, simplified semi-quantitative 
echocardiography method that was reliable and accurate for assessing 
systolic function and may be used as a screening tool in place of standard 
echocardiography. 
If heart failure is suspected, echocardiography is essential to clarify whether 
the patient has LVSD, to help establish aetiology and identify other cardiac 
abnormalities. Guidelines8•104, NICE guidance105 and the NSF for CHD132 
suggest echocardiography for all patients with suspected heart failure. 
However, echocardiography provision is limited by lack of trained technicians, 
cardiologists, equipment and potentially overwhelming numbers of patients in 
need of assessment. 
1.4.12 Other non-invasive tests in HF diagnosis and assessment 
Other investigations such as radionuclide ventriculography (RNVG), stress 
echocardiography, and cardiac magnetic resonance imaging (CMRI) may be 
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used in specialist centres if echocardiography at rest has not provided enough 
information and in selected patients with CAD or diagnostic uncertainty. 
RVNG has been used in some studies of HF and reproducibility of LVEF may 
be better than with echocardiography104. Stress echocardiography may be 
useful for detecting ischaemia as a cause of reversible or persistent cardiac 
dysfunction and in determining the viability of akinetic myocardium 104. CM RI is 
currently largely an experimental research tool for delineation of cardiac 
anatomy104. 
1.4.13 Systolic versus diastolic heart failure 
In recent years, various studies have suggested that diastolic HF may account 
for more than 50% of the hospitalisations for HF in elderly patients 133-135. The 
ESC has produced guidance130 on how to diagnose diastolic dysfunction (see 
under echocardiography section 1.4.11 ). Despite this others remain 
sceptical136•137 and deny the fact that diastolic abnormalities may play such an 
important role in HF or even exist, and suggest that the diagnosis of diastolic 
HF is overestimated in a large number of cases. 
lt is important to clarify terminology in this area. HF with preserved left 
ventricular ejection fraction (PLVEF) and HF because of left ventricular 
diastolic dysfunction (LVDD) are not synonymous 130. The former diagnosis 
implies the evidence of preserved L VEF and not the demonstration of left 
ventricular diastolic dysfunction. The diagnosis of LVDD requires 
echocardiographic evidence of abnormal diastolic dysfunction (see 1.4.11) 130. 
In a review of the topic Cohen-Solal138 felt it was definitely possible to have a 
history of chronic or, more often, intermittent HF, despite relatively preserved 
systolic function and that this accounted for a large number of 
hospitalisations. The concept of HF with preserved systolic function is 
probably heterogeneous and comprises cases of clearly altered diastolic 
dysfunction (hypertrophic cardiomyopathy, diabetes, hypertension, diabetes) 
as well as cases of transient HF where the combination of moderate diastolic 
dysfunction, mild systolic dysfunction, reduced compensatory mechanisms 
and precipitating factors (e.g., respiratory infection in an elderly person) 
operate altogether. For many patients with a diagnosis of heart failure but 
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preserved left ventricular function there is an alternative explanation for their 
symptoms - for example, obesity, lung disease, and myocardial ischaemia. 
These alternative diagnoses should be rigorously sought and managed 
accordingly137. 
Despite the guidelines it is clear that specialists disagree and diagnosis is 
difficult. lt is no surprise then that GPs are not familiar with the concept of 
systolic/diastolic dysfunction. In the lmprovement-HF survey, nearly 40% of 
GPs were unaware of it. As GPs are not familiar with the concept of diastolic 
dysfunction we cannot tell them to apply the results of 'evidence-based 
medicine' to the general population of HF as the diastolic dysfunction group 
are not represented in large clinical trials that enrol patients with LVSD. 
Therefore, we do not as yet have a clear effective therapy for diastolic 
dysfunction based on robust trial outcomes 138. 
1.5 What is the reality in investigation and management of HF in 
primary and secondary care? 
1.5.1 The use of diagnostic tests for suspected heart failure 
Symptoms and clinical signs often do not allow one to accurately differentiate 
between cardiac and non-cardiac causes of breathlessness (especially in the 
early stages of GP presentation and in women, elderly and obese). All 
patients with suspected heart failure should have further investigation 
including baseline blood tests, chest X-ray, ECG and echocardiography. 
Several studies in the USA, Finland and the UK have shown that a high 
percentage are falsely diagnosed in primary care when diagnosis is re-
evaluated by cardiac imaging or specialist review, with only around 40% to 
56% having L VSD or HF: 
Framingham: 40% (McKee1971 )50 
Boston: 42% (Carlson1985)96 
Kuopio: 50% (Remes 1991)71 
Dundee: 53% (Wheeldon 1993)39 
Nottingham: 56% (Ciarke 1994)41 
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Furthermore when patients with suspected HF in primary care are referred for 
open access echocardiography most do not have LVSD confirmed: 
Edinburgh: 
Darlington: 
Edinburgh: 
26% had LVSD (Francis 1995) 139 
20% significant LVSD (Murphy 1996) 140 
16% had LVSD (Davie 1997)75 
Those patients with L VSD would benefit from the introduction of evidence 
based pharmacotherapy. Although most patients investigated for suspected 
heart failure receive chest X-ray and electrocardiography only about a third 
undergoes echocardiographl8.4°·41 ·69, for which routine use has been 
advocated for optimal diagnosis8·101 ·141 . (See Table 1.8) 
Table 1.8: Use of ECG, CXR and echocardiography in the UK 
Author Year Setting Patients ECG CXR Echo 
with HF 
Parameshwar38 1992 London GP 117 89% 87% 28% 
Mair40 1996 Liverpool 266 80% 89% 30% 
GP 
Lip69 1997 Birmingham 90 68% 64% 36% 
GP 
Clarke41 1994 Nottingham 281 80% 75% 31% 
GP/Hospital 
Lip142 1997 Birmingham 260 100% 82% 34% 
GP/Hospital 
Parameshwar143 1992 London 140 98% 97% 58% 
Hospital 
Hill is 144 1996 Aberdeen 325 - - 37% 
(1992 Hospital 
data) 
Hillis 145 1996 Aberdeen 265 - - 72% 
Hospital 
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A likely reason for lower use of echocardiography in primary care is that open 
access echocardiography is not uniformly available to GPs across the UK. 
One survey confirmed only 30% of hospitals offered the service to GPs 146. 
1.5.2 Surveys of primary and secondary care diagnosis and 
management of heart failure across Europe 
There have been several large pan-European surveys in primary care and 
hospital practice that have reviewed the use of diagnostics for suspected HF 
and treatment for those with confirmed HF147-150. 
Hobbs and colleagues 147 conducted a postal questionnaire based survey on a 
random sample of 200 primary care physicians in each of 5 European 
countries (France, Germany, Italy, Netherlands and Spain) and of 250 UK 
primary care physicians. The adjusted response rate varied from 17% 
(France) to 56% (Britain). Primary care physicians generally underestimated 
the prevalence of heart failure. Most patients were diagnosed with symptoms 
and signs alone with only 32% having further investigations or referral for 
echocardiography. Although most primary care physicians stated they 
prescribed ACE inhibitors in heart failure, this was for only 47 to 62% of 
patients and at doses below those identified as effective in trials. There were 
obviously limitations of data including the general problem of questionnaires 
whether responses accord with actual clinical practice, and specific to these 
data, the low response rate in some countries 147. 
A further Euro heart survey 148•149 was conducted in 115 hospitals from 24 
European and Mediterranean countries. A total of 46,788 consecutive 
hospital admissions were screened yielding a total of 11 ,327 patients with 
suspected or confirmed heart failure. The treatment received by these 
patients over a 6 week period was analysed in 11 ,304 patients. Overall, ACE 
inhibitors were prescribed in 61.8% of patients and beta blockers in 36.9%. 
There was however marked variations in prescribing practice between 
countries. The proportion of patients receiving ACE inhibitors ranged from 40 
to 85%, while the proportion given beta blockers ranged from 10% to 65.8%. 
Age under 70 and the presence of co-morbidities such as diabetes, ischaemic 
43 
heart disease or stroke were strong predictors of the likelihood of receiving 
ACE inhibitor therapy. 
Cleland and colleagues 150 carried out a survey which included data from 
11 ,062 patients treated by 1 ,363 physicians in 15 European countries. In the 
IMPROVEMENT survey, while most physicians (approximately 60 - 90%) 
were aware of the beneficial of ACE inhibitors and beta blockers on 
prognosis, only 60% of patients overall were receiving ACE inhibitor therapy 
and only 34% were receiving beta blockers with considerable variations 
between countries. In the UK cohort 60% were receiving ACE inhibitors, 12% 
ARBs and only 26% beta blockers. Only 20% were receiving both an ACE 
inhibitor and a beta blocker across Europe. More over, even when treatment 
was given the doses used were often suboptimal. Overall, the doses 
prescribed were about 50% of those recommended in the European 
Guidelines: the proportion of patients receiving ACE inhibitors or beta 
blockers at target doses or higher ranged from 32 to 91% and 38 to 61% 
respectively. In patients with LVSD, ACE inhibitors were more likely to be 
prescribed and beta blockers less likely than in patients without evidence of 
systolic dysfunction 150. 
Review of these large surveys suggest that there is a temporal increase in 
ACE inhibitor use and to a lesser extent beta blocker use, but there is great 
variability between different countries and continuing failure to prescribe 
evidence based therapies for HF. Furthermore, even when ACE inhibitors and 
beta blockers were used these were often at sub optimal doses in relation to 
doses shown to be effective in mortality studies. 
1.5.3 Questionnaire studies of heart failure in UK primary care settings 
There have also been smaller surveys in two separate locations in England 
that have addressed GP knowledge about HF, the use of diagnostic tests and 
use of ACE inhibitors for confirmed HF. 
Mair and Bundred151 conducted a postal questionnaire in the Liverpool area. 
298 GPs were contacted and 148 replied (50% response rate). Around 40% 
of GPs were aware of the findings of major HF studies. Encouragingly 98% of 
GPs used ACE inhibitors in the management of HF, with 89% stating they 
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would initiate patients in practice. However, 38% said they only occasionally 
used ACE inhibitors. This was not in line with guidelines. Some of those 
reluctant to initiate therapy held the opinion that they wanted the patient fully 
assessed before starting treatment. This supports the view that that in order to 
optimise the treatment of HF, it will be necessary to improve access to 
diagnostic tests such as echocardiography. 70% of GPs wanted an OAE 
service but 26% did not and wanted further education on echocardiography 
use and interpretation of results. While GPs in this survey were using ACE 
inhibitors to some degree and were aware that echocardiography is a 
valuable tool the full benefits of early diagnosis and treatment of LVSD were 
not wholeheartedly perceived. The authors suggested that more emphasis be 
given to increasing awareness of recent changes in approach to management 
and encouraging a higher profile for HF in the GP setting. The low response 
rate of this survey in one locality limited the generalisability of results. 
Houghton and Cowley152 surveyed 515 GPs in the Nottingham Health District, 
with a 60.2% response rate. They found that although 39% of respondents 
underestimated the poor prognosis associated with HF, 98% were aware of 
the prognostic benefits conferred by ACE inhibitors. However, 43% expressed 
concerns about potential adverse effects associated with ACE inhibitors, the 
main fears being hypotension and renal impairment. GPs who were 
concerned about adverse effects were significantly less likely to have initiated 
an ACE inhibitor for HF than those who were not (p < 0.01 ). This study 
suggests that concerns about adverse events are a major factor in the failure 
of GPs to make widespread use of ACE inhibitors in the treatment of HF, 
despite that fact that symptomatic hypotension was seen in only 2% of 
patients started on enalapril 2.5 mgs twice daily in the SOL VD study 11 . The 
authors suggested that further research is needed to identify which patients 
are particularly at risk of adverse events when ACE inhibitors are commenced 
in the community and called for effective and practical guidelines for primary 
care use of ACE inhibitors. 
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1.5.4 Qualitative studies of heart failure in primary care 
Whilst quantitative surveys are useful in telling us about self reported GP 
behaviour in diagnosis and management of heart failure they do not generally 
provide information as to why they are behaving in that manner. Qualitative 
approaches often provide a better understanding of physician behaviour and 
decision making processes and may also provide reasons behind the 
evidence-treatment mismatch or gap in CHF diagnosis and management. 
Khunti and colleagues 153 undertook a qualitative study of heart failure 
management using semi-structured interviews with 38 GPs in 18 general 
practices in the Leicester area. Analysis was based on open coding using a 
constant comparative approach. Many GPs reported that they would diagnose 
HF on respiratory examination and a positive finding of basal crepitations. 
Many would arrange a chest X-ray to establish diagnosis and some arranged 
an ECG. A few GPs mentioned that they diagnosed HF with a trial of diuretics. 
Obstacles to diagnosis included lack of facilities for appropriate investigation 
(especially echocardiography) and lack of time and expertise. Many GPs were 
unaware of the impact ACE inhibitors can have on morbidity and mortality. 
Some stated that they would be reluctant to initiate ACE inhibitors in patients 
symptomatically stable on a diuretic already. Obstacles to management of HF 
included lack of time, inconvenience of monitoring patients on ACE inhibitors, 
high costs of drugs, difficulty with diagnosis, selection bias towards younger 
patients and not having the confidence to initiate ACE inhibitors. lt would 
appear from this study that although symptoms and signs are not sufficiently 
specific for diagnosing HF, many GPs treat patients on the basis of a clinical 
examination alone. Such findings suggest that there is a need for education of 
physicians about the benefits of newer therapies in heart failure. The authors 
recommended that further qualitative work is needed to identify barriers to the 
diagnosis and management of heart failure and methods of overcoming them 
and that specific implementation strategies need to be tailored to overcome 
obstacles. 
Hickling and colleagues 154 used a novel practice based approach combining 
the presentation of data on current management of heart failure with the 
nominal group technique to elicit and rank relevant barriers to effective 
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management of heart failure in general practice. There was a degree of 
selection and non-responder bias in that only ten of forty five eligible practices 
approached agreed to participate and all were part of the Medical Research 
Council General Practice framework practices in the North Thames region. 
This raises questions about generalisability to non-research practices in other 
areas of the UK. Of the 674 patients requiring investigation, only 34% were 
referred for echocardiography and only 47% with probable heart failure were 
prescribed ACE inhibitors. The barriers for the effective management of heart 
failure in general practice were thought to be complex. The main barrier to 
the use of echocardiograms in diagnosis of heart failure was lack of open 
access. The main barrier to the use of ACE inhibitors in treating heart failure 
was GPs concerns about the possible adverse effects. This study used a 
different approach to Home and colleagues who used structured qualitative 
interviews and Houghton and colleagues who used a quantitative 
questionnaire methodology. Identification of barriers to the application of 
research evidence using qualitative methods are essential if practice is to be 
improved and the authors felt that further research in this area was 
necessary154. 
Home et al155 used structured face to face interviews to elicit the views of a 
stratified representative sample of 1 00 GPs working in England and Wales 
about the diagnosis and treatment of heart failure. Questionnaire items were 
based on previous open interviews with 11 GPs and 4 hospital physicians and 
formulated by qualitative content analysis techniques. Responses to three 
heart failure case vignettes provided an indication of the degree to which GPs' 
knowledge of HF and trial results might be applied to diagnosis and treatment 
intentions. Participants were generally aware of clinical trials that showed 
prognosis could be improved by treatment, but trial results appeared to have 
little influence on treatment intentions in the three case scenarios. The major 
barriers to optimum management were the difficulties in securing a confident 
diagnosis of HF and the perceived properties of ACE inhibitors relative to 
diuretics. In the case scenarios, less than 30% reported that they would 
undertake basic investigations, such as a CXR, ECG or haemoglobin. Over 
70% relied on the patient's response to diuretics to confirm diagnosis. The 
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most frequent reasons for not prescribing ACE inhibitors were the perceived 
inconvenience in monitoring patients; the risk of adverse events (41%) and 
the view that most patients can be managed successfully on diuretics alone 
(27%). 83% of the sample was dissatisfied with the quality of information 
accompanying HF patients discharged from hospital. The results of this study 
strengthen the case for development of a collaborative model of care that 
delivers diagnostic tests and improves communication. Further support for 
GPs in the form of additional training in the diagnosis of HF and the optimum 
use of both ACE inhibitors and diuretics are needed. 
1.5.5 Summary of studies 
A number of patient or physician related factors may contribute to the under 
utilisation of heart failure therapies. Physician's perceptions of the risks and 
benefits of different therapies may influence the extent to which guidelines are 
adopted. Physicians may be reluctant to adopt new treatment approaches for 
a variety of reasons including lack of education, conservative attitudes to 
therapy, concerns about potential side effects of treatments, the complexity of 
therapy, avoidance of polypharmacy as well as lack of access to facilities to 
confirm the diagnosis of heart failure and a continuing emphasis on 
symptomatic treatment rather than using therapies with proven effects on 
prognosis. 
1.6 Availability and use of Echocardiography and diagnostic services 
for heart failure 
1.6.1 Introduction 
The NSF for CHD132 details alternative models of care which will be 
dependent on local circumstances and may include specialist one stop HF 
clinics, mobile echocardiography units, or intermediate care facilities provided 
by suitably trained and accredited GPs. Above all equity of access to all 
patients in a locality should be ensured. The following sections outline models 
that have been developed in selected UK locations and attempts to expand 
upon the relative merits of each. 
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1.6.2 Open access echocardiography 
1.6.2.1 Definition of open access echocardiography (OAE) 
Chambers et al defined OAE as echocardiography requested by a GP without 
prior assessment by a cardiologist, and produced guidelines for referral to an 
OAE service156. A non-invasive test that has the power to bridge the divide 
between community and hospital may open up the possibility of more varied 
patterns of care for patients, especially as diagnosis of heart failure in the 
early stages of disease may be difficult for GPs 157. 
1.6.2.2 Open access echocardiography studies in the UK 
Five observational cohort studies from the UK have been published, and 
Khunti has recently conducted a systematic review158. 
Francis and colleagues 139 report their experience of an OAE service in 
Edinburgh where GPs referred patients with HF or suspected HF using a 
clinical pro-forma. In a 5 month period 259 consecutive patients were seen. 
119 had already been treated for HF, 99 were untreated with symptoms and 
signs of HF and 9 asymptomatic with risk factors for LVD. 
In this study echocardiography was combined with a cardiology registrar-
based clinical assessment including further investigations performed by 
attendant medical staff. Advice on treatment was recommended. Strictly 
speaking this paper does not truly reflect an OAE service with 
echocardiogram performed and reported by a technician or clinician. 
Furthermore the conclusion that echocardiography led to advice about a 
change in treatment in 70% of patients with established or suspected HF as 
diagnosed by GPs is misleading. Their 70% represented 82 of 119 patients 
receiving treatment when referred. However, this figure should include those 
14 in the suspected HF group (n = 99) for whom the cardiologist advised a 
change in management. This would have made the true proportion of 
echocardiograms resulting in advice 44% (96/218). Generalisability of results 
was further limited by the poor uptake rate by GPs (17% [93/550]). 
Murphy and colleagues 140 introduced an OAE service that was piloted to 24 
GPs in 5 practices in Darlington. The service was audited after 250 cases 
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(mean age 71; range 16-92) referred over 22 months. The impact on clinical 
management was assessed by reviewing GP notes two months after the 
echocardiogram. Significant impairment of left ventricular function was found 
in 49 patients (20%) and significant valve disease in 20 (8%). 38 (78%) of the 
49 L VSD patients identified by OAE had been started on ACE inhibitors by 
their GP and 14 (70%) of the 20 valve lesion patients had been referred for 
cardiology assessment. The provision of an OAE service with simple 
guidelines for use was popular with GPs and the information resulted in 
appropriate management decisions being made. Following this pilot study the 
service was extended to all GPs in the locality. 
Sandler and colleagues 111 reported on the first 18 months of an OAE service 
for GPs in the Chesterfield area. A difference in this study from the Darlington 
and Edinburgh services was that apart from referral indications of suspected 
HF and unexplained breathlessness (68%), patients with atrial fibrillation and 
a heart murmur were accepted. 486 patients (mean age 68; range 13-94) 
were seen over 18 months within a mean time of 49 days (range 3 to 97 
days). LVSD was noted in about 40% of cases referred with suspected heart 
failure. Those with AF or heart murmurs were more likely to have 
abnormalities (74% and 46% abnormal respectively). Interestingly of the 
patients with suspected HF or breathlessness 27% with a normal ECG were 
found to have L VSD; a finding that contradicts guidelines that suggest that 
patients with a normal ECG are very unlikely to have LVSD. Uptake of the 
service was variable with individual GPs requesting between 1 to 27 studies in 
the 18 months. 
Lindsay and colleagues 110 reported an OAE service for suspected HF or 
dyspnoea in Glasgow. 416 patients (265 females) were referred over a 3 year 
period from 1995-1997. Overall 23% (n = 95) had impaired left ventricular 
function and 3% (n = 12) had a significant valve lesion. An important finding 
was that 60% were being treated for presumed HF with an ACE inhibitor, 
diuretic or both. However, the study showed that 73% were probably receiving 
inappropriate therapy; although it is possible they needed treatment for eo-
morbidity such as hypertension. This study and others (Sandler) found 
differences between sexes in prior treatment and referral patterns. Women 
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accounted for the majority of referrals, most of who had normal left ventricular 
function and yet were on treatment. lt is not entirely clear what the explanation 
for this is, although it may be related to the increased presence of non-cardiac 
oedema and obesity in women. A further finding of this study was the high 
NPV (96%) of a normal ECG in excluding HF. The combination of a normal 
ECG and no history of Ml increased the NPV to 99% and Lindsay and 
colleagues suggest that this could have utility in reducing the number of 
unnecessary echocardiograms if used by GPs to screen patients with 
suspected H F. 
Sim and Davies 159 reported an OAE service in Newport, Wales. Data was 
presented on the first 200 patients referred within 13 months. As with the 
Darlington service this service was introduced through educational meetings 
and the presentation of a referral guideline. Guidelines were followed in 94% 
of referrals and 90% were seen within 14 days. LVSD was found in 12% (n = 
22) and significant valvular lesions in 14% (n = 24). Uniquely the authors then 
showed high levels of patient and GP satisfaction with the service by way of a 
questionnaire. GPs indicated that they would have referred 87% of the 
patients to the hospital if OAE was not available compared to the 11% who 
were actually referred to hospital. Crude cost analysis based on this showed 
the service to be cost effective. 
1.6.2.3 Discussion of open access echocardiography services 
There has been considerable debate around the various strategies to deliver 
essential echocardiographic diagnosis of HF and subsequent treatment for 
those with LVSD157•160-166. In particular secondary care has expressed 
concerns about over referral to already "strained systems"167. Despite these 
worries the above mentioned studies have demonstrated that GPs use open 
access services appropriately111 '139•140•159. 
Review of these OAE services suggests that benefits include the potential to 
deliver early, accurate diagnosis of HF and identify important valvular lesions; 
initiate appropriate evidence based treatment139•140; and withdraw 
inappropriate medications 111 •139•159. Furthermore, this may reduce the burden 
on secondary care outpatient services and is likely to be cost 
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effective156•159•168•169. Senni and colleagues170 demonstrated that the under 
use of echocardiography appears to be associated with poorer survival and 
under use of ACE inhibitor therapy in a US population. In a Cumbrian cohort 
Toal et al44 also demonstrated that patients who had an echocardiogram were 
much more likely to be on an ACE inhibitor. lt should be remembered that 
negative results can be reassuring and management of the patients' problems 
may well have been made easier for GPs 163. 
Despite these potential benefits there have been some cautionary comments. 
Saltissi and Chambers 171 felt that echocardiography in the community needed 
quality control and felt that expansion of services may be limited by lack of 
adequately trained technicians. Chambers 156 warned that whilst OAE may 
improve the management of more patients than can be accommodated within 
the current system, at worst it could deprive some patients of a specialist 
cardiological opinion. Furthermore Khunti158 called for rigorous cost 
effectiveness evaluation of OAE services within other models of care including 
primary care HF nurse clinics or consultant led direct access HF clinics, 
before widespread establishment of OAE could be recommended. Where 
OAE is deemed the most appropriate local system, standardization of referral 
forms, and clinician generated reports incorporating treatment suggestions 
needs to be provided. 
lt has been suggested that the correct interpretation of echocardiographic 
information in a clinical context can only come from history, examination and 
other investigations. Furthermore, the introduction of newer therapies such as 
beta blockers, and new indications for older therapies such as spironolactone 
has made HF a therapeutically complex area to treat and is likely to be out 
with the expertise or comfort zone of most GPs. Partly because of this 
specialist heart failure clinics have been proposed as a benchmark of optimal 
diagnosis and care172. 
1.6.3 Specialist heart failure clinics 
1.6.3.1 An introduction 
Specialist clinics caring for patients with other common chronic disorders such 
as asthma, hypertension and diabetes are common in both primary and 
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secondary care, but few patients with HF are cared for in such clinics. There 
is observational data which suggests that patients managed in a specialist 
heart failure clinic may have improved outcomes in terms of accuracy of 
diagnosis, initiation of evidence based therapies and possibly reduced 
mortality, morbidity and hospitalisations 172"175. 
There appear to be many differing models reported in the literature. These 
include rapid access diagnostic clinics situated in secondary care and run by 
clinicians; secondary care medical clinics for ongoing management in patients 
with previously confirmed HF (invariably diagnosed during hospital 
admission); clinics set up in secondary care (and one report of a research 
clinic in primary care) as part of research projects to assess a particular 
aspect of HF management; nurse-led clinics in secondary care to optimise 
HF therapies and bridge the gap between secondary care and the community; 
and recently protocol-driven HF clinics staffed by nurses and pharmacist 
specialists. 
1.6.3.2 Secondary care heart failure clinic models 
Fox and colleagues 172 reported the success of a rapid access secondary care 
heart failure clinic in South East London serving a 290,000 population. Over a 
15 month period patients were seen usually within 24 hours of referral by a 
GP. There were 0.4 referrals per 100,000 per weekday in which 178/383 
(46%) were felt to have definite or possible HF at initial assessment and 
101/383 (21%) were found to have LVSD. 98% of these patients were started 
on an ACE inhibitor. High uptake of ACE inhibitors (80%) was also seen in a 
similar clinic in Nottingham, with Houghton and colleagues 174 also stressing 
the importance of the clinic in stopping inappropriately started medications 
including ACE inhibitors. The strength of this model lies in the fact that it 
focuses on suspected first presentation of HF rather than known HF in the 
belief that the maximum benefit for individual patients was in correctly making 
a diagnosis, defining aetiology and starting appropriate therapy, rather than 
making adjustments to existing therapies. A weakness was the fact that no 
patient education was delivered and no mention of structured follow up of 
patients after initiation of therapy was made. Referral back to the GP cannot 
be assumed to deliver evidence based therapy at target doses. 
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Galatius and colleagues 176 reported a diagnostic and therapeutic HF clinic in 
Copenhagen. Over a 21 month period 460 patients were referred, with 320 
(70%) having clinical HF and of this group 88% (n = 283) had LVSD (defined 
as LVEF s 45%). The majority of patients were started on ACE inhibitors and 
beta-blockers but importantly there was a 23% decline in HF related hospital 
admissions during the first year of the operation of the clinic. lt is not possible 
to determine whether there were any confounding factors that contributed to 
the fall in hospitalisation and it cannot be assumed that this was purely due to 
the introduction of a HF clinic model locally. 
Gates and colleagues 173 conducted a retrospective audit of 100 patients with 
confirmed LVSD attending a heart failure clinic in secondary care. Median age 
was 72 with a range of 50 to 87 years. They found that 74% were on an ACE 
inhibitor and 15 % on an ARB or vasodilator. Average length of survival from 
the first clinic attendance was 5.3 years for females and 2.97 years for males. 
Hospitalisation rates were 0.7 +/- 0.1 admissions per patient per year with a 
length of stay in hospital of 11.8 +/- 2 days for women and 10.5 +I- 2.2 days 
for men. This data suggest that attendance at a specialist heart failure clinic 
ensures optimisation of evidence based medication, reduces patient 
admission rates and duration of hospital stay. Strength of this approach was 
the emphasis placed on patient education, including a reinforcement of the 
need for strict adherence to treatment regimens. 
Introduction of evidence based therapies have been shown to be increased by 
attendance at a specialist clinic. McMullan and Silke 177 compared the rate of 
low-dose spironolactone among patients with HF in a general medical 
inpatient setting and in a specialist left ventricular dysfunction clinic in Belfast. 
38% of general medical patients and 72% of those attending the L VD clinic 
had been prescribed spironolactone. When contraindications were 
considered, more patients in the LVD clinic were treated with spironolactone 
(77% vs. 54%). 
1.6.3.3 Primary care heart failure clinics 
There are no reports of ongoing formal heart failure clinics in primary care 
although McCallum and colleagues70 set up a research funded clinic to 
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investigate whether SIGN guidelines on heart failure could be implemented in 
general practice. Of 67 patients referred for an echocardiogram 41% (n = 28) 
had LVSD. Only 58.3% of these were initially on an ACE inhibitor or ARB but 
after one year this had risen to 90.5%. Although only 22.7% were taking a 
beta-blocker at presentation, the study did not report any alteration to this 
figure after a year. 
1.6.3.4 Nurse-led heart failure clinics 
Sweden seems to be the leading nation in terms of introduction of nurse-led 
heart failure clinics, with 148 heart failure nurses in 69% of 86 hospitals. 
Within the Swedish system nurses integrate care between hospitals and the 
community and are able to titrate and alter medication based on standard 
protocols 175,178,179. 
Whilst the large majority of clinics have been observational studies Stromberg 
et al180 report a small prospective, randomised trial in Linkoping, Sweden to 
evaluate the effect of follow up at a nurse-led HF clinic on mortality, morbidity 
and self-behaviour for patients hospitalised due to HF for 12 months after 
discharge. A total of 106 patients were randomly assigned to either nurse-led 
HF clinic follow up or to usual care. There were fewer patients with events 
(death or admission) after 12 months in the intervention group compared to 
the usual care group (29 vs. 40, p = 0.03). The intervention group had fewer 
admissions (33 vs. 56, p = 0.045) during the first 3 months, and after 12 
months a 55% decrease in admissions per patient per month (0.18 vs. 0.40, p 
= 0.06) and fewer days in hospital/patient/month (1.4 vs. 3.9, p = 0.02). The 
intervention group had significantly higher self care scores at 3 and 12 months 
compared to the control group. Hence follow up after hospitalisation at a 
nurse led HF clinic can improve survival and self-care behaviour in patients 
with HF as well as reduce number of events, readmissions and days in 
hospital. This small trial needs repeating in a geographically different and 
larger cohort of patients before results can be considered to be generalisable 
to all HF populations. 
A small Scottish study studied the role of the nurse specialist. Smith and 
lrving 181 assessed the effectiveness of a nurse specialist in managing HF 
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patients in the community by conducting a before and after study. They 
compared out patient attendances and hospital re-admissions to hospital for 
the two years (April 1995-97) before the service started compared with the 
two years afterwards (April 1997-99). 61 patients with severe HF were 
enrolled. 28 died within the study period. Of those surviving total re-
admissions (bed days used) were reduced from 605 to 270 days and 
outpatient clinic attendances fell from 168 to 60. There was not a control 
group and it is therefore impossible to conclude that these results were not 
due to other confounding factors e.g. increased uptake of evidence based 
therapies that have been shown to reduce hospitalisations over the time 
period studied. 
Initiation of beta blockers in patients with LVSD is likely to need specialist 
support or attendance at protocol driven clinics. In another Swedish study in 
Goteborg, Andersson and colleagues 182 evaluated the outcome of drug 
titration in 418 patients referred to a nurse-run clinic from 1995 to 2001. 
Throughout that period most patients were discharged on ACE inhibitors and 
beta blockers. In particular beta blocker use increased during the observation 
period from 43% to 88%. Furthermore patients started on ACE inhibitor 
therapy continued taking therapy in 89% and in 95% when started on beta-
blockers. Three year mortality was reduced from 27% to 1 0% and in 
multivariable analysis survival was associated with higher ejection fraction, 
better renal function, beta blocker and ACE inhibitor use and negatively with 
digoxin therapy. As well as showing that nurse-directed titration succeeded in 
introducing more patients on beta blockers than ACE inhibitors, mortality was 
reduced during the study period. These findings suggest the observed 
benefits of beta blockers and ACE inhibitors in randomised clinical trials can 
be reproduced in everyday clinical practice through efficient medical 
treatment. 
1.6.4 Multidisciplinary heart failure management programs 
1.6.4.1 An introduction 
Whilst such clinics may improve outcomes for patients with heart failure they 
are likely to be part of a multidisciplinary heart failure management program. 
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There have been many such studies reported over the past decade and 
several meta-analyses and systematic reviews published summarising the 
available data183-186. Stewart and Blue edited the first textbook187 to cover this 
area and is unique in that it goes beyond the usual consideration of diagnosis 
and management by standard textbooks, to focus on the way to organise care 
the patient receives from an international perspective. The contributors to this 
book represent the multidisciplinary collaboration that is the hallmark of 
effective care in a HF population. 
1.6.4.2 Some examples of multidisciplinary programs for heart failure 
Rich and colleagues 188 contributed the first and also one of the larger and 
better designed case-control studies of the impact of bridging hospital and 
community care with cardiac nurse practitioners. This prospective trial 
involved 282 patients randomised to either a broad multidisciplinary 
intervention (n = 142, mean age 80 years) or usual care (n = 140, mean age 
78 years). The intervention included patient education about CHF, dietary 
assessment, counselling, social service involvement and intensive targeted 
cardiology follow up including treatment optimisation. The primary outcome 
measure was survival for 90 days without hospital readmission. This was 
achieved in 91 patients in the intervention group and 75 patients in the control 
group, a result that did not achieve statistical significance (p = 0.09), However, 
there were 94 readmissions for any reason in the control group with 53 in the 
treatment group (p = 0.02), and 54 readmissions for HF in the control group 
compared with 24 in the intervention group (p = 0.04). Patients in the 
intervention group had a higher quality of life and used fewer hospital 
resources leading to cost savings. Whilst this may be considered a modest 
impact it was suggested that wider use of such an intervention could 
substantially reduce healthcare costs for CHF patients. 
Blue and colleagues 189 conducted the only UK randomised controlled trial of 
specialist nurse intervention to date in Glasgow. 165 patients admitted with 
HF due to LVSD were randomised prior to discharge to an intervention group 
(n = 84) or usual care group (n = 81). The intervention included a number of 
planned home visits of decreasing frequency, supplemented by telephone 
contact as needed for up to one year. The main outcome measure was time 
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to first analysis of death from all causes or readmission to hospital with 
worsening heart failure. 31 patients (37%) in the intervention group died or 
were readmitted with HF compared with 45 (53%) in the usual care group 
(hazard ratio= 0.61, 95% Cl 0.38-0.96). Patients in the intervention group had 
fewer readmissions for any reason (86 vs. 114, p = 0.018), fewer admissions 
for HF (19 vs. 45, p < 0.001) and spent fewer days in hospital for HF (mean 
3.43 vs. 7.46 days, p = 0.0051). Home visiting seems to be pivotal to reducing 
admissions, perhaps by ensuring regular and effective patient contact. This 
study conducted in a city with high cardiovascular prevalence suggests that 
home based interventions from trained nurses reduce readmissions and 
should be considered as part of any effective HF service. 
1.6.4.3 Systematic reviews of multidisciplinary programs for heart 
failure 
The first two reviews by Rich 183 and McAiister and colleagues 184 concluded 
that disease management programs for the care of patients with heart failure 
that involved specialised follow up by a multidisciplinary team reduce 
hospitalisations and appear to be cost saving. McAiister et al 184 included 11 
trials involving 2,067 patients in their review. However, they felt that trials were 
too short (maximum follow-up 12 months) to show clear effects on mortality 
(RR = 0.94, 95% Cl 0.75 to 1.19). Both reviews called for further studies to 
establish the incremental benefits of the different elements of these programs. 
Phillips and colleagues 185 revisited this area and included 18 studies from 8 
countries randomising 3304 older inpatients with CHF to comprehensive 
discharge planning plus post discharge support or usual care. Fewer 
intervention patients were readmitted compared with controls (555/1590 vs. 
741/1714, NNT = 12, RR 0.75, 95% Cl 0.64-0.88). Analysis of studies (n = 14) 
reporting secondary outcomes found a trend toward lower all cause mortality 
for patients in intervention groups compared with usual care (RR 0.87, 95% Cl 
0.73 -1.03). Furthermore quality of life measures improved in the intervention 
group compared to baseline scores and there were similar or lower costs for 
medical care. The authors concluded that reduction in risk of readmission, 
trend towards improved survival, improvement in QOL, and potential cost 
savings had important implications for system change, health outcomes, and 
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resource utilisation for older patients with CHF. They recommended that the 
evidence supports routine application of comprehensive discharge planning 
plus post discharge support for older patients with CHF to optimise the 
transition from acute hospital care to home. 
A more recent British review by Holland and colleagues 186 identified 7 4 trials, 
of which 30 contained relevant data for inclusion in a meta-analysis. 
Multidisciplinary interventions reduced all cause admission (RR 0.87, 95% Cl 
0.79 to 0.95, p = 0.002). Importantly the inclusion of a further 11 randomised 
controlled trials since the Phillips report meant that all cause mortality was 
also reduced (RR 0.79, 95% Cl 0.69 to 0.92, p = 0.002) as was heart failure 
related admissions (RR 0.70, 95% Cl 0.61 to 0.81, p < 0.001). The 
conclusions are that it is possible to achieve major reductions in admissions 
and deaths of patients with HF by implementing post-discharge interventions 
delivering education and symptom self management. These interventions 
appear to be particularly effective when they are at least partly delivered in a 
patient's own home through visits, telephone calls, or more advanced 
telemonitoring or televideo techniques 190• 
1.6.4.4 Summary and future research suggestions 
Clark and Cleland191 suggest that in the UK setting whilst there was some 
formal recognition of the possible worth of heart failure nurses with 
enthusiastic developments of their roles in some areas; uptake was patchy 
and dependent in large part on the enthusiasm of a heart failure specialist in a 
local hospital. They pointed out that in many parts of the UK there are not 
enough cardiologists to serve the population, and certainly no heart failure 
cardiologist to support such a demanding new role. They felt that HF remains 
the "Cinderella of cardiology" and called for a National Service Framework for 
Heart failure with specific targets as a priority. However, they did not mention 
that it need not be a cardiologist that fronts HF services and the possibility of 
a general physician or GP specialist with an interest in heart failure may be 
equally feasible. 
lt is clear from this review of various clinics and multidisciplinary interventions 
that there are a variety of approaches with some concentrating on rapid, 
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accurate diagnosis and others on optimisation of therapies and patient 
support. A challenge for clinicians involved in the care of patients with HF will 
be to develop models of care that achieve expedient diagnosis, and offer 
systematic structured follow up. Such models need to be developed across 
the primary-secondary care interface and studies designed to study the cost 
effectiveness of introduction in different settings. Further research is needed 
to compare the impact of different models including open access 
echocardiography, hospital based and primary care based specialist clinics in 
achieving accurate timely diagnosis and evidence based treatment as well as 
improvements in QOL, morbidity, hospitalisations and mortality. 
1. 7 Treatment of heart failure 
The following section will review the evidence base behind treatment options 
for CHF from a GP perspective, although all clinicians and allied health 
professionals responsible for the optimal management of patients with CHF 
should be familiar with these treatments. 
Although the drug treatment of HF is supported by good quality randomised 
controlled trials, patients in clinical trials of HF often differ from those we see 
in everyday practice192. Applying the results of trials to older people may be 
limited by the age of the populations studied. Patients included in trials are 
often younger than the predominant HF population and are less likely to have 
co-morbidities, renal impairment and be on polypharmacy193. 
1. 7.1 Aims of treatment for heart failure 
The aims of treating HF are broadly similar in all published guidelines and 
summarised by the NSF for CHD132 as improving quality of life of patients by: 
• Improving symptoms or slowing their deterioration 
• Reducing mortality 
• Reducing the frequency of cardiac events and admissions to hospital 
• Avoiding adverse events from treatment, and 
• Improving end-of-life experiences 
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1. 7.2 Prevention of heart failure 
1. 7 .2.1 Improving the outlook for heart failure 
As with any chronic condition, prevention of CHF is better than treating the 
disease. While this is never going to be fully achievable, targeting those 
patients at highest risk of CHF (such as patients with previous Ml or with 
hypertension) is the most practical way of trying to tackle this problem. 
Drugs that tackle the underlying risk factors for CHF (such as hypertension) 
are one approach to the management of CHF, and drugs that help reduce left 
ventricular abnormalities including remodelling, (often detected by a reduction 
in the left ventricular ejection fraction (L VEF)) can improve the quality of life 
and life expectancy of these patients by slowing the progression to chronic 
heart failure. As will be discussed in this section of this review, many drugs 
have the ability to act in this way. For example, beta-blockers, ACE inhibitors 
and angiotensin recaptor blockers (ARBs) all reduce blood pressure but have 
additional benefits in patients already showing left ventricular damage or 
symptoms of CHF. 
Recommendations for treating patients with CHF and reduced left ventricular 
function are clear. In the NICE guidelines, ACE inhibitors are recommended in 
all patients with CHF due to left ventricular systolic dysfunction before the use 
of beta-blockers 105. Similarly, the American College of Cardiology and 
American Heart Association recommend the use of ACE inhibitors in all post-
MI patients regardless of LVEF and in all patients with reduced LVEF in the 
presence or absence of heart failure symptoms 194. 
Taken together, these recommendations highlight the central importance of 
ACE inhibitors in the prevention of CHF, the prevention of CHF progression 
when early signs are present, and the management of symptomatic CHF. 
However, recommendations do not always convince physicians and patients 
(as is evident with the under use of anti-hypertension treatments) because the 
evidence supporting them can be weak, contradictory or unclear. In the case 
of ACE inhibitor use in CHF management, this accusation cannot be made as 
there is now a solid, and growing, base of evidence that supports them as a 
first-choice drug. 
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1. 7 .2.2 ACE inhibitor use can reduce the risk of heart failure 
A number of well designed, large-scale studies have demonstrated the 
benefits of ACE inhibitors in different patient groups. 
The benefit of ACE inhibitor use in patients who do have left ventricular 
dysfunction is also well established. Several years ago, the SOLVD trial 
showed that ACE inhibitors (enalapril) improved survival of patients with 
reduced LVEF and CHF11 . Although no reduction in mortality was observed in 
patients with reduced LVEF but no CHF, ACE inhibitor use did reduce the risk 
of heart failure or Ml195. After 12 years however, patients in both groups who 
had received an ACE inhibitor had lower death rates than those who had not 
received an ACE inhibitor196. 
In the PROGRESS trial197, patients with no evidence of heart failure or left 
ventricular dysfunction but with previous cerebrovascular disease were given 
an ACE inhibitor (perindopril) ± indapamide or placebo. After approximately 4 
years, patients receiving perindopril ± indapamide not only experienced less 
recurrent stroke (28% reduction) and non-fatal Ml (38% reduction), but they 
also had a 26% reduction in the risk of heart failure. The reduction in the risk 
of CHF was evident in patients who had hypertension and in those who did 
not have hypertension. 
Similarly, in patients with coronary heart disease but no left ventricular 
dysfunction, the ACE inhibitor ramipril was shown to reduce the risk of a range 
of cardiovascular diseases and specifically reduced the risk of new onset 
heart failure by 23% and the risk of hospitalization for heart failure by 12%198. 
This reduction was observed after approximately 5 years in patients at high 
risk of CVD but whose average blood pressure was in the normal range. 
However, there is also excellent evidence to show that ACE inhibitors 
(perindopril) reduce CHF in patients at a much lower risk. In the EUROPA 
trial199 of patients with stable coronary heart disease, the risk of hospitalization 
for heart failure was reduced by 39% after approximately 4 years of ACE 
inhibitor use. ACE inhibitors also contribute to BP reduction and this may 
assist in the management of heart failure200. 
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1.7.2.3 Summary of prevention of heart failure 
A large body of evidence and all national treatment guidelines emphasise the 
benefits of ACE inhibitors in prevention of heart failure and the prevention of 
progression of the disease. Since these benefits are seen in virtually all 
patients with heart failure or at risk of heart failure, and given the excellent 
safety of ACE inhibitors, this is an important message. Early identification of 
at-risk patients and early treatment with ACE inhibitors and beta-blockers is 
the optimum course of action. The only note of caution is that all ACE 
inhibitors may not be the same and careful selection of the correct drug is 
essential. Post-M I mortality rates have been shown to differ with different ACE 
inhibitors (ramipril and perindopril were associated with lower mortality than 
other ACE inhibitors)201 , and future evidence may help point towards even 
more specific recommendations for the use of ACE inhibitors in CHF. Likewise 
beta-blockers that have been shown to have benefits in CHF (carvedilol, 
bisoprolol and metoprolol) should be preferred to those that have no evidence 
for use for this indication {propranolol, atenolol) or indeed may worsen 
outcomes (bucindolol)202• 
GPs have a vital role to play in early detection and treatment of the main risk 
factors for HF which may help to prevent progression to HF. By provision of 
CHD clinics in primary care GPs can address post Ml care, lifestyle 
modification, the treatment of hypertension, IHD and diabetes, smoking 
cessation and hyperlipidaemia. Identifying patients at risk of developing HF 
and initiation of ACE inhibitors, in particular may help prevent development of 
HF. Campbell and colleagues203 in a paper describing a randomised 
controlled trial of CHD clinics in primary care demonstrated that health 
outcomes can be improved and commented that primary care can develop 
holistic, structured, systematic primary and secondary care preventative 
services which diminish the need for more expensive hospital care in the 
future. 
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1. 7.3 Non-Pharmacological treatments for heart failure 
1. 7 .3.1 Do lifestyle changes improve heart failure? 
Whilst pharmacotherapy remains the cornerstone of CHF management, non-
pharmacological interventions may be useful in improving symptoms. 
Smoking and cardiovascular disease are integrally linked. Although little direct 
evidence on prognosis in heart failure exists, patients should be encouraged 
to stop smoking. Alcohol should be avoided in alcoholic cardiomyopathy, but 
moderate alcohol intake is permissible in LVSD due to other causes. Salt 
intake should be controlled especially in moderate to severe heart failure 102. 
Overweight patients should be encouraged to lose weight. Conversely, 
cardiac cachexia is a poor prognostic sign and should be addressed with the 
help of a dietician. All patients with LVSD should be offered pneumococcal 
and influenza immunisation 102. 
1. 7 .3.2 Exercise training and cardiac rehabilitation 
Exercise training, especially as part of a comprehensive cardiac rehabilitation 
programme, can increase exercise capacity, improve quality of life and muscle 
de-conditioning in stable heart failure patients, and should be encou.raged204. 
A recent meta-analysis (ExTraMATCH) also confirms exercise training 
reduces mortality and hospital admissions in patients with CHF205. There 
appears to be no evidence that properly supervised medical training 
programmes for patients with HF may be dangerous. Further research is 
needed in identifying appropriate groups of patients to targef05. 
1.7.4 Avoidance of detrimental drugs and polypharmacy in patients 
with heart failure 
Clinicians should review medication carefully in the assessment of all patients 
with HF and exercise caution in prescribing certain groups of drugs to these 
patients. Studies have shown that NSAIDs can cause CHF in susceptible 
individuals206 or lead to deterioration of renal function if eo-prescribed with 
ACE inhibitors207. Other drugs that should be used cautiously include rate 
limiting calcium channel blockers (Verapamil, Diltiazem), corticosteroids, 
flecainaide, nifedipine and tricyclic antidepressants208. 
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With the rise of polypharmacy GPs are increasingly faced with complex drug 
regimes that may make potentially troublesome drug-drug interactions more 
likely. This rise is due to various factors including increasing elderly 
populations with chronic conditions; increasing evidence based therapies for 
conditions such as HF, hypertension and IHD; increase in preventive 
treatments for IHD, osteoporosis; lower thresholds for treating hypertension, 
hyperlipidaemia and diabetes; and increased use of over the counter and 
complementary therapies. This means that GPs will need to review patients 
and rationalise drug regimens regularly. Polypharmacy may also contribute to 
under prescribing and under-dosing of appropriate treatments in HF. 
1. 7.5 Pharmacological therapies for heart failure 
There have been several major systematic reviews and guidelines from the 
UK, Europe, the US and Canada that have been presented as guidelines for 
the management of HF8-10•22•101 •102•104•141 . They provide clear 
recommendations for diagnosis and the appropriate use of evidence based 
pharmacotherapy. The following sections with outline these treatments. 
1. 7 .5.1 Diuretics 
Loop diuretics have been used in the management of heart failure for many 
years and provide rapid symptomatic relief. Despite the extensive clinical use 
of loop diuretics in heart failure, there are no large clinical trials on the effects 
on mortality. Faris and colleagues209 reviewed the current evidence 
supporting the role of diuretics in HF and identified 18 eligible small 
randomised controlled studies for meta-analysis (patient number = 928). 
Compared to active control, diuretics appear to reduce the risk of worsening 
disease and improve exercise capacity. Furthermore, conventional diuretics 
reduce the risk of death and worsening HF compared to placebo. 
Diuretics should be considered for patients with signs and symptoms of water 
retention, but renal function will need to be monitored regularly and the dose 
should be kept to the lowest effective dose. 
1.7.5.2 Angiotensin converting enzyme inhibitors 
1. 7 .5.2.1 Introduction 
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The Angiotensin-converting enzyme (ACE) inhibitors have been a major 
development in the treatment of heart failure. The benefits of ACE inhibitor 
therapy for HF have been established by large-scale clinical trials and several 
systematic reviews have summarised these trials and clinical benefits210·211 . 
1.7.5.2.2 Major trials of ACE inhibitors in HF 
The Munich mild heart failure trial212 in 1992 enrolled 170 patients with LVEF 
s 35% to captopril or placebo and showed a non significant reduction of 
deaths (4.8% vs. 12.6%; p = 0.1 0) and a reduction in progression to severe 
HF (10.8% vs. 26.4%; p = 0.01). This was one of several small trials that 
paved the way for several larger, major mortality trials in patients with HF, 
asymptomatic LVSD and following myocardial infarction. (See Table 1.9) 
Table 1.9: Major Trials of ACE-Inhibitors in HF 
Patients Mean NYHA LVEF Effects on all-cause 
(n) Follow-up Class (%) mortality 
HF 
CONSENSUS 253 188 days IV N/A All-cause mortality: 
(enalapril) At 6 months J.. 40% (p=0.0022) 
SOL VD- 2569 3.4yrs 11-111 :::;35 All-cause mortality: 
Treatment J.. 16% (p<0.0036) 
(enalapril) 
SOL VD- 4228 3.1yrs N/A :::;35 All-cause mortality: 
Prevention J.. 8% (p=0.30) 
(enalapril) 
Post-MI HF 
SAVE 2231 3.5yrs N/A :::;35 All-cause mortality: 
(captopril) J..19%(p=0.019) 
AI RE 2006 1.25yrs 1-111 N/A All-cause mortality: 
(ramipril) J.. 27% (p<0.002) 
TRACE 1749 2-4.2yrs N/A :::;35 All-cause mortality: 
(trandalopril) !22% (p=0.001) 
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Based on the results of these trials ACE inhibitors significantly reduce total 
mortality with consistent effects in a broad range of patients with heart 
failure210. They slow the progression to heart failure in patients with 
asymptomatic left ventricular dysfunction20•195·213; improve symptoms and 
quality of life11 ·20•52•195·209; enable reduction of the amount and dosage of other 
anti-failure drugs 52; reduce cardiac events 11 ·20•195•214 and reduce 
hospitalisations 11 ·20•195. European, UK and US guidelines 10·22•101 ·141 reiterate 
that patients with symptomatic heart failure and evidence of impaired left 
ventricular function should receive an ACE inhibitor, unless 
contraindicated 10•22•101 •141 . All patients with a recent myocardial infarction and 
evidence of left ventricular dysfunction, even if asymptomatic should also 
receive an ACE inhibitor10·22•101 ·141 . 
Initiation and titration to adequate therapeutic dosages, and subsequent 
monitoring of ACE inhibitor therapy has been described in detail127·141 . 
Practical recommendations for use of ACE inhibitors, beta-blockers and 
spironolactone have been published215. ACE inhibitors can be started safely 
in primary care216•217 and remain highly cost effective when the costs of 
diagnosis and starting treatment are included141 ·217-219. Nine ACE inhibitors 
are now licensed for use in HF and LVSD in the UK (See Table 1.10) 
Table 1.10: ACE inhibitors available for use in the UK. Data from British 
National Formulary (March 1999)220• 
ACE Inhibitor Usual Licensed Cost of 28 days 
maintenance indications treatment 
dosage 
Captopril 50mgs tds CHF and Post Ml £8.90 
Cilazapril 2.5mgs-5mgs od CHF £8.60-£14.95 
Enalapril 10-20mgs bd CHF and £22.06-£26.20 
prevention HF 
Fosinopril 10-40mgs od CHF £12.04-£26.00 
Lisinopril 5-20mgs od CHF and Post Ml £9.58-£13.38 
Perindopril 4mgs od CHF £12.74 
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ACE Inhibitor Usual Licensed Cost of 28 days 
maintenance indications treatment 
dosage 
Quinapril 10-20mgs od CHF £9.79-£10.07 
Ramipril 5-10mgs od CHF and Post Ml £9.95-£13.00 
Trandolapril 2-4mgs od Post Ml with LVSD £12.23-£24.46 
Moexipril 15-30mgs Hypertension only £9.80-£19.60 
1. 7 .5.2.3 Optimising ACE inhibitor dosage 
The Atlas Studj!21 was important in demonstrating the importance of using 
adequate doses of ACE inhibitors in patients with CHF. The purpose of the 
study was to evaluate the differences in morbidity and mortality between high 
dose (32.5-35mg once daily) and low dose of lisinopril (2.5mg-5mg once daily) 
over four years. Both dose regimens were similarly well tolerated but there 
was a significant 12% additional reduction in the combined end point of all 
cause mortality plus all cause hospitalization in the high dose group. There 
was also a significant 15% reduction in the combined end point of all cause 
mortality and hospitalization for heart failure. These studies suggest that we 
should be aiming for high dose ACE inhibitors as target doses. 
1. 7 .5.2.4 Current state of management in primary and secondary care. 
There have been several studies examining the uptake of ACE inhibitor use 
over a decade in UK practice, some from primary care, others from secondary 
care or across the primary-secondary care interface. The following Table 1.11 
summarises this data. 
Whilst there does appear to be a temporal increase in ACE inhibitor use this 
still remain unacceptably low given the benefits of treatment with these 
agents. The studies by Hill is and colleagues 144•145, Missouris and 
colleagues222 and the first Lip study142 were conducted in the hospital setting 
and show low ACE use even in a specialist care environment. Hillis and 
colleagues 145 completed an audit cycle and showed that introduction of 
educational programs for staff increased ACE inhibitor uptake from 40% to 
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55%. They found that patients managed by a cardiac as opposed to a general 
medical unit were more likely to have an echocardiogram (52/61 vs. 139/204; 
p<0.01) and subsequently were more likely to be treated with an ACE inhibitor 
(41/61 vs. 1 05/204; p<0.05). They also showed that older patients were less 
likely to have an echocardiogram (mean age 70 years if echocardiography vs. 
76 years if not investigated). As cardiologists tend to see younger patients this 
could be one reason why patients are more likely to be investigated by 
echocardiography and then get treated with ACE inhibitor. 
Table 1.11: ACE inhibitor use in UK practice 
Study authors Year of Patient ACE inhibitor % 
study numbers prescribed 
Hillis et al144 1992 325 40.0% 
Parameshwar et al143 1992 117 10.3% 
Clarke et al41 1994 281 17.0% 
Hillis et al145 1996 265 55.1% 
Mair et a140 1996 266 32.7% 
Lip et al69 1997 188 30.0% 
Lip et al142 1997 348 58.5% 
Missouris et al222 1997 249 57.8% 
McCallum et al70 2001 100 58.3% 
The question of titrating ACE inhibitors to target doses used in clinical trials 
was addressed by a few of these studies. Missouris and colleagues222 found 
that only 16.7% of patients discharged from St. George's Hospital, London 
were on adequate doses; Hillis and colleagues 144• 145 found that 76% in 1992 
and 55% in 1996 were not on adequate doses on discharge from Aberdeen 
teaching hospitals and that in the 1996 cohort 71 patients (26.8%) who had no 
contraindications and may have benefited from ACE inhibitors were not 
getting them at all; Mair and colleagues40 found that patients were generally 
on conservative doses of ACE inhibitors in a Liverpool GP cohort. They found 
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that perindopril was the only ACE inhibitor to be used at target doses of 4mgs 
daily possibly because of its easy two step titration as compared to four or five 
steps for enalapril and captopril. Furthermore it is a once daily product 
compared to twice daily for enalapril and thrice daily for captopril. This may 
make it more attractive to clinicians who may feel patient compliance is 
increased. 
Bungard and colleagues223 conducted a systematic review assessing 
prescribing patterns (specifically the use of ACE inhibitors in CHF) identifying 
37 studies. Studies assessing use among all patients with CHF document 
33% to 67% (median 51%) of all patients discharged from hospital and 10% to 
36% (median 26%) of community dwelling patients were prescribed ACE 
inhibitors. Rates of ACE inhibitor use range from 43% to 90% (median 71%) 
amongst those discharged from hospital having known systolic dysfunction, 
and from 67% to 95% (median of 86%) for those monitored in specialty clinics. 
Suggesting that further investigation and specialist care increases ACE 
inhibitor uptake. Moreover, the dosages used in the 'real world' are 
substantially lower than those proven efficacious in randomised, controlled 
trials, with evaluations reporting only a minority of patients achieving target 
doses. Factors predicting the use and optimal dose administration of ACE 
inhibitors were identified, and include variables relating to the setting 
(previous hospitalisation, specialty clinic follow-up), the physician (cardiology 
specialty versus family practitioner or general internist, board certification), the 
patient (increased severity of symptoms, male, younger), and the drug (lower 
frequency of administration). Bungard et al223 called for multifaceted programs 
targeted toward the population at large to try and improve optimal uptake of 
therapies proven effective in the management of patients with CHF. Recent 
data from nGMS QOF data suggests uptake of ACE inhibitors in CHD patients 
with HF due to LVD have increased significantll81 . 
However, initiation of evidence-based therapy may be limited by worries about 
treatment side effects, blood monitoring workload, polypharmacy and drug 
interactions. Although confidence in using ACE inhibitors is increasing a 
substantial minority of GPs still had concerns, especially in elderly patients. 
The lack of evidence of benefit in patients with heart failure over the age of 75 
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years and of any substantial controlled trial in patients with apparent heart 
failure and well-preserved left ventricular systolic function, a common finding 
in elderly patients, may be common reasons why ACE inhibitors appear to be 
underused in heart failure224. Philbin suggested that age bias, use of 
alternative vasodilators (nitrates), prevalence of renal impairment and 
'diastolic' HF, and substandard quality of care led to low ACE inhibitor usage 
in a US community setting225 . Monitoring of ACE inhibitors raised some 
concerns both in terms of workload and uncertainty as to how often 
monitoring tests are needed. A questionnaire study found that although 85% 
of GPs checked renal function before ACE inhibitor initiation, only 34% did so 
after start of treatment and 15% never checked renal function226. Observation 
of guidelines for appropriate monitoring of renal function may help minimize 
this problem. 
1. 7 .5.2.5 Summary of ACE inhibitor therapy for heart failure 
Uncertainty about diagnosis coupled with uncertainties about treating elderly 
patients and concerns about adverse events of ACE inhibitors 152 may explain 
the low uptake of treatment in primary care224 . The benefits of ACE inhibitor 
therapy are being lost either by their lack of use at all140•227-230 or by the use of 
sub-optimal doses40•222·224•231 ·232. This also appears to be the case in hospital 
practice 143,222. 
1. 7 .5.3 Beta-blockers for heart failure 
1. 7 .5.3.1 Introduction 
Until recently it was perceived and accepted that beta-blockers were 
contraindicated in the management of heart failure233. However a Swedish 
study in the early 1970s indicated that adrenergic beta blocking agents could 
improve heart function in at least some patients with advanced congestive 
cardiomyopathl34. The evidence for the beneficial role of beta-blockers in the 
management of heart failure is now very substantial and summarised in 
several systematic reviews235-239. 
1. 7 .5.3.2 Landmark beta blocker studies 
Over the years a strong evidence base has accumulated from randomised 
control trials and systematic reviews that adding beta blockers to standard 
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therapy with diuretics and ACE inhibitors in patients with moderate or severe 
heart failure reduces mortality and the rate of hospital admissions. Three trials 
are considered to represent landmark status in establishing the place of beta-
blocker therapy for patients with LVSD. (See Table 1.12) 
Table 1.12: Landmark beta blocker trials for heart failure 
USCP 1997240 CIBIS 11 199914 MERIT-HF 199918 
Number of patients 1094 2647 3991 
Mean Age 58 (18-85) 61 (18-80) 64 (40-80) 
Male Sex(%) 77 81 78 
NYHA Class(%) 11 53 0 41 
Ill 44 83 56 
IV 3 17 3 
Primary Endpoint Various Mortality Mortality 
Total no. of deaths 54 384 362 
Mean Follow-up 6.5 months 1.3 years 1 year 
Concomitant 
medications(%) 
Diuretic 95 99 91 
ACE inhibitor 95 96 90 
Digoxin 91 52 64 
Target dose 25/50 mgs 10 mgs 200 mgs 
Proportion reaching 80 43 64 
target dose (%) 
Proportion stopping 
medication (%) 
Placebo 18 15 15.3 
B-blocker 11 15 13.9 
Total Mortality RRR65% RRR 34% RRR34% 
ARR4.6% ARR 5.5% ARR 3.8% 
Morbidity 
Hospitalisation RRR27% RRR 20% Not reported 
Combined death and RRR 38% RRR21% Not reported 
hospitalisation for a 
cardiac cause 
1. 7 .5.3.2.1 A critical appraisal of the CIBIS 11 trial 
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The CIBIS-11 trial was based on the first CIBIS study241 , which showed a non-
significant 20% reduction in mortality but a significant reduction in hospital 
admissions as a result of worsening heart failure241 . CIBIS-11 was the first of 
the very large beta-blocker trials in heart failure with sufficient power to 
address all cause mortality as the primary endpoint. Hence it can be 
considered to be a seminal landmark study. 
2647 patients, aged 18-80 years, with left ventricular ejection fraction s 35% 
and NYHA class Ill or IV, receiving standard therapy (diuretic plus ACE 
inhibitor/other vasodilator) were recruited. 
There was a statistically significant reduction in all-cause mortality of 34% 
(hazard ratio 0.66 (Cl 0.54-0.81) p < 0.00001) in the bisoprolol group. All-
cause hospital admission, all cause cardiovascular death and combined 
endpoint were all significantly reduced by 20%, 29% and 21% respectively ( p 
values 0.0006, 0.0049 and 0.0004 respectively) in the bisoprolol group. 
Permanent withdrawals were virtually identical in each group (15% of total 
patients) (p value 0.98). Exploratory analyses showed statistically significant 
reductions in sudden death (44%) and hospital admissions for worsening 
heart failure (36%) with bisoprolol (p values 0.0011 and 0.0001 respectively). 
The bottom line result of this study is a substantial reduction in all cause 
mortality seen in bisoprolol treated patients with chronic heart failure of 
moderate severity. 
There were some possible weaknesses and limitations on application of these 
results in pragmatic management of heart failure patients. CIBIS 11 was a 
European trial with the greatest percentage of patients (30%) coming from 
Russia and 11.6% from Poland. This raises concerns as to whether these 
patients were typical of those from Western Europe as a whole. However, it 
appeared all patients were receiving ACE inhibitors so there were no reasons 
to believe they were treated differently from elsewhere in Europe. 
Patients studied were relatively young (mean age 61) and mostly male. 
Although the typical age group and sex is under represented in the data, there 
were some patients up to 80 years of age included in CIBIS I (and MERIT-
HF18). Whether we are justified in treating very elderly heart failure patients 
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with beta-blockers is, as yet, not absolutely clear. However, if patients are in 
other respects similar to those in CIBIS 11, there is no apparent reason why 
they should not also be started on treatment, providing systems are in place 
to ensure safetl42. The SENIORS study recently confirmed the safety, 
tolerability and mortality benefits of nebivolol in elderly patients with systolic 
and diastolic heart failure243. 
Most patients had moderately severe heart failure (NYHA Ill) with an ejection 
fraction of s 35%. lt is not always easy to measure ejection fraction in practice 
and many patients have mild heart failure (ejection fraction > 35 % and < 
45%). This trial does not tell us whether the same mortality benefits apply to 
patients with mild heart failure, although subsequent trials with metoprolol18 
and carvedilol12 have shown morbidity and mortality benefits in this group. 
Benefits were seen in patients in NYHA IV; however only stable patients were 
enrolled so the use of beta-blocker treatment in non-ambulatory class IV 
patients, especially with recent instability or decompensation, needs to be 
defined. Beta-blockers (bisoprolol) also appear to be cost effective244. 
1. 7 .5.3.2.2 The MERIT -HF trial 
MERIT-HF18 enrolled 3,991 patients with symptomatic CHF and LVEF s 40% 
at entry. Patients were randomly allocated to either receive Metoprolol (12.5 
or 25mg once daily titrated to a target dose of 200mg once daily) or placebo in 
addition to their standard therapy including ACE inhibitors. Following a clear 
difference in outcomes which emerged before the scheduled completion date, 
the study was stopped early. The result showed a highly significant 34% 
reduction mortality between those who received metoprolol versus those who 
did not. There was a significant 41% reduction in sudden death and a 
significant 49% reduction in death from worsening heart failure. 
1. 7 .5.3.2.3 The US Carvedilol program (USCP) 
The US Carvedilol Program240 consisted of 4 separate studies each with a 
separate primary endpoint other than survival but survival in the overall 
program was monitored by a single safety committee. 1094 patients (mean 
age 58 [range 18-85]) randomised to carvedilol or placebo were studied over 
a relatively short mean follow up period of 6.5 months. There was a 65% 
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reduction in deaths (3.2% vs. 7.8%); 27% reduction in cardiovascular 
hospitalisation (14.1% vs. 19.6%) and 38% reduction of combined endpoint of 
death or hospitalisation for any cause (15.8% vs. 24.6%). 
Guidelines 104·105 now suggest that all patients with LVSD of any degree be 
offered a beta-blocker and these three studies have helped inform evidence-
based guidance on which policy statements such as the NSF for CHD are 
based. 
1. 7 .5.3.3 More recent beta blocker studies 
As the first three major trials did not address use of beta blockers in severe 
HF, elderly patients, mild L VSD after myocardial infarction more recent 
studies have been conducted to address these important areas. The COMET 
trial15 was designed to give a head to head comparison between two beta 
blockers previously shown to reduce HF mortality. (see Table 1.13) 
Table 1.13: Major recent Trials of Beta-Blockade in HF 
Patients Mean NYHA LVEF Effects on all-cause 
(n) Follow- Class (%) mortality 
up 
HF 
COPERNICUS246 2289 10 111-IV <25 All cause mortality 
months !35% (p = 0.00013) 
SENIORS246 2135 3.5yrs I-IV <35 All-cause mortality: 
! 14% (p=0.039) 
COMET16 3029 4.9yrs 11-IV <35 All-cause mortality: 
,!, 17%(p=0.0017) 
Post-MI HF 
CAPRICORN12 1959 1.25yrs N/A <40 All-cause mortality: 
,l,23%(p=0.03) 
The CAPRICORN study 12 recently demonstrated that all cause mortality was 
lowered by carvedilol compared with placebo (12% vs. 15%; hazard ratio 0.77 
[95% Cl 0.60-0.98], p = 0.03) in patients after an Ml complicated by LVSD 
(LVEF s 40%). These beneficial effects are additional to those of evidence-
based treatments for acute Ml including ACE inhibitors. 
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The COPERNICUS trial245 found that the addition of carvedilol to standard 
therapy for about ten months improved survival compared with placebo in 
2,289 patients (LVEF<25%) who had symptoms at rest or on minimal 
exertion. All cause mortality 11.2% vs. 16.8%; (RRR 35% [95% Cl 19-48%]; p 
= 0.00013). In the only head to head comparison of beta blockers previously 
shown to reduce mortality in HF the COMET trial15 assigned 1511 patients 
with CHF (NYHA 11-IV) to treatment with carvedilol and 1518 patients to 
metoprolol. Over 58 months mean study period carvedilol all cause mortality 
was 34% and metoprolol 40% (Hazard ratio 0.83 [95% Cl 0.74-0.93], p = 
0.0017). Incidence of side effects and drug withdrawals did not differ by much 
between the two study groups. These results suggest that carvedilol extends 
survival compared with metoprolol in CHF patients. Practical applicability of 
these results are limited in the UK by the fact that metoprolol is not licensed 
for use in CHF. 
The only trial with a beta blocker not to demonstrate benefit was BEST202 . 
This showed no significant difference in all-cause mortality between 
bucindolol (30%) and placebo (33%) after two years in 2,708 patients with 
moderate to severe HF (LVEF s 35%) 
lt is likely that the differences in the two above studies relate to differences in 
the characteristics of the beta blockers rather than differences in the 
populations studied. lt has been suggested that carvedilol has additional 
properties including alpha blockade and antioxidant activity, which may be 
important in severe HF in particula~45 • 
1. 7 .5.3.4 Systematic review of effect of beta blockers on HF mortality 
Doughty RN et al239 conducted a systematic overview of 24 randomised trials 
to assess the effect of beta blocker therapy on mortality in patients with heart 
failure. This involved 3141 patients with stable heart failure. They found a 
31% reduction in the odds of death among patients treated with a beta blocker 
(p = 0.002). 
1. 7 .5.3.5 Systematic review of effects of beta blockers on left ventricular 
function 
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Lechat P et al239 undertook a meta-analysis of 18 published double blind, 
placebo controlled trials of beta blockers in heart failure with a combined data 
base of 3023 patients. This showed evidence of a favourable effect of beta 
blockers on left ventricular ejection fraction, and a combined risk of death and 
hospitalization for heart failure. Beta blockers increased the ejection fraction 
by 29% and reduced the combined risk of death or hospitalization for heart 
failure by 37% (p < 0.001 ). 
1.7.5.3.6 Traditional contraindications and cautions to the use of beta 
blockers - are they justified? 
Recently some of the traditional contraindications and cautions to beta 
blockers have been questioned; in particular opinion has focused on chronic 
obstructive pulmonary disease (COPD), peripheral arterial disease, diabetes 
mellitus and the elderly. lt is important to address these areas in order not to 
deprive patients with these eo-morbid conditions and HF the opportunity to 
benefit from beta blocker therapy. 
1.7.5.3.6.1 Beta blockers in chronic obstructive pulmonary disease 
A recent Cochrane review assessed the effect of cardio selective beta 
blockers on lung function in patients with COPD. Eleven randomized blinded 
controlled trials of single dose treatment, and eight treatments for a longer 
duration ranging from 2 days to 12 weeks were reviewed. Cardio selective 
beta blockers given as a single dose or for a longer duration produced no 
statistically significant change in FEV1 or respiratory symptoms compared to 
placebo. They also did not significantly affect the FEV1 treatment response to 
beta2 agonists. Furthermore, there were no COPD exacerbations or 
hospitalizations during the periods of study in either group247·248. 
This meta-analysis indicated that cardio selective beta blockers are safe in 
patients who have COPD with or without a reversible component. The 
Cochrane review concluded that cardio selective beta blockers given to 
patients with COPD do not produce a significant short term reduction, 
however these trials were small and of short duration and not applicable to 
patients with severe COPD247·248. 
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Salpeter et al249 conducted a meta-analysis that also demonstrated that cardio 
selective beta blockade given in mild to moderate COPD did not produce 
clinically significant adverse respiratory effects in the short term and that they 
should not be withheld from such patients. The reviewer stated that long term 
safety, especially during an acute exacerbation still needed to be established. 
These findings were in keeping with Cochrane review advice 
1.7.5.3.6.2 Beta blockers in peripheral arterial disease 
lt has been suggested that beta blockers are contraindicated in the presence 
of peripheral arterial disease. A meta-analysis conducted to determine 
whether or not beta blockers exacerbate intermittent claudication found no 
significant impairment of walking capacity compared with placebo250. Only 
one of the studies including in the meta-analysis reported that certain beta 
blockers were associated with worsening intermittent claudication. These 
were not the agents currently licensed for the use of heart failure, namely 
bisoprolol and carvedilol. 
The results of the meta-analysis strongly suggested that beta blockers do not 
adversely affect the symptoms of intermittent claudication in patients with mild 
to moderate peripheral arterial disease. 
Therefore in the absence of other contraindications beta blockers can 
probably be used safely in such patients with heart failure250. 
1.7.5.3.6.3 Beta blockers in diabetes 
lt is known that non-selective beta blockers inhibit insulin secretion and can 
impair glucose tolerance as well decrease catecholamine-mediated response 
to hypoglycaemia with decreased awareness and delayed recovery of 
hypoglycaemic episodes. These effects are less pronounced with newer 
cardia-selective beta blockers. 
Shekelle PG et al251 undertook a meta-analysis of published and individual 
patient data from 12 large randomized clinical trials of ACE inhibitors and beta 
blockers and concluded that both groups of drugs provided life-saving benefits 
in most of the sub-populations assessed in patients with or without diabetes. 
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Jenas M et al252 conducted a study looking at the usefulness of beta blocker 
therapy in patients with non-insulin dependent diabetes mellitus and coronary 
artery disease. 2, 723 non-insulin-dependent diabetic patients were included 
and three-year mortality was estimated in patients receiving (n = 911) and not 
receiving beta blockers (n = 1 ,812). Total mortality during the three-year 
follow-up was 7.8% in those receiving beta blockers compared with 14% in 
those who were not. This translates to a 44% relative risk reduction and a 
further 42% reduction in cardiac mortality was also noted. Multivariate 
analysis in this study identified beta blocker therapy as a significant 
independent contributor to improved survival. The evidence would suggest 
that the benefits of beta blockers in diabetic patients with or without heart 
failure outweigh the possibility of slight impairment of glucose tolerance. 
1.7.5.3.6.4 Beta blockers in older people 
Epidemiological data shows that older patients constitute the majority of those 
with chronic heart failure30. However it is apparent that beta blockers are 
underused in this age group, partially due to the perception of potential 
adverse effects and drug interactions. Furthermore HF patients in the 
community tend to be older and with more concomitant disease than those in 
the majority of clinical trials of beta blockers and indeed most other drugs that 
are of benefit in LVSD. 
In the CIBIS-11 trial14 the age limit was 80 and the mean age 61. In the 
MERIT-HF trial18 age limit was 90 and mean age 64. Subsequent analysis 
from both these studies shows mortality reductions in patients 70 to 80 similar 
to those in younger patients253. 
Sin-Don D et al254 observed in a retrospective study of 11,942 older patients 
over the years of 65 with heart failure (1, 162 taking beta-blockers), that beta 
blocker use was associated with substantial reductions in all-cause mortality, 
heart failure mortality and hospitalizations due to heart failure. 
The recent SENIORS studj46 has shown beta-blockade can be safely 
initiated, was well tolerated and improved outcomes in over 2000 patients with 
a clinical diagnosis of chronic heart failure and a mean age of 76 years. 
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Nebivolol treated patients showed a significantly reduced all-cause mortality 
or rate of hospitalisation for cardiovascular events (SENIORS). 
Whitham and Colleagues255 evaluated how well older heart failure patients 
tolerate beta-blockers in everyday clinical practice. In a retrospective case 
note analysis, 226 patients with a clinical diagnosis of heart failure and 
evidence of LVSD were studied in the specialist heart failure clinic of a large 
teaching hospital. They observed that a high proportion of older heart failure 
patients tolerated beta-blockers, with 60% of those aged 75 or over having 
been tried on a beta-blocker versus 69% of those aged less than 75, and of 
those tried, 80% of those aged 75 or over were still taking a beta-blocker at 
the time of the survey, versus 86% of those aged less than 75. Significant 
factors identified for failing a trial of beta-blocker therapy were worse NYHA 
status (3-4) and worse left ventricular function, but importantly not age. 
Baxter and colleagues256 demonstrated in a small prospective observational 
cohort in Sunderland that 69% of patients with a mean age of 78 (range 70-89 
years) tolerated bisoprolol. Mean tolerated dose was 7.6mg (range 1.25mgs 
to 10mgs), which is similar to that seen in CIBIS 11. Despite concerns that beta 
blockers may worsen HF symptoms in older patients there was no evidence of 
a negative impact on symptoms or exercise capacity in patients who tolerated 
bisoprolol. 
Whilst age should not be a contraindication to beta-blocker use in heart 
failure, older patients are more likely to suffer from multiple pathology and 
concomitant disease. Hence a wise balanced approach needs to be made 
between the modest survival benefit and the adverse effects on quality of life 
in elderly patients, when deciding whether or not to use beta-blockers257. 
1. 7 .5.3. 7 Outpatient initiation of beta-blockers for heart failure 
There is now overwhelming evidence that beta blockers are beneficial in all 
grades of heart failure. Large randomised controlled trials confirm that they 
confer morbidity and mortality benefits, improve quality of life and reduce 
hospitalisations236•238•239. Despite this, it is likely that clinicians including GPs 
will initially be reticent in initiation of beta-blockers for heart failure patients. 
The cost of hospitalisation can be decreased by 10% by commencing patients 
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with heart failure on beta-blockers; however use in clinical practice is still low 
especially in the UK13. lt is estimated that only 22% of suitable patients are on 
beta-blockers in the UK. lt is probable that this is partly due to the difficulty of 
implementing therapy on an outpatient basis. 
Currently two beta-blockers (carvedilol and bisoprolol)220 have a UK licence 
for the use in heart failure. Both agents should be initiated at a low dose and 
slowly titrated up to achieve doses achieved in the major clinical trials. 
Lee and colleagues258 looked for a safe regime for outpatient initiation of beta-
blockers in heart failure patients. They studied 70 patients with NYHA 111-IV 
heart failure. They were able to establish 88% of these on a beta-blocker with 
only 12% discontinuing due to side effects. None of these needed 
hospitalisation. Only 2 patients (3%) reported side effects during the two-hour 
monitoring period and they experienced mild wheezing that did not need any 
medical intervention. This study suggests that with simple precautions most 
patients with heart failure can be safely established on a beta-blocker in an 
outpatient setting. This can be enhanced by using specialist nurses260. 
Hypotension, a side effect, may be less prevalent than previously believed243• 
These studies would suggest that with simple precautions, most patients with 
HF can be safely established on a beta-blocker in a community setting. 
Reorganisation of heart failure services may be necessary to ensure that 
suitable patients are considered for beta blockers. Heart failure clinics and 
liaison nurses may have a useful role in this area259. lt seems that 
establishment of programmes across the UK could lead to significant savings 
on hospitalisation costs for the NHS and this patient group. Further research 
is needed into initiation and titration of beta-blockers in chronic heart failure 
within a primary care setting. 
1. 7 .5.3.8 Ongoing Research with beta blockers for heart failure 
The introduction of ACE inhibitors and subsequently beta blockers was a 
major breakthrough in the pharmacological treatment of chronic heart failure. 
ACE inhibitors and beta blockers significantly reduce mortality and morbidity, 
favourably alter the cause of this disease, and therefore constitute a 
fundamental part of CHF therapy. 
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Despite this significant progress CHF remains a major health problem, and 
there is an undisputable need to optimize currently established therapy. This 
issue becomes particularly important with beta-blockers. Despite clear 
recommendations that beta-blockers should be considered in all stable 
patients with CHF, they are still underused in every day clinical practice. 
There are arguments suggesting it is superior to introduce a beta-blocker prior 
to an ACE inhibitor in patients with CHF, including early benefits (within 2 
weeks) of reduction of incidence of sudden death in some beta blocker 
mortality studies (CIBIS Ill- rationale)260. The question which drug should be 
initiated first in CHF is being addressed in CIBIS 111260. 
1. 7 .5.4 Aldosterone receptor antagonists for heart failure 
Spironolactone is a competitive aldosterone antagonist. The RALES Study 19 
demonstrated that Spironolactone improved all cause mortality (27% RR, 
p<0.0001 ), reduced hospitalisations for all cardiac causes (30% RR) and for 
worsening heart failure (35% RR). Patients with moderate to severe LVSD 
should be considered for treatment with low dose spironolactone (25-50mgs) 
if they remain symptomatic on an ACE inhibitor and a beta blocker. 
The use of an aldosterone antagonist with diuretics and ACE inhibitors raises 
concerns about renal impairment and hyperkalaemia. A population-based 
time-series analysis by Juurlink and colleagues261 demonstrated an abrupt 
rise in the rate of prescriptions for spironolactone and in hyperkalaemia-
associated morbidity and mortality in Canada following the publication of the 
RALES study. 
In another study by Bozkurt and colleagues262 of 377 patients started on 
spironolactone for heart failure following the publication of RALES, 24% 
developed hyperkalaemia (>6 mmoi/L) compared with 2% in RALES. These 
types of studies are important if we are to see evidence based medicine 
translated into practice. Large studies often exclude certain groups of patients 
and certain co-morbidities that are encountered when prescribing to elderly 
patients in the community. For example in the Bozkurt et al study262, 40% of 
patients were taking potassium supplements, 46% were diabetic, 31% had 
renal insufficiency- all exclusion factors for patients enrolled in RALES19. 
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Berry and McMurray described four cases of serious and, occasionally serious 
hyperkalaemia in patients with CHF (NYHA Ill) where spironolactone was 
added to conventional therapy. 
Close monitoring and judicious use of spironolactone is necessary when 
prescribing in real life practice. Berry and McMurray called for mandatory, 
close monitoring of blood chemistry after starting spironolactone, and advised 
that spironolactone should be stopped immediately if diarrhoea develops263. 
Eplerenone is a newer aldosterone antagonist with potentially fewer side 
effects. In the recent EPHESUS stud/64 addition of 25-50mgs of eplerenone 
to optimal therapy reduced morbidity and mortality among patients with acute 
Ml complicated by LVSD and HF. The rate of serious hyperkalaemia was 
5.5% in the eplerenone group and 3.9% in the placebo group (p = 0.002). 
Incidence of gynaecomastia and impotence in the eplerenone group was no 
greater than in the placebo group. As these are common problems with 
spironolactone eplerenone should be a suitable alternative in management of 
HF due to LVSD. 
1.7.5.5 Angiotensin 11 receptor blockers (ARB) for heart failure 
ACE inhibitors only partially block the renin-angiotensin system. ARBs act at 
the angiotensin 11 recaptor site itself and may more completely block its 
pressor actions. Furthermore, unlike ACE inhibitors they do not inhibit 
bradykinin breakdown, and are less likely to cause a troublesome cough. 
Theoretically ARBs may be combined with an ACE inhibitor therefore offering 
greater efficacy or be used as an alternative to ACE inhibitors. Many studies 
have addressed these hypotheses265. 
One meta-analysis demonstrated that the combination did not reduce 
mortality compared to ACE inhibitor monotherapy. However, a significant 
reduction in hospitalisations was seen265. 
Neither ELITE 11 (with losartan) 17 nor Vai-HeFT (with valsartan)21 
demonstrated mortality benefits with an ARB over an ACE inhibitor. 
ELITE 11 17 hypothesised that losartan monotherapy would be superior to 
captopril in improving survival. 3,152 patients with NYHA 11-IV (LVEF s 40%) 
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were randomised to losartan 50mgs or captopril 50mgs three times a day. No 
difference in all cause mortality was demonstrated between losartan (17.7%) 
and captopril (15.9%) (Hazard ratio 1.13 [95% Cl 0.95-1.35; p = 0.16]) over a 
median follow up of 1.5 years. lt is important to note that these results do not 
necessarily mean that losartan is as effective as captopril at improving 
survival as the study was designed to demonstrate superiority, and not to 
show equivalence. 
The Valsartan Heart Failure Trial (Vai-HeFt)21 compared valsartan with 
placebo when added to standard therapy including ACE inhibitors and beta 
blockers in 5,010 patients with mild to moderate heart failure. Patients treated 
with valsartan and standard therapy were significantly less likely to reach the 
combined end point of all cause mortality and morbidity (P=0.009). This 
benefit was mainly due to a reduction in hospitalisation due to heart failure. 
There was no difference in the other primary end point of all cause mortality21. 
The recent CHARM (Candesatran in HF - Assessment of Reduction in 
Mortality and Morbidity) studies have addressed 3 groups of patients, 
including those with preserved systolic function 13.CHARM Alternative 
(n=2028) enrolled patients intolerant of ACE inhibitors and candesatran 
significantly reduced the risk of cardiovascular death or hospitalisation for 
CHF, with an overall risk reduction of 23% (p=0.0004) compared to placebo13. 
In CHARM Added (n=2548) with patients prescribed optimal conventional 
therapy for CHF including an ACE inhibitor addition of candesatran 
significantly reduced the risk of cardiovascular death or hospitalisation by 15% 
(p=0.011 ). This result is in contrast to Vai-HeFT, which had suggested a triple 
combination of ACE inhibitor, ARB and beta blocker may be associated with 
adverse outcomes 13. 
CHARM Preserved (n=3025) in patients with HF with preserved LV systolic 
function candesatran did not demonstrate a statistically significant reduction in 
cardiovascular death or hospitalisation for CHF but did significantly reduce the 
risk of development of new diabetes, with an overall risk reduction of 40% 
(p=0.005)13. 
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Current advice should be that ARBs might be considered as a replacement for 
patients with LVSD intolerant of ACE inhibitors. In light of the CHARM Added 
results a combination of ACE inhibitor and Candesatran may be considered in 
certain groups of patients still symptomatic on optimal conventional 
therapies 13. No other studies have assessed the combination of ACE inhibitor 
and ARB to date. 
1. 7 .5.6 Digoxin and heart failure 
1.7.5.6.1 A historical perspective 
Digoxin is a cardiac glycoside derived from Digitalis purpurea (Fuchsius 1542) 
or lanata. In 1785 William Withering published 'An Account of the Foxglove 
and Some of its Medical Uses - With Practical Remarks on Dropsy and Other 
Diseases'. James Mackenzie (1835-1925) found that Digitalis was effective in 
slowing the rate of the heart irrespective of correction of heart failure but it 
was Arthur Cluny (1866-1926) who developed the pharmacology that led to 
the isolation of digoxin266. 
1.7.5.6.2 Early studies of digoxin in heart failure 
Withdrawal studies showed that patients' HF and exercise tolerance 
deteriorated after withdrawal of digoxin in about a quarter of cases267•268. 
However, the value of digoxin in patients with HF due to LVSD or preserved 
systolic function was not established from prospective randomised controlled 
trials. 
1. 7 .5.6.3 The Digitalis Investigators Group (DIG) study - a critical review 
This prospective, randomised, placebo controlled trial16 was designed to test 
the hypothesis that digoxin would reduce mortality and hospitalisation for 
patients with heart failure and normal sinus rhythm. 
The main study16 enrolled 6800 patients with heart failure, in sinus rhythm and 
LVEF s 0.45. An ancillary study included 988 patients with heart failure and 
preserved systolic function (LVEF > 0.45) and in sinus rhythm. The average 
age was 63 in both groups. The primary endpoint was all cause mortality with 
secondary endpoints of cardiovascular mortality, death due to worsening 
heart failure, hospitalisation due to worsening heart failure and other causes. 
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Digoxin did not reduce all cause or cardiovascular mortality (risk ratios 0.99 
(Cl 0.91-1.07) and 1.01 (Cl 0.93-1.1 0) respectively, with p values 0.80 and 
0.78 respectively), but it reduced the rate of hospitalization for worsening 
heart failure (0.88 (Cl 0.77-1.01) p value 0.06). Pre-specified subgroup 
analysis showed that those with lower ejection fractions, enlarged hearts and 
those in NYHA Class Ill or IV derived more benefit from digoxin 16. 
These findings define more precisely the role of digoxin in the management of 
chronic heart failure. 
However there are possible reasons why results may not be applicable in my 
local setting: the mean age of patients was 63, which is considerably lower 
than HF population (mean age 76), and it was a US study with high previous 
digoxin use (44%). Furthermore there were possible methodological 
weaknesses in that no attempt was made to optimise treatment according to 
plasma level- many patients may therefore be under treated. Could adjusting 
the dose according to plasma level have provided additional clinical benefits? 
This question is likely to remain unanswered. There was also a statistically 
significantly higher number of patients in the placebo group who were put on 
open label digoxin and this could have been a possible confounding factor in 
analysis. 
1.7.5.6.4 How should we use and monitor digoxin in heart failure? 
NICE guidance105 recommends that digoxin is used for patients in sinus 
rhythm with worsening or severe HF due to LVSD despite ACE Inhibitor, beta-
blocker and diuretic therapy, and in patients with atrial fibrillation and any 
degree of HF. 
Routine monitoring of serum digoxin concentrations is not recommended. A 
digoxin concentration measured within 8-12 hours of the last dose may be 
useful to confirm a clinical impression of toxicity or non-compliance 
The serum digoxin concentration should be interpreted in the clinical context 
as toxicity may occur even when the concentration is within the 'therapeutic 
range' 
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1.7.5.7 Summary of main treatments for HF due to LVSD 
The following table summarises the use of therapies shown to be of benefit in 
HF due to LVSD. All patients should be considered for ACE inhibitors and 
beta blockers unless compelling contraindications exist. Diuretics, digoxin and 
spironolactone should be considered in selected patients. All GPs should be 
aware of these indications: 
Table 1.14 Summary of Treatment of HF due to LVSD 
NYHAI NYHA 11 NYHA Ill I NYHA IV 
~· 
Diuretics if symptomatic 
·~ . . .. .. ·- ~ 
ACE inhibitors (AliA or nitrate/hydralazine if ACEi contraindicated) 
-
.. ~ 
Beta-blockers once stable 
Oigoxin if in Atrial Fibrillation or stilfsymptoms 
on above treatments 
Spironolactone .if symptoms on 
above treatm~nts 
---- ·--·-
1.7.5.8 Antithrombotic agents and heart failure 
Patients with HF are particularly prone to thrombotic complications. AF, 
ventricular and atrial dilation, and venous stasis all contribute to the risk. 
Where there is a clear indication, such as AF, warfarin should be given. 
Many patients with CAD and CHF are on aspirin. Systematic review evidence 
supports the fact that aspirin reduces the risk of vascular events in patients 
with atherosclerotic arterial disease269. However, there have been 
suggestions that aspirin may reduce the benefits of ACE inhibition in patients 
with CHF270, although other systematic reviews refute this claim271 . Specific 
randomised controlled trial (RCT) evidence for the benefit of aspirin in CHF 
patients is lacking. Studies are underway to address this270. Until such 
evidence is available, NICE guidance 105 suggests the use of aspirin (75-
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150mgs daily) for patients with the combination of CHF and atherosclerotic 
arterial disease (including CAD). 
1.7.5.9 Lipid lowering agents-should all patients with heart failure be on 
a statin? 
Many patients with coronary artery disease (CAD) and LVSD receive a statin. 
RCTs have shown that statins reduce the frequency of ischaemic events and 
prolong life expectancy in patients with CAD, as well as reducing the risk of 
development of heart failure272 . However, most statin trials have excluded 
patients with CHF. Further evidence from large-scale statin trials are needed 
in CHF273. 
The CORONA study274 (a double-blind, placebo controlled RCT) with 
rosuvastatin in subjects with symptomatic L VSD is due to report in 2007. 4950 
patients are being enrolled, with a planned primary endpoint of cardiovascular 
death or non-fatal Ml or non-fatal stroke. Until such evidence is available 
NICE guidance suggests patients with a combination of CHF and CAD should 
receive a statin in line with current indications for secondary prevention. 
1. 7 .5.1 0 Anti-arrhythmic agents and heart failure 
About half of patients with HF die suddenly. This could be due to arrhythmia, 
but evidence increasingly suggests that coronary occlusion plays an important 
role. Both atrial and ventricular arrhythmias occur, especially atrial fibrillation 
and flutter, and ventricular tachycardia. Palpitations should always be 
investigated further in HF patients. 
The CAST trial275 demonstrated increased mortality in patients after Ml with 
the once commonly used class 1 and 3 antiarrhythmic drugs (encainide and 
flecainide) The safest drug in HF is amiodarone as it is the least negatively 
inotropic of the available drugs. Studies276 and meta-analyses277 have 
suggested it could give a survival advantage to some groups of patients. 
However, its use, especially in primary care is limited by the need for 
specialist initiation, regular monitoring and a poor side effect profile. 
Thyroid and liver function tests should be done regularly to check for side-
effects of hypothyroidism, hyperthyroidism or hepatitis. Worsening 
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breathlessness should always raise the suspicion of pulmonary fibrosis, which 
is rare but can be rapidly fatal. Other amiodarone side-effects include skin 
photosensitivity or grey-blue discoloration, corneal deposits or optic atrophy, 
myopathy, neuropathy. Drug interactions can be a problem; in particular it can 
increase the activity of warfarin or digoxin. 
1.7.5.11 Calcium channel blockers and heart failure 
There is no place for the routine use of calcium channel blockers in the 
treatment of HF104. In particular, the rate-limiting drugs verapamil and 
diltiazem are potentially deleterious. The short-acting dihydropyridines, such 
as nifedipine, should be avoided. 
However, amlodipine is helpful in patients who also have IHD and angina. lt is 
safe in HF278, and could even be of benefit in dilated cardiomyopathy279. In the 
PRAISE study amlodipine (n = 571) did not increase cardiovascular morbidity 
or mortality in patients with severe heart failure compared to placebo (n = 
582)278_ 
1. 7.6 Monitoring of patients with heart failure 
All patients with CHF due to LVSD need regular monitoring, as many of the 
agents used in its treatment can lead to electrolyte imbalance, renal 
dysfunction and cardiac rhythm abnormalities. The frequency of monitoring 
depends on the stage of disease, severity and drug therapy. Monitoring 
intervals should be short if clinical status or treatment changes have been 
made (e.g. ACE inhibitor dose increased) and is suggested six monthly for 
stable patients with LVSD105. Minimum requirements are for assessment of 
fluid status, cardiac rhythm and BP, laboratory assessment of renal function 
and ideally assessment of functional capacity. Patients should be asked about 
potential drug side effects and the development of anxiety or depression, a 
common occurrence in CHF. Appropriate education of patients and carers 
about self-monitoring is desirable. 
There is no evidence for the use of serial cardiac imaging or natriuretic 
peptides in the monitoring of patients with LVSD, although trials on the latter 
have commenced and should report within 2-3 years. Specialist HF nurses 
are playing an increasingly important role in monitoring and education of 
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patients, and nurse led interventions have been shown to reduce hospital 
admissions and re-admissions 189. 
1.7.7 Device therapies for heart failure 
Cardiac resynchronisation therapy (CRT) re-times the failing heart and 
increases cardiac output and systolic blood pressure, reduces mitral 
regurgitation and improves left ventricular function without increasing 
myocardial oxygen demand280. CRT should only be considered in patients 
with documented cardiac dyssynchrony who are symptomatic despite 
maximal tolerated pharmacotherapy. 
Patients with LVSD who have a prolonged QRS duration (>120ms) may 
benefit from cardiac resynchronisation therapy (CRT) with biventricular 
pacing. Biventricular pacing improves symptoms and exercise capacity and 
seems to reduce symptoms of mitral regurgitation. Patients may also be 
considered for an implantable defibrillator if deemed to be at risk of potentially 
fatal arrhythmias. The Comparison of Medical Therapy, Pacing and 
Defibrillation in Heart Failure (COMPANION) trial was stopped prematurely 
because of a highly significant 20% reduction in the primary endpoint of all 
cause mortality or all cause hospitalisation in the CRT arm281 . Further work is 
needed to establish the practical application of this new technology for the 
benefit of patients with LVSD and cardiac dyssynchrony. 
1. 7.8 The treatment of heart failure with preserved left ventricular 
ejection fraction or diastolic dysfunction 
There is little evidence from clinical trials or observational studies on how to 
treat PLVEF or LVDD. This means that recommendations offered by various 
guidelines are speculative and often based on the understanding of the 
cardiac haemodynamics of PLVEF and L VDD and the knowledge of how 
various drugs may alter those haemodynamic abnormalities seen in these 
conditions. 
There is little evidence that patients with PLVEF or LVDD benefit from any 
particular drug therapy104. The DIG ancillary study16 of 988 patients with HF 
and PLVEF showed some benefit in a composite endpoint of death or 
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hospitalisations for HF, but no significant reduction in all cause or 
cardiovascular mortality. The recent CHARM Preserved trial13 demonstrated 
that inhibition of the renin-angiotensin system by high dose candesatran 
(32mgs) reduced cardiovascular mortality or hospitalisations for HF slightly 
and HF hospitalisations significantly but did not alter mortality. Neither of 
these studies conducted any objective assessment of diastolic dysfunction, 
therefore results cannot be extrapolated to those with LVDD. 
The mainstay of management of PL VEF and LVDD is aggressive 
management of risk factors including adequate BP control and treatment of 
AF. Certain drugs may have theoretical and practical benefits but their use is 
not based on any clear trial evidence: 
• Diuretics may be used to treat fluid overload but over diuresis may be 
deleterious by reducing preload and therefore cardiac output104. 
• ACE inhibitors lower BP and aid regression of cardiac hypertrophy, as 
well as improving diastolic relaxation and cardiac distensibility 
directly104. 
• Beta blockers may help increase diastolic filling time by lowering of 
heart rate104. 
• Candesatran may reduce hospitalisations from HF13. 
• Verapamil may work in the way beta blockers do and has been shown 
to improve functional capacity in patients with hypertrophic 
cardiomyopathy and diastolic dysfunction282•283 
PLVEF and LVDD treatment can be difficult and unsatisfactory. lt should be 
managed by a specialist in HF and GPs should be encouraged to refer such 
patients if encountering diagnostic or therapeutic difficulties. 
1.8 Guidelines for diagnosis and management of heart failure 
1.8.1 Introduction 
Evidence-based guidelines for the diagnosis and management of heart failure 
8
•
10
•
22
•
101
-
104
•
141 all recommend that echocardiography is the "gold standard" 
investigation for accurate objective determination of cardiac function. Yet, 
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GPs are faced by a lack of uniform availability of services 146; difficulty in 
interpretation of technical results; and disagreements about whether an open-
acces~ echocardiography service should be provided139·140·157·159•161 . Other 
options suggested are a hospital based and controlled service162•164•174 or 
open-access services for echocardiography with specialist follow-up when 
deemed appropriate by the GP166. 
1.8.2 The National Service Framework for Coronary Heart Disease -
what are the implications for primary and secondary care? 
The NHS is currently undergoing major reorganization, in part in response to 
the increasing needs of an ageing population. Among the elderly the 
incidence of heart failure is rising to epidemic proportions, and the delivery of 
consistent, coordinated and effective care for'sufferers of chronic heart failure 
(CHF) has become a major challenge. The UK has one of the highest rates of 
coronary heart disease (CHD} in Europe and heart failure is one of the major 
consequences of CHD, illlpqsingan enormous clinical and financial burden 
en UK health services 132,193•284•285. 
The N~tional Service Framework (NSF) for CHD132 acknowledges that death 
rates from cardiovascular disease remain unacceptably higher in the United 
Kingdom than in the majority of European countries. A reduction in 'lhis 
mortality is a national priority. The NSF, which aims to "transform the 
prevention, diagnosis and treatment of coronary heart disease", includes a 
section (chapter 6) dealing with provision of services for heart failure. 
·. ' 
The NSF reinforces the need for accurate identification of CHF patients, and 
states that patients should be offered appropriate investigation to confirm or 
refute the diagnosis of CHF. The NSF is clearer in its treatment 
recommendations. lt specifies that all appropriate patients with heart failure 
should receive first line treatm~ntwitti:ari ACE inhibitor; as these agents have 
be~·n shown" to prolong· tife·~;;- d~tay' disease prc)gression and improve 
symptoms: . : " ~ . \ ; : • • : f . ; 
·,.I ; .· <·. ,· ;-;.: !-. ·' ..• ;_ ' 
The NSF ··states that both· _primary care practices and hospitals should 
,. . '- ,,. . . ·. .' 
' . . -
und~rtake an annual audit of CHF care, and that hospital CHF care must be 
consisient where more· thah one team is· involved. The use of hospital-wide 
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protocols is therefore recommended. Clear communication between the 
secondary and primary care sectors is also vital. 
The recommendations contained in the NSF may go some way towards 
improving some of the current inequalities in CHF care provision across the 
country. The document does not, however, address key organizational issues 
at the heart of CHF care in the future, and at best simply consolidates the 
provision of existing services .. 
As there is. currently no new f!Jnding to support implementation of any of the 
proposals for CHF care in the NSF, development of improved access to 
diagnostic services and specialist heart f(lilure clinics is likely to remain ad hoc 
. '~ • . , . ~ • • ~ • '. • ~ .. :_ . : · .. • 'I 
at best, despite the. acknowledged att~ndant mortality and morbidity of heart 
failure; and despite evidence from other clinical areas such as stroke and 
cancer that patient care is significantly improved by the provision of specialist 
services. 
1.8.3 National Institute for Clinical Excellence guidelines for CHF 
In July 2003 the National Institute for Clinical Excellence (NICE) 105 published 
guidelines for CHF that builds on the NSF for CHD132. The NICE guidelines105 
emphasise the need for coordinated application of treatments in a structured 
manner that includes confirming the diagnosis, coordinating care and 
involving the individual patient. lt is a comprehensive evidence - based 
document that has 92 recommendations in total with some key 
recommendations outlined (see Box 1.1 below). 
Both the NSF for CHD132 and NICE guidelines 105 recognise that current care 
is less than optimal, and in particular acknowledge the need for palliative care 
for patients with end-stage disease. Neither guideline addresses the 
management of patients who suffer heart failure in the immediate aftermath of 
an M I. This group in particular is at risk of further cardiac deterioration due to 
cardiac damage and remodelling with a mortality of up to 20% at six months. 
Whilst hospital based services increasingly need to focus on this particular 
group of patients, multidisciplinary care in general practice will also be needed 
to deliver ongoing care for those with and without subsequent HF. 
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Leslie and Colleagues286 sent a questionnaire to 717 GPs with a 53% 
response rate. They showed that, although most GPs were aware of the 
existence of a national guideline, many had not read it. There was little or no 
difference in the knowledge level for various evidence-based treatments 
between GPs who had or had not read the guideline, suggesting that reading 
guidelines may not be a key factor in determining knowledge. 
Box 1.1 Key recommendations of NICE CHF guidelines 
Diagnosis 
• Diagnosis of HF should be reviewed, and confirmed 
• Echocardiography should be performed 
Treatment 
• All patients with L VSD should be considered for an ACE inhibitor 
• All patients with L VSD should be considered for beta-blockers, after 
diuretic and ACE inhibitor therapy even if asymptomatic 
Monitoring 
• All patients require regular monitoring 
• A clinical assessment of functional capacity, fluid status, cardiac 
rhythm and cognitive and nutritional status 
• A review of medication, and investigation including serum urea, 
electrolytes and creatinine 
Discharge from hospital 
o Should occur 'only when condition is stable and the management 
plan is optimised' 
• The primary care team, patient and carer must be aware of the 
management plan 
Supporting patients and carers 
• Management of heart failure should be seen as a shared 
responsibility between the patient and healthcare professional 
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1.8.4 Implementation strategies in heart failure 
Sackett stated that 'evidence is only worthwhile if it translates into clinical 
benefit'287• As has been discussed already many studies suggest that despite 
the availability of numerous clinical guidelines for the management of HF, care 
remains suboptimal. The ACC/AHA guidelines 10 suggest that the literature on 
implementing practice guidelines for patients with HF can be divided into 2 
areas: isolated provider interventions and disease management systems. 
Furthermore the role of general physicians, primary care physicians and 
cardiologists in the management and implementation of guidelines has 
attracted considerable study. 
Freeman and Sweeney explored the reasons behind why GPs may not 
implement evidence288. They used a qualitative methodology using Balint-
style groups with 19 GPs. The particular feature of these groups that 
distinguished them from standard focus groups was that each meeting 
focused around the case notes of a particular patient, the doctor-patient 
relationship, and the feelings that were generated. Six main themes were 
identified that affected the implementation process: the personal and 
professional experiences of the GPs; the patient-doctor relationship; a 
perceived tension between primary and secondary care; GPs' feelings about 
their patients and the evidence; and logistical problems. One doctor 
commented on the use of ACE inhibitors, "The problem is starting him on the 
ACE because he is very anxious about medication change, and every time 
you change the medication it entails another four or five visits to go and see 
him and to try and reassure him that he is on the right medication." These 
themes show the complexity, fluidity and adaptive nature of implementing 
evidence in everyday clinical practice288. Further qualitative work in the 
context of HF diagnosis and management is needed to identify barriers and 
potential strategies for implementing evidence based treatments. 
1.8.4.1 Isolated provider interventions and academic detailing 
Review of the literature suggests that changing physician behaviour is needed 
to improve care of patients with HF. However a controlled trial has shown that 
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simple dissemination of a HF guideline followed by written and verbal 
reminders about recommended actions was unable to change the treatment 
of HF in the intensive care unif89 . More recently posting treatment 
recommendations to primary care physicians did not improve the quality of 
care for patients recently discharged with Ml or HF290. Multifactorial 
interventions that simultaneously attack different barriers to change tend to be 
more successful than isolated efforts. For example, academic detailing, which 
involves intensive educational outreach visits that incorporate communication 
and behavioural change techniques, has been effective and is commonly 
used by pharmaceutical companies291 . 
Academic detailing is one of the few educational interventions that have 
consistently demonstrated improved physician performance292 . Several review 
articles looking at continuing medical education (CME) have concluded that 
community-based strategies such as academic detailing (and to a lesser 
extent, opinion leaders), practice-based methods such as reminders, and 
patient-mediated strategies appeared to be the most effective activities in 
changing physician performance and/or health care outcomes293-295• Methods 
that are practice and community based rather than didactic also appear to be 
effective strategies for implementing clinical practice guidelines296. Local 
agents, empowered by resources, are best equipped for co-ordinating 
implementation activities297. Academic detailing and other practice-based 
education may well form the cornerstone of continuing professional 
development in general practice298. 
Academic detailing, audit and feedback, as well as individualised teaching in 
response to real events in practice have been shown to improve physician 
performance299•300 and appropriateness of prescribing practices301 •302 . An 
academic detailing approach has been shown to improve GPs' abilities in the 
diagnosis of depression303 and the recognition and treatment of asthma304. 
Several randomised-controlled trials have shown that educational 
programmes utilising academic detailing can modify prescribing practices 
within the community setting in a diverse range of therapeutic areas305-309• 
These studies have been successful in reducing the excessive use of 
drugs306•309•310, increasing the evidence-based use of medication305•308 or 
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improving the dosage prescribing of an agene07. Educational outreach 
('academic detailing') has been shown to improve clinical decision making to 
enhance the quality and cost-effectiveness of care291 and improve drug 
prescribing in primary care311 . 
In summary dissemination of a practice guideline must be accompanied by 
more intensive educational and behavioural interventions to maximise the 
chances of improving practice patterns in the management of HF10• Some 
uniformity may be achieved by developing a robust method for integrating 
evidence into rational, educational, and interventional computer-delivered 
guidance312•313. 
1.8.4.2 Disease management systems for heart failure 
The disease management approach views HF as a chronic illness that spans 
the home as well as outpatient and inpatient settings. Most patients have 
multiple medical, social, and behavioural challenges, and effective care 
requires multidisciplinary systems approaches that address these various 
difficulties 10. This area has been discussed elsewhere (Section 1.7.4). 
1.8.4.3 Who should provide care for patients with heart failure? 
There have been several studies that have addressed the effects of physician 
specialty on the knowledge, management and outcomes of patients with 
HF314. A study of 5 US states demonstrated substantial hospital to hospital 
variation in the quality of care for patients with HF315. Perhaps not surprisingly 
several studies indicate that primary care physicians as a group have less 
knowledge about HF and adhere to guidelines less closely than 
cardiologists232•316-318. Furthermore, studies have noted better utilisation of 
echocardiography and diagnostic testing319•320, increased use of ACE 
inhibitors321 , better adherence to guidelines322 and better outcomes in patients 
cared for by cardiologists rather than general physicians318•320•323. Whilst 
some studies suggested that care by cardiologists was not economical324 , 
others have not shown any cost differences between care provided by 
cardiologists rather than general physicians325•326. 
Comparisons have also been made between cardiologists and heart failure 
specialists and whilst both generally manage their patients in conformity with 
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guidelines, HF specialists are more aggressive in initiation and use of ACE 
inhibitors at target doses327. This may, in part, explain the success of the HF 
clinic model and raises the question as to whether a clinician (e.g. general 
practitioners with a specialist interest in cardiology, geriatrician or general 
physician) with adequate training and experience could manage HF just as 
well if not better than a cardiologist without a specific interest in HF. This is 
particularly relevant in the modern NHS climate of sub specialisation in 
cardiology and the move away from generalist care. 
However, there are potential problems with many of these studies of specialty 
differences. Some were self reported practice and physician knowledge, thus 
may not correlate with actual practice and are subject to non-responder bias 
(almost all had less than 60% response rate). All but one were observational 
studies so may be subject to bias and confounding factors (e.g. patient 
selection, variable response rates and differential recall) that may affect the 
validity of the results. Different types of patients are seen by different 
physicians (a form of selection bias) with cardiologists more likely to see 
younger patients with less co-morbidities and often higher socio-economic 
status than geriatricians. All but Davie et al (UK)321 and Bellotti et al (ltaly)322 
were studies conducted in the USA, hence may not be generalisable to the 
UK setting, especially as types of insurance and health plans in the US setting 
can affect clinical outcomes in patients (e.g. comprehensive cover means a 
patient is more likely to receive appropriate investigation and treatment). 
Finally economic studies tended to be based on costing of single episodes of 
care rather than long term or continuing costs of care. 
In reality close cooperation between cardiologists, general physicians and 
GPs will be necessary to provide care to all patients with HF, including the 
elderly and those with eo-morbid conditions328•329. Primary care physicians 
with knowledge and experience in HF should be able to care for most patients 
with uncomplicated HF. By contrast, patients who remain symptomatic despite 
basic medical therapy and have other cardiac conditions (e.g. AF, VHD, or 
CAD) may benefit from care directed by physicians who have special 
expertise and training in the care of patients with HF10. 
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Chapter 2. 
Barriers to accurate diagnosis and effective management of heart 
failure in general practice - a qualitative study 
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Abstract 
Background 
Heart failure is a common condition with high morbidity and mortality, even 
when mild. lt is largely managed in primary care. Evidence suggests that there 
are wide variations in the standards of management and the clinical 
application of guidelines, but there is a paucity of data from general practice 
as to why this is. 
Aim 
To ascertain the beliefs, current practices and decision-making of general 
practitioners in the diagnosis and management of suspected heart failure in 
primary care, with a view to identifying barriers to good care. 
Methods 
A qualitative approach utilising focus groups with 30 general practitioners from 
four primary care groups in North East England using a stratified, purposive 
sampling strategy. The focus group contents were transcribed and analysis 
followed the principles of "pragmatic variant" grounded theory and content 
analysis. 
Results 
Three categories were identified contributing to variations in medical practice 
and why general practitioners experienced difficulties in diagnosing and 
managing heart failure. 
1. Clinical practice uncertainty, including lack of confidence in establishing 
an accurate diagnosis, worries about using ACE inhibitors, beta-blockers and 
spironolactone in often elderly, frail patients with eo-morbidity and 
polypharmacy. 2. Lack of awareness of relevant research evidence in 
what was perceived to be a complex and rapidly changing therapeutic field. 
Doubts about applicability of research findings in primary care and information 
overload also emerged. 3. Influences of individual preference and local 
organisational factors. Medical training, negative anecdotal experiences and 
outside agencies influenced general practitioner behaviour and professional 
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culture. Local factors included the availability of diagnostic services, resources 
(e.g. accessible cardiologists) and primary-secondary care professional 
interactions and seemed to shape primary care practice and decision-making 
processes. 
Conclusions 
The National Service Framework for coronary heart disease stresses that the 
substandard care of patients with heart failure is unacceptable. This study 
identified barriers to be overcome in locality specific and multifaceted 
implementation strategies across primary and secondary care. Single 
strategies e.g. provision of guidelines, are unlikely to have an impact on 
clinical outcomes and new, conjoint models of care need to be explored. 
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2.1 Introduction 
Heart failure is difficult to define and diagnose49•103•330. lt is common, 
increasing in prevalence and incidence29 and has high morbidity and mortality 
akin to common cancers53•331 . lt is largely managed in primary care39•332 
imposing a heavy burden on the NHS60, and accounting for 5% of medical 
admissions, and high readmission rates60. As populations age and patients 
with ischaemic heart disease, the main cause of heart failure54, survive 
cardiac events and live longer, the public health burden of heart failure is 
likely to increase. Two large studies have shown that heart failure impairs 
quality of life more than any other common chronic medical condition, 
including hypertension, arthritis, chronic lung disease and angina56•57 . 
Diagnosis by clinical assessment is difficult and is correct in less than half of 
cases when confirmed by echocardiography71 •140. Heart failure is relatively 
poorly managed in general practice for many reasons40•41 •147•152•155•333. These 
include diagnostic uncertainty41 ·155, lack of access to diagnostic services 147, 
lack of awareness of research evidence and guidelines 152•333, worries about 
adverse effects, cost and inconvenience of ACE inhibitors40•152 and poor 
communication between primary and secondary care155. The detailed reasons 
behind the apparent variability of practice are in need of further elucidation. 
Much of the current evidence on how to diagnose and manage heart failure 
comes from a secondary care perspective where the difficulties of primary 
care, including differences in patient populations, are not necessarily 
appreciated. Studies have usually relied on quantitative methods, with little 
exploration of the complexity of general practice and its relationship with 
patients and with secondary care147•152. 
The aim of this study was to ascertain the beliefs, current practices and 
decision-making of general practitioners around the diagnosis and 
management of patients with suspected heart failure within primary care with 
a view to identifying barriers to optimal care. 
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2.1.1 Choice of methodology 
2.1.1.1 Research methodology 
A qualitative rather than quantitative methodology was felt to be appropriate in 
the complex context of decision making by GPs in dealing with heart failure 
patients. Qualitative methods are useful where it is sought to understand 
rather than prove; describe and interpret rather than measure and predict with 
the aim of sharpening discussion and disentangling complexity334• 
Consideration was given to the use of a questionnaire survey, semi-structured 
interviews or focus group discussions. 
Advantages of questionnaire surveys are that data collection is systematic 
and they are easy to administer with respondents completing in their own 
time; they are easy to use with a large population in a shorter time than 
interviewing; respondents have relative anonymity; they do not have to speak 
to the interviewer and thus be personally linked to their responses (this may 
give more truthful answers, rather than the participant "telling the interviewer 
what he thinks they want to hear"); and are easy to code and analyse by 
computer33s-337. 
Disadvantages are that appropriate questions may be difficult to devise; the 
interviewee may be unable to elaborate on their responses and the 
researcher is unable to probe to find out more; they may have a lower 
response rate than interviews as they lack the personal touch and it cannot be 
certain whether the questionnaire was completed by the intended respondent 
or by someone else335•336•338. Questionnaire studies are often hampered by 
low response rates, ambiguity of questions and doubts as to whether 
responses accord with actual clinical practice335. 
Face-to-face interviews can be either semi-structured or unstructured and 
tend to have a higher response rate owing to the presence of the 
interviewer339•340. Generally they are more costly and time consuming than 
postal questionnaires. 
With semi-structured interviews, topics and questions are specified in 
advance and the researcher works through an interview guide using their 
judgement to decide which questions to ask. Advantages are that data 
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collection is systematic; interviews are conversational and relaxed and the 
researcher can use their judgement about which topics and questions to 
probe and pursue339•340. Disadvantages are that if the researcher adapts the 
topics, questions and sequence for each individual subject, the interview 
experience is different for each person taking part in the study 339•340. This 
may reduce the comparability of responses and it is possible that key 
questions or topics may be dealt with superficially, or missed out 
altogether340·341 • 
Unstructured interviews are often experienced as informal conversations, 
rather than a data collection exercise. Advantages are that interviewees are 
free to respond in their own way and to give as much detail as they wish; they 
are able to give their opinions and discuss their own experiences; the 
researcher is able to probe to find out more and can hopefully obtain accurate 
and truthful information on attitudes and values339•340. Audio taping and 
transcribing the interviews ensures internal validity and credibility341 . 
Disadvantages are that analysis can be difficult and time consuming because 
of the volume and variety, and because each interview is unique, it can be 
difficult to compare interview results; interviews can last a long time and 
hence only a small number of respondents can be interviewed and this in turn 
may reduce generalisability to a specific population339-341 . Furthermore, 
general practitioners are busy individuals and difficult to tie down to individual 
interviews. 
Focus groups comprise a group discussion focussed on a particular topic 
where the members usually have something in common342. Discussions are 
led by a facilitator and are time and task limited. Their strengths are that they 
are a good way of discovering peoples attitudes, beliefs and perceptions on a 
particular subject; they provide data rich in human experience (a reflection of 
real life experiences of group members); researchers are able to collect 
"beyond the quantitative tick box" and encourage spontaneity and candour; 
data can be collected in a short time from multiple participants and tape 
recording and transcription means data is accurate and not missed; they are 
cost effective and require fewer resources, including time, than personal 
interviews343; results can be generalisable if groups are chosen carefully and 
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thus representative of the study population340·342. Weaknesses are that a good 
facilitator is needed who can encourage people to talk about their experiences 
and ideas. They may be dominated by one or two outspoken individuals and 
may be threatening to some participants, they may "put words in peoples 
mouths", be time consuming to transcribe and analyse and can be expensive 
if secretarial time is needed to transcribe and participant expenses are to be 
paid340,342. 
General practitioners are comfortable with small group meetings. The group 
dynamics allow for "an informal, supportive group of people with similar 
backgrounds to put people at ease and encourage them to express their 
views freely and frankly"344. In this study, uni-disciplinary groups encouraged 
freedom of expression. The direct interaction allows greater potential for the 
researcher to clarify questions, minimise misunderstandings and observe non-
verbal responses345. 
Heart failure is a complex disorder. Focus group methodology was felt to be 
appropriate for generating "the rich details of complex experiences and the 
reasoning behind [an individuals] actions, beliefs, perceptions and attitudes" 
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. Focus groups are useful when it comes to investigating what participants 
think, but they excel at uncovering why participants think as they do347. This 
was felt to be a good method for exploring why gaps between evidence and 
practice exist in primary care management of heart failure. 
The purpose of conducting focus group interviews was to get a detailed view 
of the thoughts and decision making of GPs as they go through the process of 
making a diagnosis of heart failure. This is added to by semi-structured 
interviews of hospital clinicians (see Chapter 3) who may approach the 
diagnosis from a different angle. This is because their patients are different, 
often sicker, and with more resources available including rapid access to 
investigations (such as echocardiography), more time for patients on wards 
and at clinics and the backup of junior staff. Using specific localities it was 
possible to investigate if there were local variations in service provision that 
influenced general practitioners beliefs, practices and decision-making in the 
those localities. 
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2.1.1.2 Sampling strategy 
Qualitative inquiry typically focuses in depth on relatively small samples 
selected purposefully (non-probability sampling) whereas quantitative 
methods typically depend on larger samples selected randomly (probability 
sampling). Probability sampling depends on selecting a truly random and 
statistically representative sample that will permit confident generalisation 
from the sample to a large population, whereas the logic and power behind 
purposeful sampling lies in selecting information-rich cases for study in 
depth348• Patton has described 16 different strategies for purposefully 
selecting cases and more than one qualitative sampling strategy may be 
used. In this study it would not have been appropriate to sample by random 
probability methods because the large numbers needed would be limited by 
time and financial constraints. Purposeful sampling allowed the selection of 
cases for in-depth study, using a smaller sample size that would be 
manageable within the time and financial constraints of the study. More than 
one qualitative sampling strategy would be necessary to fit the purpose of this 
study and to answer the research question. A homogenous group was 
studied (GPs only) and a combination of stratified purposeful sampling and 
random sampling was employed. Stratification illustrates the characteristics of 
particular sub groups (gender, ethnicity, geographical locality, GP partnership 
size, training practice status, part-time or full-time status) and facilitates 
comparison. Taking a random sample within localities and within practices 
adds credibility to sampling when potential purposeful sampling would yield 
too large a sample to be easily managed. Other potential approaches could 
have been to employ a convenience or maximum variation sampling strategy. 
Although convenience sampling saves time, money and effort, it is lower on 
rationale and credibility. With maximum variation sampling a wide range of 
variations or dimensions of interest is selected (e.g. low and high ACE 
inhibitor prescribing, low and high documented heart failure diagnosis, low or 
high use of open access echocardiography facilities). These may identify 
common patterns that cut across variations but identification of these variants 
would be difficult given the fact that (1) ACE inhibitors are also used for 
hypertension, (2) doubts still exist about the diagnosis of heart failure, (3) not 
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all practices have access to echocardiography and (4) practitioners may 
prefer to refer to a consultant more readily or even exclusively when heart 
failure is considered. Patton suggests that more than one sampling strategy 
may be necessary dependent on research, and evaluation often serves 
multiple purposes348. 
2.1.1.3 Sample Size 
In qualitative research the quality of the sample is not dependent on the size 
of the sample. The intent is to achieve 'theoretical saturation' akin to 
redundancy. Researchers watch for patterns in interview results and will 
sample until they discover that they have 'saturated' the theory or found 
redundant information. In focus group research the rule of thumb has been to 
conduct 3 or 4 focus groups for a particular audience and then decide if 
additional groups should be added to the study349. Large-scale studies of 
divergent populations often require more groups but the goal is to determine 
the variability of the concept or an idea. Michael Patton offered examples that 
may be helpful in explaining a small sample size to quantitative researchers 
who may be sceptical about the scientific basis of qualitative research348; 
"Piaget contributed a major breakthrough to our understanding of how 
children think by observing his own 2 children at length and in great depth. 
Freud established the field of psychoanalysis based on fewer than ten client 
cases." 
The validity, meaningfulness and insights generated from qualitative inquiry 
have more to do with the information richness of the cases selected and the 
observational/analytical capabilities of the researcher than with sample 
size348. Sample size will then depend on the research question(s) to be 
answered, the purpose of the inquiry, how the findings will be used, what is at 
stake, what will be useful, what will have credibility and what can be done with 
the available time and resources. In the heart failure context previous studies 
have explored GP behaviour at breadth rather than in-depth40.41. This is 
helpful in exploring a phenomenon and trying to document diversity or 
patterns but does not necessarily tell us the causes of diversity. Guba and 
Lincoln350 stated that the size of the sample is determined by informational 
considerations. If the purpose is to maximise information, the sampling is 
107 
terminated when no new information is forthcoming from new sampled units, 
then redundancy is the primary criterion. This is what Glaser and Strauss351 
called "saturation point". In the end sample size adequacy like all aspects of 
research is subject to peer review, consensual validation and judgement348. 
What is crucial is that the sampling procedures and decisions be fully 
described, explained and justified so that information users and peer 
reviewers understand the context of the results. 
2.2 Method 
2.2.1 Subjects, Setting and sampling strategy 
Focus groups of general practitioners were used. The study was set in 
Northeast England in a locality with six Primary Care Trusts covering a 
population of 617,532 with 316 general practitioners in 88 practices. 
Participants were selected using a mixed purposive sampling strategy348 from 
an up-to-date health authority general practitioner register. The register was 
divided into the 6 separate PCG areas (Darlington, Durham-Dales, 
Sedgefield, Durham and Chester-le-Street, Easington and Derwentside). lt 
was decided that we would conduct 4 focus group interviews initially and the 
first 4 localities on the above list were chosen at random by my secretary. 
Initially 8 GPs from each of these localities were chosen randomly from 32 
different practices. Stratification of general practitioners allowed proportionate 
representation of gender, ethnicity, geographical distribution, employment 
status (part-time or full-time) and practice size (group or single-handed) and 
attempted to avoid selecting general practitioners from the same practice. 
Forty-one general practitioners were contacted by telephone and a follow-up 
letter detailed the broad purpose of the focus groups, venue and timing, and 
included a brief demographic questionnaire. 9 GPs from the original 32 could 
not participate for a variety of reasons including work and holiday 
commitments, and these were replaced at random from the register. 4 groups 
of 8 GPs were then finalised. 2 GPs were unable to attend on the day of the 
focus groups. Local venues were used to facilitate maximum general 
practitioner attendance. Early evening timing was suitable for busy general 
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practitioners and helped reduce interruptions by surgery staff or patients. 
Postgraduate education allowance certification and a small honorarium may 
have helped enhance recruitment. Eleven participants were unable to 
participitate or did not attend; their demographic and professional 
characteristics did not differ from those who did attend. The groups comprised 
six to eight participants and a eo-moderator was used in three of the four 
focus groups. Moderators or facilitators were provided with advice and tips on 
running a successful focus group. 
The 30 participants (males 25, overall age range 33-64 years, years since 
graduation 10-42 years) represented a wide range of practice size and length 
of experience, including three from single-handed practices. Twenty-seven 
were full-time, three part-time and 20 (66%) had open access 
echocardiography. The male to female ratio of general practitioners in the 
locality was 3:1 and in the focus groups 5:1. 
The full demographic details of the 30 participating general practitioners 
obtained from a questionnaire collected at the focus group session is 
illustrated in Table 2.1 below. I believe that conducting focus groups in 
different localities with variable access to echocardiography and potentially 
different referral patterns was advantageous in ascertaining more varied views 
of GP experiences. 
A list of points to be considered was compiled from a literature review and 
was used to assist the discussion (see appendices 8 and 9). The sessions 
(lasting between 65 to 90 minutes each) were audio taped, transcribed 
verbatim by a medical secretary and then corrected and verified by the 
principal investigator (AF). 
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Sex Age Years University Doctors in Patient Part-time Open Estimated 
Qualified practice list size or full-time Access referrals I 
Echo month 
Darlington PCG 
Male 43 20 Belfast 3 5000 FT Yes <1 
Male 48 25 St Mary's 7 11700 FT Yes 0 
Female 34 11 Cork 8 14500 PT Yes <1 
Male 43 20 Newcastle 4 7200 FT Yes <1 
Female 39 16 Glasgow 5 9300 PT Yes 1 
Male 44 21 St Mary's 5 8500 FT Yes 1-2 
Male 58 31 Glasgow 2 4500 FT Yes 1 
Male 58 31 London 6 16000 FT Yes 0 
Sedgefield PCG 
Male 34 12 Newcastle 7 14500 FT Yes 0-1 
Male 37 16 Newcastle 7 14500 FT Yes <1 
Female 44 18 Cambridge 1 2100 FT No 0 
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Sex Age Years University Doctors in Patient Part-time Open Estimated 
Qualified practice list size or full-time Access referrals I 
Echo month 
Male 36 12 London 5 9000 FT No 0 
Male 51 26 India 1 1200 FT No 0 
Male 36 14 Leeds 5 9600 FT Yes <1 
Male 37 15 Dundee 10 17000 FT No 0 
Male 64 42 Liver:pool 3 6500 FT Yes 0 
Durham & Chester le Street PCG 
Male 42 20 Newcastle 3 4300 FT Yes >1 
Male 33 11 Leeds 5 10000 FT Yes 2/3 
Male 48 23 Manchester 5 9200 FT No 0 
Male 37 13 Aberdeen 10 20000 FT Yes <1 
Male 49 26 India 1 2200 FT Yes <1 
Male 46 24 London 13 23000 FT No 0 
Male 47 14 Birmingham 5 8500 FT Yes 0 
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Sex Age Years University Doctors in Patient Part-time Open Estimated 
Qualified practice list size or full-time Access referrals I 
Echo month 
Male 42 19 Dundee 5 8500 FT Yes 1 
The Dales PCG 
Male 35 11 Belfast 5 8600 FT No 0 
Male 49 21 Newcastle 5 10200 FT No <1 
Male 35 12 Newcastle 6 13000 FT No 0 
Male 42 10 Newcastle 5 7400 FT No 0 
Female 41 13 Aberdeen 7 10500 PT Yes <1 
Female 42 21 Sheffield 2 2500 FT Yes <1 
Summary 
25M/5F 33-64 10-42 1-13 2100- 27 FT/3 PT 20 Yes/10 0-2/3 
23000 No 
-
Table 2.1 Characteristics of the 30 participating GPs 
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2.2.2 Analysis 
The analysis followed "pragmatic variant" grounded theory and content 
analysis principles351 -355. Transcripts were read and broad themes identified 
as the groups progressed. This iterative process allowed ideas and thoughts 
that were emerging to be brought back to subsequent groups. The iterative 
process started during the interviews as I took notes of new concepts or ideas 
as they emerged. The tape recordings were transcribed after each interview 
and corrected by AF whilst listening to the tape recordings. This allowed me to 
start coding (indexing) with margin notes as the research progressed. I was 
then able to take these new ideas back to the next group. Examples of this 
include the concept of ageism in heart failure diagnosis and treatment, the 
influence of rural geography on access to investigations, patient choice in 
determining investigation and treatment from the Durham-Dales group that 
were then explored further in the subsequent Sedgefield group. These issues 
had not been discussed in the first (Darlington) group. 
Deviant case analysis was used to question widely accepted practice351 . 
Examples of this include: 
1. A GP who did not use OAE even when available. This was contrary to 
the prevalent view that OAE should be available to primary care and 
led to me exploring the reasons behind this in more detail both during 
subsequent groups and from the data already collected. 
2. A GP who would never tell a patient they had heart failure. This was 
then debated in further groups with some other GPs agreeing with this 
course of action for fear of affecting patient quality of life. This was 
challenged by other GPs who believed in openness in patient 
communication and argued that this would improve compliance with 
therapy. 
3. A GP who admitted all patients with suspected heart failure contrary to 
the widespread practice of initial treatment and investigation in primary 
care. This was discussed at subsequent groups and the reasons for 
investigation in primary care versus admission explored. 
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No new major themes arose by the end of the fourth focus group implying that 
'saturation'351 was becoming evident. The transcripts were read several times, 
data organised into codes (within highlighting of data and margin notes) from 
which categories were identified and major themes constructed by AF and 
APSH. There was a systematic collection of emergent codes that were 
organised into outline categories and then outline broad themes. Multiple 
colour-coded copies (a different colour for each focus group) of transcripts 
were produced and a cut and paste process using scissors and A 1 sheets 
used to paste into analytical categories. Transcripts (annotated with margin 
notes) and outline codes/categories/themes were presented to APSH and 
JJM. All three investigators (Ahmet Fuat, Jerry Murphy, Pali Hungin) 
contributed to multiple coding by meeting up and after discussing the 
codes/categories and hence final themes were agreed. Examples of codes 
include clinical history, symptom presentation, clinical signs, patient 
examination, definition of heart failure, barriers to diagnosis, diagnostic tests 
including ecg, chest xray and echocardiogram, defensive medicine, referral to 
hospital and GP education were all grouped under a category of the 
diagnostic process which was then included under the broad theme of clinical 
practice uncertainty along with availability and use of echocardiography and 
treatment issues. I had initially identified 5 broad themes: 
1. The diagnostic process; 
2. Treatment issues; 
3. Ignorance of relevant research evidence; 
4. Influences on individual practice preference and; 
5. Local influences. 
After our research group meeting this was changed to 3 themes; 
1. Clinical practice uncertainty; 
2. Lack of awareness of relevant research evidence and 
3.1nfluences of personal preference and local organisational factors 
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All 3 researchers were then involved in deciding how the research would be 
written up, presented and also which journals should be targetted for 
publication. 
Analysis was enhanced by constant comparison351 with the transcripts and 
available research in this field from the initial literature review. This process 
allows each item to be checked or compared with the rest of the data to 
establish analytical categories and is central to the grounded theory approach 
to analysis356. 
Glaser and Strauss suggested that the grounded theory approach to data 
analysis produces explanations or theories that are derived from the dataset 
itself rather than from a researcher's prior theoretical viewpoint. In practice, 
however it is unlikely that a researcher would not have carried out a thorough 
literature review or formulated some idea of the content of the data likely to be 
collected356. 
I adopted the Melia model of pragmatic variant grounded theory352 , whereby 
added value was achieved by identifying new themes from the data alongside 
those that could have been anticipated from the outset. 
A constant comparative method357 was used to continuously compare the 
views and experiences of GPs who had been selected purposively in order to 
illuminate subtle but potentially important differences. An example of this 
would be my approach to the issue of underuse of ACE inhibitors where I 
summarised the potential reasons behind this from the available studies and 
then explored these in my own study; 
1 Diagnostic uncertainty150 
3 Ignorance of heart failure studies 151 
2 Lack of use of echocardiography services 151 
4 Worries about hypotension 151 
4 Worries about valvular disease (especially aortic stenosis) 151 
6 Cost of drugs 151 
3 Slowness of symptom relief151 
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3 Underestimation of poor prognosis associated with HF152 
4 Concerns about adverse events 152 
1 Difficulties of securinga diagnosis and differential diagnoses 153-155 
4 Perceived inconvenience of use and adverse effects of ACEi153-155 
3 View that patients can be managed successfully with diuretics 153-155 
5 Type and quality of information transfer from secondary to prim ay care 153-155 
2 Lack of open access echocardiography 146 
1 Differences in use of clinical information77 
Constant comparative analysis of the focus group database and above 
studies explored and verified the reasons behind underuse of ACE inhibitors 
and the following categories were constructed (numbers correspond to the 
numbers in the above list); 
1 Diagnostic uncertainty 
2 Lack of access to diagnostic echocardiography 
3 Ignorance of research evidence 
4 Adverse events from ACE inhibitors 
5 Poor communications between primary and secondary care 
6 Economic considerations 
Data analysis was commenced after the first focus group and this iterative 
process added value to subsequent focus groups. 
Multiple coding is felt to equate to the quantitative equivalent of "inter-rater 
reliability" and is a response to the charge of subjectivity sometimes levelled 
at the process of qualitative data analysis356•358. This demands the cross 
checking of coding strategies and interpretation of data by independent 
researchers. Unlike "inter-rater reliability", the degree of concordance 
between researchers is not that important; what is of value is the content of 
disagreements, the insights that discussion can provide for refining coding 
frames and its capacity to furnish alternative interpretations356• 
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2.2.3 Respondent validation 
Respondent validation involves cross checking research findings with 
participants in order to protect against misrepresentation of views expressed 
during the focus group interviews359. All 30 participants were sent a report 
summarising the study results and conclusions, along with a respondent 
validation form (Appendix 1 ). Each report was highlighted on an individual 
basis for each investigator. This had the advantage of allowing each 
participant to check that their own responses were represented appropriately 
as well as giving them an overview of the full research analysis. Of 28 replies, 
27 "strongly agreed" or "agreed" and one "neither agreed, nor disagreed" that 
the report was an accurate representation of their opinions and the group 
outcomes. 
I could have used respondent validation in a more iterative manner by asking 
participants to check interim findings and transcripts of individual focus 
groups. The advantage of this could have been that respondents' reactions to 
emerging findings could have helped refine explanations further. 
Disadvantages are that the researcher seeks to give an overview of research 
findings whereas respondents have individual concerns and this could have 
led to discrepant accounts especially if I had chosen to disregard my own 
interpretation and accepted those of respondents at face value. Furthermore, 
asking respondents to read drafts woud have made considerable demands on 
their time and may have led to delays in analysis. 
I therefore opted for a simple respondent validation approach but asked for 
participant comments. Comments were received from 14 of the participants 
and some stimulated further analysis as well as leading to adaptation of the 
final report. An example of this is where a GP made the following comments 
that led to a review of the final report; "I can recognise a few of my comments 
and most peoples concerns are broadly similar to mine. One major factor I 
don't feel is mentioned significantly are the differences treating new and 
established cases. I tend to follow the guidelines for new cases but not for all 
'established' cases for a number of reasons which are reasonably 
documanted in the summary". 
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Others agreed with the report; "virtually everything I learnt at medical school 
has now been turned on its head and shown to be unsafe or unsound. Trying 
to keep reasonably up to date with everything else one is expected to do 
makes clinical practice almost impossible. Your paper mirrors pretty much 
how I feel" 
I did find use of respondent validation more than just an approving bumper 
sticker for this qualitative study356 
2.3 Results 
Three major themes were identified which contributed to reasons for the 
variation in medical practice and why general practitioners experienced 
difficulties in diagnosing and managing heart failure. The themes were clinical 
practice uncertainty, lack of awareness of relevant research evidence and 
influences of personal preference and local organisational factors. 
2.3.1 Clinical practice uncertainty 
Most participants expressed a lack of confidence in establishing the diagnosis 
of heart failure. This affected the management of the individual patient. Under 
this theme three main categories were identified: the diagnostic process, 
availability and use of echocardiography services, and treatment issues. 
2.3.1.1 The diagnostic process 
Heart failure was perceived to be a difficult diagnosis to make in general 
practice because of several factors: 
• Problems with the subtlety of clinical symptoms and signs: 
"Some of the clinical signs, if you have a raised JVP or third 
heart sound, hepatomegaly, are often difficult in the obese to 
detect, and ankle oedema is common anyway'' 
"The fact that people as they get older tend to get crackles in 
their chest almost as a matter of normality, well because they 
have crackles it doesn't usually mean failure does it?" 
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• Difficulty in differential diagnosis especially in elderly patients with eo-
morbidity e.g. chronic obstructive airways disease and obesity: 
"I think heart failure would be not too difficult a subject if it 
occurred in young fit people but the biggest problem is that it's 
always inevitably older people who get it. lt's a eo-pathology 
intermingled with other things and that makes it often quite 
difficult to disentangle" 
• Time constraints and a generally increasing general practitioner 
clinical and administrative workload: 
"20 plus patient surgeries and having to try and stick to close to 
10 minutes, it can be quite difficult to do a really full assessment" 
• Lack of availability of diagnostic tests including electrocardiography, 
chest X-ray and echocardiography, and lack of confidence in 
interpretation of the results of these tests: 
"You get a kind of slightly reduced ejection fraction and you 
know an iffy tricuspid valve or two and you know you're not 
really that much further forward' 
"We are aware that echocardiograms help but we've had 
problems with access to them" 
''They [echos] are not as accurate as one sometimes is led to 
believe and I agree with [other GP], I think sometimes they can 
confuse the issue rather than clarify it" 
• Inertia or fear of initiating action because of anxieties about committing 
to an intensive course of action, including investigations, initiation, 
titration and monitoring of therapy: 
"I think it's the milder degrees of heart failure . . . that is the 
difficulty. But once you've diagnosed it you're committed to a 
course of action and I suppose it seems quite a drastic course of 
action, you've obviously got the diuretics, ACE inhibitors, and 
possibly other medication as well, full investigations and I 
suppose that could lead to a bit of inertia, couldn't it. Somebody 
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with a bit of swollen ankles, you're not quite sure whether it's HF 
or orthostatic oedema or whatever and you say we'll see how it 
goes instead of committing yourself to investigation for fear of 
what you might have to do in the long term." 
• Patient choice, including reluctance to be investigated or treated 
further: 
"Some patients obviously don't want to be hospitalised or don't 
want a second opinion, and sometimes don't want to go to 
hospital, so you end up treating them yourself' 
2.3.1.2 Availability and use of echocardiography services 
Perceived handicaps included the variability of open access 
echocardiography within the same locality; 66% of the participants had this 
facility. Some of the inequality was due to the continuation of access acquired 
previously by general practice fund holders. A number of the open access 
services had been funded through pharmaceutical sponsorship but 
disappeared as "monies dried up." A further perceived problem was the 
variability in echocardiography reporting, some by technicians and others by 
clinicians and a lack of guidance for their use or of standardisation of request 
forms. 
Some general practitioners did not use open access echocardiography even 
when it was available, chiefly because of not being able to understand 
technical results and the inconvenience caused to often very ill patients. (See 
Box 2.1 below) 
lt was apparent that general practitioners were less likely to use open access 
echocardiography when reports were technical and lacked a clinical opinion 
than when a clinician-guided report was available. In these circumstances 
they either treated symptomatically or referred to hospital; a lack of open 
access was cited as a reason for increased referrals. Apprehensions were 
expressed about overloading cardiology services, especially with patients who 
appeared well: 
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"I think there is also a feeling that it's almost an inappropriate cardiac 
referral ... the cardiologists are so busy and when you first make the diagnosis 
they (the patients) are often actually not that poorly ... " 
Box 2.1 : Difficulties for General Practitioners around Echocardiography 
• Uncertainty about the significance of results and interpretation of technical 
reports: 
"The problem with echocardiograms is that I really just don't understand 
them. I don't think of myself as being really. that old, I mean I'm 43 ... 
and when I went through my post-registration years echocardiograms 
just weren't around ... I just don't know where I am with them. WHen 
does an ejection fraction of such and such percent stop being 
reasonable and start being a problem?" 
consultant opinion: 
"I would rather refer than do an echocardiogram, the interpretation of 
which I am not confident with" 
"I'm not confident in diagnosis of heart failure. I think I just like to have it 
rubberstamped" 
• Distance to nearest echocardiography clinic may inconvenience patients: 
"lt takes a whole day to go to hospital, and for an elderly person with 
breathlessness that's a long day, ambulance there and back, sit in a 
waiting room, and patients do it once and they won't do it again and 
they don't all have relatives to take them in" 
2.3.1.3 Treatment issues 
Diagnostic uncertainty cast doubts on the development of individual treatment 
strategies for patients. The treatment process was an area where further 
barriers to evidence based practice were identified. 
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There was a good awareness of non-pharmacological advice and 
interventions such as weight reduction, tailored exercise, salt restriction for 
patients with heart failure22. Most agreed on the importance of patient 
education but some expressed concerns at informing patients about the 
diagnosis as this might lead to anxiety. This was countered by those who felt 
that openness and patient involvement enhanced compliance. 
Although attitudes were felt to be changing, there were still worries 
surrounding the use of ACE inhibitors. Concerns remained about their 
commencement in primary care as opposed to in hospital, partly because of 
previous teaching and a fear of side effects, mainly hypotension, in the 
community setting. (See Box 2.2 below) 
Even if ACE inhibitors were initiated in primary care a further barrier was the 
inability to attain the recommended doses as in major studies and guidelines22 
(See Box 2.3 below) 
There was widespread awareness of beta-blocker use in heart failure259 but a 
unanimous feeling that it should be a "hospital initiated thing", because of a 
fear of patients collapsing in the community setting. Most were apprehensive 
about their use and one GP voicing fears indicated that it was "commonsense 
for general practitioners to be a little bit reticent." Most general practitioners 
mentioned medical school teaching that emphasised beta-blockers were 
contraindicated in heart failure: 
"If still seems a contradiction when we were taught beta-blockers 
precipitate cardiac failure. I'm sure we've all seen that happen and to 
turn round and prescribe them, it goes against the grain a bif' 
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Box 2.2: Concerns about using ACE inhibitors in General Practice 
• Concerns about use in elderly patients and those with renal impairment 
and worries about side effects including cough, postural hypotension 
and renal failure: 
"I'm not too sure exactly at what degree of renal impairment one 
should wony too much" 
• Polypharmacy and drug interactions was considered a barrier, 
especially in the elderly: 
"The other thing that raises its head is polypharmacy here, where 
you have got your people who have been chewing their aspirin for 
years, that a lot of these will be on statins, anti-arlhritic drugs. 
You've got your ACE inhibitors and diuretics. Well that's five or six 
(drugs) and I think you're going to have rebellion on your hands 
from people who say they are on far too many tablets ... " 
• Ageism was flagged up as a consideration in all four groups: 
"I think there is an ageist agenda with it as well because you know 
somebody of 60 who has got hearl failure, you're going to be much 
more aggressive with than someone who is 78, not just in terms of 
making the diagnosis but the investigations and treatment" 
• A few general practitioners were happy to keep patients on diuretics and 
"spare them the ACE inhibitor unless they are getting worse" 
• There was a minority perception that diuretics alone are "OK in mild 
hearl failure" 
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Box 2.3: Barriers to achieving optimal ACE inhibitor doses in General 
Practice 
• Worry that the diagnosis of heart failure was incorrect: 
"But it worries me that if you are pushing the ACE inhibitors up to the 
maximlJm dose which you are recommended to do, that you've got your 
diagnosis right in the first place" 
• Although some awareness of the benefits of high dose existed there 
appeared to be a lack of knowledge of target doses used in major tnals 
• Worries expressed about "huge doses" leading to side effects and 
intolerance 
• Reluctance to increase dose if patient was asymptomatic or stable: 
"If you've got someone who is stable, you're sometimes a bit reluctant 
to increase the dosage of any medication if the condition is well 
contro1/ed" 
already been on a low dose for a while" 
Most general practitioners indicated that they were unaware of the place for 
other agents including spironolactone and angiotensin 11 antagonists in 
treatment of heart failure22 . Despite its previous use over many centuries 
digoxin posed a problem: 
"I'm not (even) up to speed with spironolactone or beta-blockers yet" 
"But you compartmentalise drugs and my compartment for digoxin is 
atrial fibrillation and you find it difficult to move digoxin out of that one 
and I don't think I've ever initiated digoxin for heart failure" 
"Digoxin: I wouldn't use it in sinus rhythm" was a common response 
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2.3.2 Lack of Awareness of Relevant Research Evidence 
All focus groups discussed their views on the dissemination of research 
evidence, guidelines and applicability of evidence in primary care. Information 
overload was seen as a common cause of stress and concern in primary care. 
Many worried about the "rapidity of change in all fields" and "keeping up to 
date with changes", but felt that we "owe it to our patients" to be in touch with 
recent developments. 
Existing guidelines about the diagnosis and management of heart failure and 
the use of ACE inhibitor therapy were not familiar to most participants. To 
some extent this was due to "guideline fatigue"; one general practitioner felt 
"bombarded and bamboozled by guidelines" 
Specific to heart failure was the lack of awareness of the importance of 
confirming left ventricular systolic dysfunction, differences between systolic 
and diastolic heart failure and the significance of New York Heart Association 
(NYHA) classification (a system of grading the severity of heart failure) in 
categorising heart failure. There was lack of knowledge as to how NYHA 
classification could be used to provide a prognosis and guide management. 
Some general practitioners were happy to keep patients on diuretics alone, 
possibly unaware of potential benefits of ACE inhibitors, beta-blockers and 
spironolactone22•259. Most had little knowledge of the place for agents other 
than diuretics and ACE inhibitors and there was a feeling from some quarters 
that heart failure should be managed in secondary care: 
"Can we adequately manage heart failure in general practice, given the 
modem advances that we are all unsure about?" 
2.3.3 Influences of personal preference and local organisational factors 
Medical training, anecdotal experiences and outside agencies (Health 
Authorities, Primary Care Groups and the pharmaceutical industry) emerged 
as influences on individual clinician behaviour and professional culture. In 
some instances this was deeply entrenched and perversely also affected 
newer influences. An example of this was a participant from a large teaching 
practice who justified his reluctance to refer all patients for echocardiography; 
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the factors behind this are likely to be complex and relate to coming to terms 
with a rapidly changing medical environment: 
"I got through the whole of hospital training and we didn't use 
echocardiograms. In cardiology we managed everyone with heart 
failure without an echocardiogram" 
Another GP was reluctant to accept the use of beta-blockers in heart failure: 
"I think that's the trouble with the older generation. Medical school 
taught us 'Beta-blockers and HF - no', People don't change that 
thought no matter what the evidence may be" 
A clinician's anecdotal experience naturally shapes their thinking and may 
colour judgement processes in their management of heart failure patients. 
This seemed to be most prominent when considering treatment options: 
"Renal function has always worried me ever since I put a lady on an 
ACE inhibitor and knocked her into renal failure and I have always 
been rather sort of worried about that since then" 
"So he [cardiologist] tried him on carvedilol and he bombed out straight 
away. So I've always been a bit wary about its use" 
Local organisational factors around the provision of diagnostic services such 
as open access echocardiography, resources, lack of cardiologists, and 
primary/secondary care professional interactions shaped general practitioner 
practice and decision-making processes. A locality based, contextualised 
approach was found acceptable: 
"A locally drawn up set of guidelines which are pertinent to the local 
situation, that is primary and secondary care situations, drawn up by 
representatives from both primary and secondary care and other 
interested stakeholders that is owned by everyone who is going to use 
them" 
"We are in an imperfect health service and we are resource starved, 
and if like every other medical problem we deal with, if we wanted to 
manage heart failure as we would like to, it's going to have significant 
resource implications" 
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In relation to the referral to cardiologists of patients with suspected heart 
failure, the general practitioner's decision was influenced by waiting lists and 
the local availability of consultants: 
"Being pragmatic you look at waiting lists, we've got some very good 
geriatricians who have excellent clinical skills and certainly if the patient 
has got multiple pathologies I would have no hesitation in referring to 
them" 
2.4 Discussion 
2.4.1 Summary of main findings 
lt is recognised that heart failure is poorly treated in the United Kingdom, 
mainly because of inaccurate diagnosis and inappropriate treatment, including 
the use of heart failure therapy in a large group of patients who do not actually 
have heart failure41 •44 . A major reason for failing to make an accurate 
diagnosis is that the symptoms and signs are not highly specific73. This study 
provided information about the difficulties perceived by general practitioners in 
achieving accurate diagnosis and instituting modern therapy22. 
The most accurate method of diagnosis involves the use of echocardiography, 
but this study confirmed a variation in its availability146 and discovered that 
practitioners were not confident about interpreting results. At the same time, 
there was a reluctance to refer to a consultant for a definitive diagnosis 
because of a fear of overloading services and a continuing perception that 
heart failure remains a primary care problem. 
lt is evident that the diagnosis and management of heart failure has evolved 
dramatically such that it relies upon specialised investigations and drug 
regimens that often require specialist input. Clinicians who trained within the 
previous paradigm have essentially not come to terms with the more modern 
approach. In turn, there has been insufficient development of services to 
capitalise on modern management. 
Paradoxically, there was a good appreciation by the general practitioners of 
the benefits of modern treatment, particularly ACE inhibitors as from large-
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scale trials22. Although confidence in their use has increased, a substantial 
minority of general practitioners were reluctant to use them, especially in the 
elderly. This was related to fears about side effects, especially hypotension 
and collapse in the community setting, and the lack of contextualised primary 
care monitoring guidelines. 
Polypharmacy was viewed particularly negatively. lt is known that if between 
one and five drugs are prescribed, the likelihood of adverse drug reactions is 
3.4% rising to 24% with six or more360. The increased numbers of tablets 
likely to be required by the elderly with concurrent conditions such as diabetes 
and its associated problems was considered daunting and detracting from 
compliance. In such situations, decisions about the most appropriate 
regimens were likely to be weighted by the requirements of the different 
conditions and perceived returns from intervention. Although chronic heart 
failure is serious and progressive with proven benefit from appropriate drug 
intervention many clinicians do not find it easy to judge the extent of 
worthwhile return in older patients with underlying problems such as 
ischaemic heart disease. Patients already diagnosed with heart failure who 
appear stable on conventional therapy but who might benefit from newer 
interventions259 also posed a dilemma; many clinicians were reluctant to 
initiate newer treatments, some of which, such as digoxin and 
spironolactone22 have ironically, been around for decades. 
The majority of GPs accepted that patient education was essential when 
making treatment considerations. Discussions around this area were in 
concordance with published advice on lifestyle and non-pharmacological 
management127·361 . Some, however, had difficulty in telling patients that they 
had heart failure. A recent qualitative study highlighted the fact that patients 
have questions about their illness that they felt unable to ask their doctors, 
and that some patients would welcome timely and frank discussion about 
prognosis. lt was suggested that effective and better ways of communicating 
with patients with chronic heart failure need to be tested362. This may then 
have positive influences on compliance with treatment. 
Ageism in cardiology has received much publicity lately363•364 and was an 
issue discussed in all four groups. The general feeling was that age should 
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not be a barrier to investigation and treatment of HF, but a holistic approach to 
patient care should guide the physicians' actions. With increasing age, men 
and women with suspected heart failure are less likely to have undergone 
echocardiography or to have received an ACE inhibito265 . Major trials, 
physician practice, and service developments have neglected older people. 
This imbalance needs to be redressed. 
Sub-optimal care often results from factors outside the immediate control of 
the general practitione233. Local circumstances, such as resource allocation, 
priorities, and consultant attitudes, are crucial. This study confirmed that 
general practitioners perceived this to be the case for heart failure. The 
increasing involvement of primary care in planning local services via Primary 
Care Groups may alleviate this providing they can work effectively with 
secondary care. 
2.4.2 Study Strengths and Limitations 
The qualitative methodology for this research lent itself well to discovering the 
barriers to optimal care. Rigour was enhanced by multiple coding and 
respondent validation359; the personal and intellectual bias of the principal 
investigator was minimised by using a eo-moderator in three groups, by 
allowing discussions to develop naturally and by reporting the wide range of 
perspectives. This was aided by the moderator striking a balance being non-
prescriptive and attempting to cover the majority of the topics in the discussion 
list. Open ended questions such as "what areas of heart failure care would 
you like to discuss" often led to discussion by the majority of participants e.g. 
"I think there is an ageist agenda with it as well because you know 
somebody of 60 who has got heart failure, you're going to be much 
more aggressive with than someone who is 78, not just in terms of 
making the diagnosis but the investigations and treatment" 
"Well it is a major thing throughout cardiology isn't it? When you stop 
offering older people treatments that can prolong their lives." 
Deviant case analysis351 enhanced the validity of the findings by questioning 
widely accepted practice. Generalisability from qualitative research remains 
an issue with some. Guba and Lincoln have introduced the concept of 
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transferability as an alternative to generalisibility350. This implies that the onus 
is on the reader to evaluate the methods, setting and results and decide if 
these are transferable to their own situation. We believe that the findings of 
this study can be transferred to the majority of settings in the United Kingdom. 
2.5 Conclusions 
There is an inherent dilemma in the management of heart failure. Advances in 
science have outstripped the ability and capacity of NHS delivery systems; 
rapidly changing therapeutic paradigms have confused clinicians, sometimes 
because drugs previously regarded as dangerous, such as beta-blockers, are 
new cornerstones and others expelled from the arena, such as 
spironolactone, are back in vogue. Previous work has explored general 
reasons why general practitioners do not always implement best evidence288. 
This study identified specific barriers that need to be overcome if aiming for 
state of the art management. Particular factors needing attention are better 
and clearer information, improved availability and a useful translation of 
results from diagnostic methods, and expedient access to specialist advice 
when there is doubt. Strategies for this might include the development of heart 
failure clinics and involving general practitioners and nurses with a specialist 
interest within an integrated care pathway. The National Service 
Framework 132 stresses that substandard care for heart failure is unacceptable 
and there is a pressing need for such new, conjoint strategies. 
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Chapter 3. 
The diagnosis and management of heart failure across primary-
secondary care: a qualitative study of specialists' views and attitudes 
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Abstract 
Background 
The management of heart failure has altered greatly and good outcomes are 
dependent on an accurate, specific diagnosis and modern therapy. In 50% of 
cases heart failure is diagnosed in hospital, with high readmission rates. 
There is evidence of variation in the diagnosis and management practices 
between specialists and hospitals, compromising uniformly high standards. In 
turn, this is likely to affect quality of ongoing management in primary care. 
Aim 
To explore specialists' attitudes and practices in the diagnosis and 
management of heart failure with a view to identifying barriers to provision of 
uniformly high standards of care. 
Methods 
A qualitative approach utilising semi-structured interviews with twelve 
clinicians (2 cardiologists, 2 specialist general practitioners, 4 geriatricians and 
4 general physicians) in northern England, using a purposive sampling 
strategy. Interviews were transcribed and analysis followed the principles of 
"pragmatic variant" grounded theory and constant comparison. 
Results 
Three major themes were identified that contributed to variations in practice. 
(a) Diagnostic difficulties including access to echocardiography, failure in 
establishing the aetiology of heart failure, and the assessment and 
management of increasingly elderly patients with co-morbidities (b) Treatment 
issues, dependent on consultant experience and interest in heart failure, and 
barriers to initiation of evidence-based therapies (c) Service delivery 
problems influenced locally by NHS resources, competing clinical priorities 
and a lack of speciality responsibility for heart failure. 
Conclusions 
Variable opinions and practice in the diagnosis and management of heart 
failure in hospitals and across primary-secondary care was confirmed. Many 
of the problems were common to primary care. Newer models, including 
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expedient diagnostic facilities, inpatient integrated care pathways and 
structured care protocols need developing. Primary Care Trusts and hospitals 
need to work together to achieve conjoint working patterns to improve patient 
care. 
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3.1 Introduction 
The quality of heart failure management in primary care is variable and often 
sub-optimal. Recent research has shown that clinical practice uncertainty, lack 
of awareness of relevant evidence, influences of individual practice 
preference and local organisational factors were major reasons for this 
variability in general practice366. 
There is evidence that hospital care is also sub-optimal222 and subject to 
variability between hospitals367, especially between different medical 
specialities such as cardiology and geriatrics316•323. Much of these data are 
from the USA and there is a paucity of similar information from UK hospital 
practice. Such information is needed for the configuration of services to 
uniformly high standards. The aim of this study was to ascertain from hospital 
consultants and specialist general practitioners in cardiology, reasons behind 
variations in the diagnosis and management of heart failure, and to identify 
barriers to the provision of uniformly high standards of care. 
3.2 Methodology 
3.2.1 Justification for the choice of methodology 
Qualitative data are often relatively unstructured: they come in the form 
presented by the subjects of the research rather than being pre-packaged by 
the researcher339. The researcher therefore needs flexibility and adaptability 
to respond to the research subjects rather than imposing a structure upon 
them. The researcher is, in effect, creating a natural situation, be it a 
conversation or a group discussion in order to collect the data340. 
Consideration was given to three methods of collecting the information 
needed to answer the research question. The possibilities included using a 
questionnaire, in-depth interviews (structured or semi-structured) or group 
interviews (often called focus groups). The potential advantages and 
disadvantages of each method were considered before choosing a data 
collection strategy. 
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Of those, structured questionnaires have the ability to collect unambiguous 
and easy to count answers leading to quantitative data for analysis335. 
However, they are not good at collecting information about attitudes, 
behaviour and social processes. Furthermore, questionnaire studies are often 
hampered by low response rates, ambiguity of questions and doubts as to 
whether responses accord with actual clinical practice. 
Focus groups are used as a research method to find out what groups of 
people think and how they discuss issues and ideas together368. The group 
dynamics are utilised to generate data342•369•370. GPs tend to feel comfortable 
with small group meetings, which are often employed in primary care for 
management, education or informal discussion sessions371 -373. Although this 
worked in bringing groups of GPs together in a non-threatening environment 
to discuss the broad area of heart failure374, it was not felt that this would work 
with groups of specialists. One reason for this was that group culture might 
have been dominated by clinicians (possibly cardiologists), who potentially 
have a deeper understanding of heart failure. This may then have interfered 
with individual expressions by other clinicians and potentially limited 
participation by all present. Furthermore, it would have been logistically very 
difficult to get busy clinicians from different localities together at the same 
time. 
Structured interviewing is a process whereby 'the interviewer asks each 
respondent a series of pre-established questions with a limited set of 
response categories'339. The disadvantages of this method are similar to 
those of questionnaire surveys, in particular the responses are recorded 
according to coding systems that have already been established and the 
interviewer is usually given guidance on deviating from this sequence and 
trying not to interpret the meaning of answers. Errors can arise from 
respondent behaviour; questionnaire design faults and interviewer technique 
and one of the major disadvantages are that they inadequately assess the 
emotional and behavioural dimension. 
Semi-structured interviews on the other hand allow the respondent to express 
their ideas in their own way, using their own words and determining the range 
of aspects and issues they want to raise339•340. The advantages are that the 
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interviewer can probe fully for responses and clarify any ambiguities. More 
complicated and detailed questions can be asked and information of greater 
depth can be obtained. Inconsistencies and misinterpretations can be 
checked and open-ended questions can be used for topics that are largely 
unknown or complex. This may be of value in pilot studies, which may then 
inform the development of further projects. They also provide "rich and 
quotable material, which enlivens research reports"375. However, there are 
potential disadvantages in that interviewer bias375 can creep in. Interviewer 
training and use of methods in establishing rapport with participants, putting 
them at ease and appearing non-judgemental, can reduce this340. I was 
aware of this before starting the interviews and having had training in 
interviewing and appraisal skills felt comfortable with the process. Additional 
bias can creep in if language interpreters are used for some participants but 
this was not necessary in this study. 
Use of an interview guide was helpful in remembering the points to be 
covered and suggesting ways of approaching and talking about topics, as well 
as reminding the interviewer about probes and ways of asking questions. 
Semi-structured interviews were used. In this setting this methodology is 
useful in understanding the complex behaviour of clinicians, does not impose 
any pre-determined categorisation limiting the field of inquiry and allows the 
participants to introduce their own agendas339. 
3.2.2 Subjects, setting and sampling strategy 
The study was conducted in North East England. A purposive sample376 of 
hospital specialists and specialist general practitioners was taken from five 
acute hospital trusts involved in the direct management of heart failure across 
nine primary care trusts in Durham and Tees Strategic Health Authority. 
Specialist general practitioners were identified as those specifically employed 
in cardiology on a part-time basis and actively involved in providing cardiology 
services. Of thirteen clinicians initially contacted twelve agreed to interview, 
one clinician declining without a reason. The participants comprised two 
consultant cardiologists (one secondary and one tertiary care based), four 
geriatricians (one with a cardiology interest who provided echocardiography to 
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hospital colleagues and a restricted service to general practitioners), four 
general physicians (one with a cardiology interest providing echocardiography 
to his hospital) and two general practitioners performing echocardiography 
within limited open access schemes. Specialists were aged between 36 and 
57 (mean 47), had been qualified between 12 to 32 years (mean 23) and had 
clinical experience as consultants or general practitioners with a specialist 
interest in cardiology of between 2 to 22 (mean 12) years. For a brief 
description of demographic data see table 3.1. 
Table 3.1 Participant demographics 
Sex Age Speciality Hospital Years Years as 
qualified specialist 
Male 42 Cardiology Durham 19 8 
Male 56 General Darlington 32 22 
Medicine 
Male 47 Elderly Bishop 25 18 
Care Auckland 
Male 38 Cardiology Middlesbrough 16 6 
Male 54 General Bishop 30 19 
Medicine Auckland 
Male 36 General Darlington 12 4 
Medicine 
Male 42 GP Bishop 18 2 
Specialist Auckland 
Female 40 Elderly Durham 14 3 
Care 
Male 51 Elderly Durham 29 20 
Care 
Male 52 GP Sunderland 25 7 
Specialist 
Male 57 General Bishop 30 18 
Medicine Auckland 
Male 53 Elderly Darlington 24 15 
Care 
A list of discussion points was formulated following a detailed literature review 
on the management of heart failure and the identification of barriers to its 
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managemene66(Appendix 2). The interviews were audio taped, transcribed 
and verified by the principal investigator (AF). 
3.2.3 Analysis 
Analysis followed "pragmatic variant" grounded theory352 and content analysis 
principles351 . Tape recordings were listened to and new points and ideas 
emerging were taken back to subsequent interviews. This iterative process 
allowed re-testing of theories and ideas, which were often of pertinence to a 
particular locality. The iterative process started during the interviews as I took 
notes of new concepts or ideas as they emerged. The tape recordings were 
transcribed after each interview and corrected by AF whilst listening to the 
tape recordings. This allowed me to start coding (indexing) with margin notes 
as the research progressed. I was then able to take these new ideas back to 
the next interview. Examples of this include the concept of "transient" heart 
failure, palliative and hospice care, the influence of cognitive impairment on 
initiation of evidence based therapy and dietary assessment of patients with 
cardiac cachexia that were all new concepts discussed during an interview 
with an elderly care physician. These were then added to my list of topics to 
discuss at future interviews as well as acting as a stimulus to review previous 
studies. None of these concepts had been mentioned in previous qualitative 
studies in heart failure153"155. 
By the end of the 12 interviews it was apparent that there were no new major 
themes emerging, that "saturation"351 was evident and it was decided not to 
conduct further interviews. The transcripts were read several times, data 
organised into codes (within highlighting of data and margin notes) from which 
categories were identified and major themes constructed by AF and APSH. 
There was a systematic collection of emergent codes that were organised into 
outline categories and then outline broad themes. Multiple colour-coded 
copies (a different colour for each focus group) of transcripts were produced 
and a cut and paste process using scissors and A 1 sheets used to paste into 
analytical categories. Transcripts (annotated with margin notes) and outline 
codes/categories/themes were presented to APSH and JJM. All three 
investigators (Ahmet Fuat, Jerry Murphy, Pali Hungin) contributed to multiple 
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coding342 by meeting up and after discussing the codes/categories341 and 
hence final themes were agreed. Examples of codes included under the 
category of use of evidence based therapy were eo-morbidity, accurate 
diagnosis, beta-blockers, ACE inhibitors, digoxin, diuretics, spironolactone, 
ageism, level of patient understanding, cognitive function, polypharmacy, side 
effects, transalation of evidence into practice, NYHA classification, personal 
experience in treatment, drug interactions. This category was ultimately 
included under the broad teme of clinical uncertainty. 
Analysis was enhanced by constant comparison351 with the transcripts and 
available research in this field from the initial literature review. 
Respondent validation359 to affirm the validity of the findings was conducted 
by sending all 12 participants a report summarising the results and 
conclusions and asking for feedback and level of agreement with the report. 
Of the 12 replies, 8 agreed, 3 strongly agreed and 1 neither agreed nor 
disagreed that the report was an accurate representation of their comments 
and views. Each report was highlighted on an individual basis for each 
investigator. This had the advantage of allowing each participant to check that 
their own responses were represented appropriately as well as giving them an 
overview of the full research analysis. 
I could have used respondent validation in a more iterative manner by asking 
participants to check interim findings and transcripts of individual interviews. 
The advantage of this could have been that respondents' reactions to 
emerging findings could have helped refine explanations further. 
Disadvantages are that the researcher seeks to give an overview of research 
findings whereas respondents have individual concerns and this could have 
led to discrepant accounts especially if I had chosen to disregard my own 
interpretation and accepted those of respondents at face value. Furthermore, 
asking respondents to read drafts woud have made considerable demands on 
their time and may have led to delays in analysis. 
I therefore opted for a simple respondent validation approach but asked for 
participant comments. Comments were received from 4 of the participants. 
One example highlighted the fact that individual concerns taken at face value 
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could have led to a discrepant account if I had not had an overview of all the 
interview data. "Very interesting. I'm not sure your conclusions stem from the 
data. Integrated care pathways in particular can cause collateral damage 
preventing any further thought about the diagnosis, which may be wrong and 
prevent flexible individual treatment. May be this is just my problem and what 
is heart failure?" I reviewed the data again around understanding of definition 
of heart failure and clinical care pathways and felt confident that the report 
represented a breadth of opinion. The respondent validation process was 
useful in informing the analysis of this study. 
3.3 Results 
Three major themes were identified contributing to reasons for variation in 
clinical practice across the primary-secondary care interface: (a) diagnosis, 
including access to echocardiography (b) treatment issues relating to patients 
with heart failure and (c) influences on service delivery. 
Introductory comments in the interviews invariably recognised the enormity of 
heart failure as a problem, and the rapidity with which new managements had 
evolved. The poor quality of life many of these patients experience was 
highlighted together with the improved prognosis newer approaches offered. 
"I think for the foreseeable future.... we will see an increasing number 
of heart failure in the community and think we should be prepared to 
deal with them" (AM4) 
"I don't think anyone should underestimate the enormity of the problem" 
(RP5) 
"One of the difficulties in heart failure is keeping up with the changes in 
treatments" (AH3) 
"Heart failure is changing rapidly'' (PT2) 
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3.3.1 Diagnosis 
3.3.1.1 Need for an accurate diagnosis 
The participants identified with the difficulties general practitioners face in 
diagnosing heart failure366 but were positive about the ability of general 
practitioners to keep abreast of new knowledge: 
"What surprises me about general practice is how up to date people do 
remain... it's surprising how many general practitioners are actually 
ahead of you. They are sending people up for beta-blockers and it's 
encouraging that people can self-educate." (HB1 0) 
However, only two consultants felt general practitioners could diagnose heart 
failure clinically without echocardiography. The relative inaccuracy of the 
diagnosis of heart failure (as confirmed from primary care studies) was 
understandable as this was a difficult diagnosis unaided. There were 
particular problems surrounding the identification of systolic and diastolic 
heart failure, even if echocardiography reports were available. Confirming the 
diagnosis of left ventricular systolic dysfunction is a prerequisite to maximising 
the benefits from modern therapy and getting this diagnosis right in a timely 
manner was important. 
"Diagnosis of heart failure is difficult even for hospital doctors - forget 
about general practitioners" (AM 1) 
"There are some problems sometimes with diagnosing heart failure 
because you have to make the distinction between systolic and 
diastolic dysfunction and I'm not sure sometimes whether people know 
how to handle an echo report that says good ejection fraction, say 
55160% but there is evidence of diastolic filling impairment and they 
think 'What do I do next?"' (PC 1) 
"Heart failure is a hard thing to define in the first place, but I think we 
need to be talking about systolic heart failure ... we need to be 
differentiating those patients with left ventricular systolic dysfunction 
and getting them onto evidence based therapy" (MC 1) 
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A clinical diagnosis might be easy in overt left-ventricular failure but was 
difficult in mild chronic failure. A number of factors were identified contributing 
to diagnostic problems: a lack of sensitivity and specificity of symptoms and 
signs; increasing numbers of elderly patients with eo-morbidity and time 
restraints within the consultation. 
" ... 1 certainly don't find it easy sometimes and again I think signs like 
that in the elderly can be quite difficult" (PE1) 
"If's very time consuming bringing them back and reviewing and that 
sort of thing" (RP3) 
Specialists appreciated that general practitioners had difficulty with lack of 
access or delays of access to further investigations including 
electrocardiography, chest X-ray and echocardiography. There was some 
disagreement as to the potential utility of chest X-ray and electrocardiography 
in establishing an accurate diagnosis of heart failure and about the limitations 
of general practitioners and junior hospital staff in interpreting 
electrocardiograms. 
"I think an electrocardiogram is always going to be helpful but that's 
something you can do in primary care if the general practitioners have 
the confidence to interpret that, but then again you have to understand 
that some patients with bad heart failure have normal 
electrocardiograms" (AMC 1) 
"I mean some cardiologists would say that someone who has got a 
normal ECG are unlikely to have heart failure but at the end of the day 
they have been interpreted by cardiologists or cardiology registrars and 
I think it's a different ballgame when you've got GPs ... " (AH3). 
Several consultants expressed concerns over the use of echocardiography, 
its reporting and interpretation. 
"Echocardiography, I have a problem with at times. Interpretation is 
very subjective and we can get enormous surprises and odd results. 
We are using a one off number (ejection fraction) - nowhere else in 
medicine do we do this e.g. blood pressure, peak expiratory flow rate, 
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renal function we take a series of results before deciding on a course of 
action" (PT1) 
"I couldn't interpret them. If you gave me images or technical data I 
couldn't - there are one or two figures I understand but I would not feel 
competent without a clinical interpretation of it" (AMC3). 
3.3.1.2 Presenting picture 
Many clinicians felt that the importance of past history and assessment of risk 
factors for developing heart failure were being forgotten. lt was pointed out 
that the search for the cause of heart failure was often neglected and this had 
a major bearing on further treatment. 
"I think we have to have a high level of suspicion and people who are 
presenting with symptoms suggesting heart failure we should 
concentrate on high risk people with ischaemic heart disease, 
hypertension, diabetes, especially if they have atrial fibrillation and if 
they had a suspicion of thyroid disease and alcoholism" (AM 1). 
"The other problem I have with open access clinics is that there is this 
feeling that sometimes that's the diagnosis completed. They (the 
patients) are breathless so get an echo and it says left ventricular 
dysfunction so they've got heart failure. Fine. They haven't looked at 
the cause and personally I do an angiogram on all my heart failure 
patients who are reasonably young" (MS3). 
3.3.1.3 Transient Heart Failure 
One consultant talked about the phenomenon of 'transient heart failure' (HB1) 
causing difficulties in establishing a confident diagnosis and establishing a 
management plan. Only two consultants (both geriatricians) mentioned the 
potential use of biochemical markers such as 8-type natriuretic peptide in 
guiding general practitioners in further investigation and diagnosis of heart 
failure: 
"Not that I am au fait with it but obviously there is B-type natriuretic 
peptide coming out. People say that it's going to be good but without 
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having any personal experience. .. . lt sounds a nice idea to have a 
blood test (for heart failure)". (RP4) 
Table 3.2: Difficulties in diagnosing and managing Left Ventricular 
Systolic Dysfunction 
o Lack of sensitivity and specificity of symptoms and signs 
o Increasing number of elderly patients with eo-morbidity 
o Time constraints faced by consultants and general practitioners 
o Difficulties in definition of systolic and diastolic heart failure 
o Lack of, and delays in, access to diagnostic tests 
o Difficulties in diagnostic utility of chest X-ray and electrocardiogram -
including difficulties in interpretation by general practitioners and 
junior hospital physicians 
o Concerns over use, reporting and interpretation of echocardiogram 
o Phenomenon of "transient" heart failure 
3.3.2 Treatment 
3.3.2.1 An accurate diagnosis as a pre-requisite 
lt was felt the first step had to be the establishment of an accurate diagnosis. 
There was broad consensus that categorisation of the degree of failure (mild, 
moderate or severe) should guide treatment and follow up but there was little 
mention of the New York Heart Association classification which is broadly 
accepted as a means of heart failure categorisation which links with prognosis 
and treatment strategies. Pinpointing the aetiology of the heart failure prior to 
embarking on treatment was emphasised. One cardiologist felt strongly that 
all younger patients with ischaemic heart failure should have angiography. 
"In terms of the New York Heart Association classification we all have a 
rough idea what it is but you don 't ever put down that this patient has a 
class 1, class 2 etc- we don't do that." (PC5). 
"I think the ischaemic heart failure patient is still getting a slightly raw 
deal in that as soon as they clearly co-exist, I think they should be 
getting referred for full assessment at a very early stage to work out 
144 
which ones actually need to be treated with revascularisation by 
whatever means, maybe bypass surgery or angioplasty. I believe that 
will be helpful in terms of prognosis" (MS3) 
3.3.2.2 Use of therapies 
lt was noted by some participants that there was a lack of confidence and 
reluctance in the initiation of therapy by general practitioners and even by 
some hospital consultants. Consultant experience and 'interest' in heart failure 
in both inpatients and outpatients was considered a potential influence on 
whether or not patients received evidence-based therapy. 
"There is a reluctance and lack of confidence in introducing angiotensin 
converting enzyme inhibitors and if they (general practitioners) 
introduce them they keep them on the smallest dose and they don't 
progress the dose to be compatible with the clinical trials... and beta-
blockers are new to the hospital doctors- forget resistance and difficulty 
to introduce beta-blockers in general practice" (AM 1) 
"I think the majority (of consultants) are comfortable with heart failure 
but they have different degrees of interest ... The degree of effort that's 
put into it and the degree of follow up do vary between consultants. 
Some consultants will just stick them on a diuretic because they are 
symptomatically better". (RP3) 
The practice of inappropriate diuretic use (both under and over use) by 
general practitioners and consultants was mentioned. A cardiologist 
discussed the concept of "dynamic diuretic dose" rather than the static diuretic 
dose employed by most physicians. He went on to suggest that patients be 
given the authority and education to change diuretic dose and implied that this 
may keep patients out of hospital. Despite this he admitted that this was 
something primary and secondary care clinicians had not addressed yet: 
"The dose of diuretic should be seen as something dynamic rather than 
being fixed and we haven't addressed that yef' (MC5). 
"General practitioners don't feel comfortable changing medication but 
patients should be taught how to change that depending on their 
symptoms .... And we haven't focussed on that enough in the past. I 
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haven't. I just put them on a certain amount of diuretic. They come 
back and they get more and more congested and end up in hospital or 
they come back dry as a stick" (MC5). 
Only two clinicians mentioned non-pharmacological treatments. These 
included training and conditioning, and the dietary assessment of patients with 
heart failure. Overall it was felt that clinicians did not deal with this area well. 
"The other thing I think we're bad at, not necessarily on the wards 
because the nurses are very clued up, is getting dietary assessments 
on people with cardiac failure ... " (HB9) 
3.3.2.3 Elderly patients 
The treatment of elderly patients was also discussed in terms of poor quality 
of life, lack of compliance with medication and potentially high levels of 
psychomotor side effects from use of multiple medications. Preference for a 
holistic patient-centred approach was expressed and a geriatrician mentioned 
a lack of consideration of the presence of cognitive impairment in elderly 
patients when it came to deciding on treatment strategies. 
"If's less easy to advise them on what to do. I would say that over 
three quarters of the patients I see haven't got the cognitive function to 
make judgements themselves. So you say to patients 'weigh yourself 
daily' well they wouldn't" (HB6) 
3.3.2.4 Constraints on the use of evidence-based drugs 
Many of the barriers perceived by general practitioners366 were also 
experienced in secondary care when it came to usage of beta-blockers, 
spironolactone and digoxin, and to a lesser extent, ACE inhibitors. These 
barriers included worries about the treatment of elderly patients, allowances 
for eo-morbid conditions, such as chronic obstructive airways disease which 
might preclude treatment with beta-blockers, drug interactions, poor cognitive 
function, problems associated with polypharmacy and the fear of inducing 
iatrogenic disease 
"Particularly there is an ageist thing - the older you are the more likely 
you are just to be stuck on a diuretic and sent home, without thinking of 
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the other issues like aspmn, warfarin, God forbid, ACE inhibitors, 
spironolactone, beta blockers - all that sort of thing"; (RP3) 
"The other is eo-morbidity. A lot of these people will have chronic 
obstructive pulmonary disease so you would be worried about beta-
blockers. They may be real vasculopaths so you would be worried 
about the ACE inhibitor in relation to putting them into renal failure." 
(RP3) 
" ... and also the difficulty in instructing patients (about medication) 
because I do think you have to have a certain level of understanding. 
(HB8) 
"And also you have got multiple pathology leading to multiple drugs 
and these weren't the only drugs on offer. You have a gut instinct that 
to send somebody out on 10 different drugs is not good medicine" 
(RP3); 
"Well it (beta-blockers) won't save any of my 89 year olds if the blood 
pressure is too low." (HB6) 
The majority of consultants felt they were 'hesitant' at prescribing beta-
blockers even though they understood the strong evidence-base for their use. 
Part of this hesitancy related to frequent monitoring of patients once a beta 
blocker had been initiated. 
"To be honest with you I'm not terribly good at the beta b/ockers idea. 
I'm teaming twenty years of avoiding beta-b/ockers and also it's a 
hassle. You have to be honest- it means you have to keep the person 
under frequent review. You have to bring them back to you outpatient 
department - I'm not so good on that but I know that's something we 
should be doing" (RP3) 
"You are speaking to someone who is just coming to terms with use of 
beta blockers in heart failure. Five years ago you would fail your 
membership for saying it. Rightly or wrongly my view of the 
management of heart failure or left ventricular dysfunction is ACE 
inhibitors plus a minor diuretic as a first line approach and I suspect 
that many patients could be managed in that way" (AMC3) 
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3.3.2.5 Palliative care 
The question of palliative care for these patients was flagged up as being an 
overlooked area, despite the fact that the National Service Framework for 
CHD23 and guidelines34 recommend end of life support for patients with end-
stage heart failure: 
"There is the palliation issue. That's cropped up in the National Service 
Framework and that is an area that cardiologists at any rate have not 
paid a huge amount of attention to in the past ... The palliation issue is 
very important as they have got someone to contact for support and 
the Macmillan nurses could be roped in when people have a very short 
life expectancy. That wouldn't be unreasonable. You would like to 
think that patients get that sort of support". (MC5) 
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Table 3.3: Reasons behind reluctance in initiation of evidence-based 
therapy 
o Lack of an accurate diagnosis of left ventricular systolic dysfunction 
o Lack of consultant and general practitioner experience and interest in 
heart failure 
o Lack of application of New York Heart Association classification in 
deciding treatment options 
o Managing increasingly elderly and frail patients 
0 eo-morbid illnesses e.g. chronic obstructive pulmonary disease, 
peripheral vascular disease 
o Contraindications and fear of drug interactions; polypharmacy 
o Physician variability in knowledge of evidence base for heart failure 
o Fear of inducing iatrogenic disease 
o Reluctance in treating "mild" left ventricular systolic dysfunction 
o Time constraints - especially to monitoring and follow up 
o Hesitance in beta-blocker use due to prior conditioning 
0 Lack of palliative care services and support 
o Inappropriate diuretic use - lack of "dynamic diuretic dosing" 
3.3.3 Influences on Service Delivery 
3.3.3.1 Gaps between evidence and practice 
This raised animated responses amongst all the participants. There was a 
common feeling that despite the availability of evidence and even good 
resources in many places it was essentially the current organisation of the 
pathways of care that compromised the quality of delivery of heart failure care 
(see Table 3.4). 
"To do a good job people have got to have time and the resources to do it and 
if that means more specialtst nurses or more delegation - I don't think 
anybody should underestimate the enormity of the problem" 
" .... there doesn't seem to be any standardisation of care [for heart failure] 
across the country" 
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There were problems common to each of primary and secondary care: lack of 
clinicians' experience and interest in heart failure, availability and access 
problems around diagnostic facilities, competing health priorities and the 
influence of policy makers, including national initiatives such as the National 
Service Framework (see Table 3.4). Most interviewees offered their vision of 
how services could be reconfigured to overcome barriers and to improve the 
overall management of heart failure patients (see Table 3.5). 
3.3.3.2 Who should manage heart failure? 
There was disagreement as to whether heart failure should be managed in 
primary or secondary care. Half of the interviewees felt that it could be 
adequately managed in primary care: 
"Heart failure ought to be a general practice disease" (PT1) 
"General practitioners can treat mild and moderate cases themselves" 
(EE1) 
"So I have to say no, again there will be some general practitioners 
who are interested and follow literature and give a good service to their 
patients and there are others who will not - definitely there are some 
who will not read the literature .... because heart failure may not feature 
as a problem in general practice. They may see few cases in a year 
unless they have an interest" (AM3) 
"Increasingly... I think people are moving towards saying it is a 
sufficiently difficult diagnosis with additional resource implications, that 
specialist heart failure clinics are the best way of doing it" (MS2) 
One cardiologist questioned the definition of open access echocardiography 
and highlighted problems. Furthermore, it was felt that open-access service 
discouraged the search for aetiology of heart failure: 
"If, by open access, it is a clinician led service with a clinical report then 
it's not a general practitioner diagnosing it. All he's doing is reading the 
clinician's letter. So I have a problem with the concept of open 
access... what people refer to are not open access echo they are one-
stop heart failure assessment clinics. The clinic that started it all off 
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was run by a cardiology registrar and patients had electrocardiograms 
done, they had a clinical examination done, they got blood pressure 
measured and then an echocardiogram and then the clinical report was 
issued with recommendations for treatment . . . I think that's vety 
different from open access echo where a technician just writes the 
same technical report .... " (MC 1) 
Many of the participants felt that it was desirable that one clinician in a locality 
take the responsibility for heart failure management. The choice of speciality 
would be dependent on the interests of the key players: local cardiologists, 
general physicians, geriatricians or general practitioner specialists. 
"I think it should be referred to somebody who is interested in 
management of heart failure and who has knowledge of 
echocardiography and able to interpret the results and have some 
input. I feel heart failure is a general physician and geriatrician 
responsibility - it's not a pure specialist cardiology domain because 
(patients) don't always see the cardiologist". (AM3) 
Waiting times in cardiology were seen as a problem and changes in out of 
hours care in general practice were seen by some hospital clinicians to be 
increasing the admission rates of patients with heart failure. Also, it was 
considered that specialist cardiology care was not necessarily the answer 
because of the increasing numbers of patients with heart failure referred. 
"I suspect certainly 10-15 years ago some people might have stayed at 
home in the evening or the middle of the night with a shot of frusemide 
and some diuretic to take the following morning. That's not an option 
any more really in the way urgent care is now practised". (RPS) 
The majority of the participants felt that heart failure should be managed by 
conjoint working between primary and secondary care. Doctor and carer 
education, multidisciplinary guideline production and dissemination and 
clinical governance were desirable as potential answers to remedying 
shortfalls but models with joint primary and secondary care were needed to 
attain National Service Framework targets 132• There were parallels with other 
chronic diseases such as diabetes and hypertension. In these chronic 
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conditions, shared care is now becoming the norm. Under a similar shared 
care scheme general practitioners could manage patients in certain 
categories with hospitals managing others. 
"I think there are parallels for any chronic disease process and how we 
actually work better together ... " (AMC5). 
"There are some patients who you never get stable. . .. That sort of 
patient is often just better continuing to attend the hospital clinic and 
because that way we can give very ready access to inpatient 
treatment. .. I agree that there could be a model for the patient just 
presenting in middle to late life with classical heart failure. They get 
referred to hospital, and get the diagnosis confirmed. Over the course 
of two or three months they get established on standard therapy, the 
balance gets optimised and then they return for long-term follow up to 
the general practitioners. That could certainly work for a large 
proportion of these people" (MS3). 
"Disseminating the expertise outwards rather than sucking everything 
in because logistically I don't think we can cope with it. Not unless we 
acquire a whole load of cardiologists" (AMC5) . 
Table 3.4: Influences on Service Delivery 
o Clinician experience and "interest" in heart failure 
o Lack of availability of diagnostic services 
o NHS resources (financial and manpower) 
o Competing clinical priorities 
o Influences of local policy makers (primary and secondary care) 
o Lack of specialty responsibility for heart failure in a locality setting 
Table 3.5: Suggestions for Service Delivery 
o Shared care schemes across primary and secondary care 
o Inpatient integrated care pathways 
o Specialist heart failure clinics including "one-stop" option 
o General practitioners with a specialist interest in heart failure 
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o Specialist heart failure nurses working across the interface 
o Palliative care for heart failure 
o General practitioner academic detailing 
o Locally owned protocols 
3.4 Discussion 
This qualitative study confirmed variable opinions and practice in the 
diagnosis and management of heart failure in UK hospital practice and across 
the primary-secondary care interface. Difficulty in establishing an accurate 
diagnosis, concerns about availability, reporting and interpretation of 
echocardiography, multiple barriers to initiation of evidence-based therapy 
and local organisational influences were similar to themes identified from 
research with general practitioners366. 
3.4.1 Methodological considerations and limitations 
This methodology proved to be effective to this research. The rigour of the 
study was increased by multiple coding342 and respondent validation359 . 
Although the number of participants was small, purposive sampling376 
generated rich data from the interviews. The characteristics of the participants 
were felt to be broadly similar to specialists across British hospitals. The 
personal and intellectual bias the principal investigator (AF) may have exerted 
on the interviews was minimised by allowing discussions to develop naturally, 
tape recording all data and by reporting a wide range of different perspectives 
from all twelve interviews. 
Questions are often raised about generalisability of the results of qualitative 
studies of this nature. Qualitative studies are not intended to be generalisable 
to all clinical situations or localities. However, as the organisational factors are 
unlikely to vary across the country we believe the results are transferable to 
other localities wishing to tackle heart failure diagnosis and management. 
3.4.2 Potential solutions 
Standard 11 of the National Service Framework for coronary heart disease 132 
recommends that all patients with suspected heart failure should have 
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echocardiography. Thus there needs to be a consistent and systematic 
approach to identify patients with heart failure or those at high risk of its 
development, deliver appropriate care to those so diagnosed and to offer 
regular review. Currently, management of heart failure is variable in both 
primary and secondary care sectors. One of the problems in hospitals seems 
to be that care is frequently fragmented with different specialty consultants 
and often-inexperienced junior staff looking after such patients. The 
increasing sub-specialisation of consultants, the admission of patients under 
an on-call consultant who may have little experience or interest in heart 
failure, and pressure for early discharge before investigations are completed 
are likely contributory factors to sub-optimal management. Of pressures facing 
clinicians, trying to determine optimal drug regimens, polypharmacy, drug 
interactions, eo-morbidity and the reduced cognition of some elderly patients 
were seen as the greatest. 
Recently, structured care in hospital based nurse-led clinics, such as provided 
by the Omada programme377, has demonstrated an improved outcome in 
heart failure patients and is an example of models of care suggested in the 
National Service Framework132. Systematic structured care has also been 
shown to increase the uptake of ACE inhibitors in primary care patients with 
heart failure70. However, it is likely that there will be reticence in the uptake of 
beta-blockers and spironolactone without a definitive, accurate diagnosis of 
left ventricular systolic dysfunction and at least some expert input. 
There has been much debate as to how the diagnosis of heart failure should 
be secured. Some argue for open access echocardiography to be available to 
all general practitioners139•140•157 others feel that a specialist opinion should be 
sought163•166. However, open access is not uniformly available across the 
UK146, largely due to lack of trained technicians and some general 
practitioners have concerns about interpretation of technical results366. A 
specialist opinion in every situation is impractical due to long hospital waiting 
lists and the increasing numbers of patients with heart failure378. 
Newer models of care are needed. An integrated care pathway that bridges 
primary and secondary care is desirable. A question which arises is whether 
every patient with suspected heart failure needs to be seen by a cardiologist 
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or another physician with good access to diagnostic facilities, or whether by a 
hospital clinician at all. There is a good argument from the views collected that 
a diagnostic service could be established without the intervention of a hospital 
specialist, although treatment itself may require a clinician with special 
expertise. One way of delivering this could be a general practitioner 
specialisUnurse specialist run one-stop heart failure clinic, taking referrals 
from primary and secondary care. Inpatient care pathways for those admitted 
with heart failure also need to be introduced to ensure uniform procedures for 
diagnosis and treatment. Specialist heart failure nurses could then follow 
patients discharged back to primary care 184 as well as responding to referrals 
of patients felt to be decompensating or needing palliative care. Newer 
screening methods such as 8-type natriuretic peptide offer opportunities for 
diagnostic strategies379 but need further evaluation within a pragmatic primary 
care setting. 
The findings of this study confirm that there is a lack of uniformity in the 
diagnostic and management services for heart failure in the secondary care 
sector, between clinicians and between institutions. Specialists' opinions 
about the ability of general practitioners to deliver effective care vary; in 
general, primary care alone cannot deliver a uniformly high standard service 
even with the provision of diagnostic facilities. Conversely, a service geared 
entirely toward secondary care provision is untenable because of workload 
and follow-up implications. There is a pressing need for the exploration of 
conjoint service provision encompassing the possibility of a non-cardiologist 
centred service. From this research, exploring the views and experiences of 
specialists, there is much variation in practice within secondary care itself; a 
specific heart failure service would benefit patients across the interface. 
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Chapter 4. 
One stop diagnostic clinic for suspected heart failure and the Darlington 
integrated heart failure service - a descriptive study 
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Abstract 
Heart failure due to left ventricular systolic dysfunction (L VSD) carries a high 
morbidity and mortality. LVSD merits rapid, accurate diagnosis in order to 
initiate evidence based management strategies. The Darlington heart failure 
services model, part of the South Durham Heart Failure Network, was devised 
to overcome barriers to accurate diagnosis and effective management of 
heart failure. lt involves rapid diagnosis of L VSD and ongoing heart failure 
management. A weekly one-stop diagnostic clinic, run by a GP specialist and 
a heart failure nurse, is jointly funded by the PCT and the NHS Trust. If LVSD 
is confirmed, a management plan is formulated which includes patient 
education and initiation of evidence-based therapy. The heart failure nursing 
service is invaluable in bridging the gap between primary and secondary care. 
Local guidelines, together with continuing education of GPs and practice 
nurses, and the new GMS contract, should further increase the uptake of 
evidence-based therapies at target doses. 
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4.1 Background 
Chapters 2 and 3 have highlighted significant barriers to accurate diagnosis 
and effective management of heart failure across primary and secondary care. 
Even when facilities for the accurate diagnosis of HF exist (open-access or 
consultant screened echocardiography) the application of effective therapy 
remains a problem in general practice40•366•380. Relatively low rates of usage of 
ACE inhibitors, beta-blockers and spironolactone are likely to be related to a 
number of complex factors, e.g., difficulties in interpretation of 
echocardiography results, waiting times, lack of familiarity of regimens, 
apprehensions about adverse effects, and workload pressures 155•366. 
Furthermore target doses of these agents are often not achieved40•41 •44•70•223. 
There is a pressing need to explore alternative management approaches, 
which eliminate or minimise obstacles and are conducive to the appropriate 
management of that group of patients most likely to benefit from modern 
therapy. 
In addition, (i) there needs to be equity of access for patients with heart failure 
to the most effective and cost-effective treatment available. General 
Practitioners should be in a position to be able to offer or arrange optimal 
management. However, there is a widening "practice-evidence" gap (ii) 
although evidence based guidelines105•127•141 •233 have established the need for 
an accurate diagnosis of heart failure, essentially with echocardiography, the 
rate of "over-diagnosis" remains around 40%39·71 , with less than 40% of 
patients receiving ACE inhibitors41 (iii) doubts remain about the effective use 
of echocardiography services, and many secondary care clinicians favour 
referral to hospital163•164 (iv) there is increasing pressure within the NHS 
towards the implementation of evidence-based clinical guidelines 105•127•141 •233 
(v) the needs of PCTs to collaborate with secondary care for the provision of 
services creates an urgent need to resolve this clinical/ health services issue. 
(vi) the advent of clinical governance is a further imperative towards 
streamlining the provision of care in this field. 
The National Service Framework for Coronary Heart Disease (NSF for CHD) 
recommendations include echocardiography for all patients with suspected 
heart failure, and development of a consistent and systematic approach to 
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identify patients with heart failure or at high risk of developing it, and delivery 
of appropriate care to those diagnosed with heart failure, together with regular 
review132. 
Hence, possible drivers for change in the management of heart failure due to 
left ventricular systolic dysfunction (LVSD) include the extensive evidence 
base and the various national guidelines22·105•379. In addition, the NSF for 
CHD132, the new General Medical Services contrace81 and the CHD and 
Primary Care Collaborative (including MINAP, the Myocardial Infarction 
National Audit Project) are policy-based strategies that are helping to close 
the evidence-treatment gap. 
The NSF for CHD proposes development of newer models of care for 
diagnosis and management of LVSD132• Coinciding with a government call for 
more GPs with a specialist interest we established a GP specialist led one-
stop diagnostic clinic to enable expedient diagnosis and appropriate initiation 
of evidence based therapy if LVSD confirmed. Development of the service 
considered barriers to accurate diagnosis and effective management of heart 
failure across primary and secondary care identified from qualitative research 
projects described in chapters 2 and 3, and incorporated some of the 
solutions proffered by participants and researchers. 
4.2 Aims of the service 
The aims of the heart failure diagnosis clinic are: 
• To provide rapid access to diagnostic facilities for patients with 
symptoms consistent with heart failure. 
• To provide a consistent approach to the diagnosis of heart failure in the 
locality. 
• To maximise treatment, according to evidence-based guidance and 
local protocols for patients with confirmed LVSD. 
• To be innovative in the approach to service provision and share our 
successes with others. 
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4.3 Clinic structure 
4.3.1 Service outline and funding 
The current heart failure service is outlined below: 
Figure 4.1 Heart failure services in Darlington 
Rapid diagnosis of LVSD - one-stop clinic 
South Durham Local Guideline/Protocol/Care Pathway and basic formulary 
Heart failure nursing service 
Ongoing LVSD management including drug titration 
-Primary care (CHD and HF clinics/HF nursing service) 
-Secondary care (nurse/pharmacist titration clinics) 
Palliative care 
The one-stop diagnostic clinic was established in January 2002 as a joint 
venture between Darlington PCT and South Durham NHS Trust and the 
British Heart Foundation funds a specialist nurse. Whilst there have been 
other reports of rapid access clinics 172"174 we believe this is the first GP 
specialist led diagnostic and management clinic. 
The one-stop clinic is run by a GP specialist and a heart failure nurse. The 
service is based upon local heart failure guidelines and protocols. The weekly 
clinic runs in parallel to a consultant cardiologist's clinic and is sited within the 
general medical outpatient department of Darlington Memorial Hospital. The 
clinic template allows for 6 new and 5 follow up patients. 
There was much discussion about where the clinic should be based. PCT 
managers were keen on the clinic being in primary care, in line with an NHS 
push to moving services from secondary care into primary care and the 
introduction of payment by results. We argued that the hospital setting had the 
advantage of having the best echocardiography equipment and the best, fully 
trained, highly skilled technicians; access to a consultant opinion if needed; 
availability of other diagnostic tests including ECG, Chest X-ray and exercise 
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treadmill test; follow up of abnormal blood test results by consultant when GP 
specialist not available; immediate access to the warfarin clinic and availability 
of secretarial and administrative support. 
4.3.2 Referral criteria 
Patients access the clinic via: 
• GP referral for patients with suspected heart failure. 
• GP or heart failure specialist nurse may refer patients with confirmed 
heart failure who require symptomatic assessment. 
• Referral from cardiology clinic or other physicians who require 
evaluation of patient's symptoms. 
For GP referrals there is a standard one page referral form (Appendix 3). 
Referral forms for the heart failure diagnosis clinic are received and processed 
by the central appointments patient office; patients then receive clinic 
appointments via post. All patients are sent an information leaflet regarding 
the diagnostic clinic and which has been produced by the heart failure team 
(Appendix 4). 
The GP is asked to undertake baseline blood tests; ECG and chest X-ray. 
At the clinic all patients have clinical assessment, relevant blood tests, chest 
X-ray (if not done by GP), ECG, echocardiography and selected patients 
undergo pulmonary function tests. The decision to include a chest x-ray was 
debated but it was felt that as NICE guidance recommends this investigation 
in assessment of patients with suspected heart failure, it should be 
included105. British Society of Echocardiography accredited cardiac 
physiologists perform echocardiography. Left ventricular function is assessed 
by "eyeball" assessment, with Simpson's rule and wall motion index 
measurements when possible. The patient brings the report back to the clinic 
in a sealed envelope. The cardio-respiratory laboratory provides 6 dedicated 
echocardiography slots for use by the clinic. Appendix 5 outlines the clinic 
function and patient pathway. 
Patients in whom heart failure or LVSD is not confirmed are discharged back 
to the GP or, if necessary, to another physician (e.g. respiratory physician or 
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general cardiologist). If LVSD is confirmed, a management plan is formulated 
which includes patient education and initiation of evidence-based treatment. 
BNP and NT proBNP16 were used initially as research tools in the clinic 
(funded respectively by the PCT and Roche Diagnostics). This study identified 
a cut off point of 150pg/ml for NT proBNP382, which was used by GPs to triage 
referrals to the diagnostic clinic within the setting of a pilot project. These 
studies were designed to answer some pragmatic questions around the 
practicability of use in primary care, appropriate cut off points, cost benefit, 
and the role of electrocardiography in this setting. These studies are reported 
in detail in chapters 6 and 7 of this thesis. 
4.3.3 Staffing of clinic 
4.3.3.1 Role of the GP specialist in cardiology 
The GP specialist in cardiology provides the main clinical leadership to the HF 
team and was instrumental in persuading Darlington PCT and South Durham 
NHS Trust to adopt and fund a one-stop diagnostic clinic model. 
The role of the GP specialist includes: 
• Clinical assessment of all referred patients. 
• Order appropriate baseline investigations (bloods, Chest X-ray, ECG 
and echocardiogram). 
• Assimilation of all clinical and investigative data to establish a working 
diagnosis. 
• Once LVSD confirmed determine a management plan. 
• Decide on referral to tertiary care for specialist services e.g. cardiac 
resynchronisation therapy, coronary angiography (CABG or 
angioplasty), valve replacement. 
• Decision to discharge or follow up patients. 
• Refer onto other secondary care specialists including cardiology and 
respiratory medicine. 
• Offer clinical advice to local GPs and others working with HF. Patients 
who are deteriorating clinically can be fitted into the one stop clinic for 
review and management. 
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• Further education of local GPs, district and practice nurses, specialist 
nurses, patients and carers. 
• Sharing good practice - other GP specialists from across the UK have 
sat in the clinic and taken away ideas for initiating similar services in 
their own localities (from Isle of Lewis to London) 
• Clinical audit and evaluation of the service 
4.3.3.2 Role of the specialist heart failure and auxiliary nurse 
The specialist nurses see patients in clinic after they have received the 
appropriate diagnostic tests and heart failure confirmed by medical 
practitioner at the clinic. 
The specialist and auxiliary nurses provide the link between the diagnosing 
clinician, the patient and the organisation of community based care. They 
collate the results, counsel the patients and carers and ensure follow-up in the 
clinic, GP or domiciliary setting. They are also responsible for effecting the 
day to day management of the HF patient in relation to specific items such as 
daily weighing to evaluate fluid overload and exercise regimes. 
If patients require a home visit after diagnosis, an appointment will be made 
during the heart failure clinic. 
4.3.3.3 Role of the consultant cardiologist 
Dr Jerry Murphy was supportive in the setting up and running of the clinic. 
His main roles include: 
• Overall clinical responsibility for patient care and 
• Advice to GP specialist and specialist nurses in interpretation of 
complex or difficult investigative data (including ECG, Chest X-ray, 
echocardiograms, CT scans) and management issues 
4.3.4 Heart failure review clinic 
Pressures on workload generated by follow up patients, especially those 
needing beta-blocker titration in the one stop diagnostic clinic led to 
development of a nurse led review clinic, complemented by involvement of a 
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pharmacist. Continuing education of GPs to up titrate beta-blockers was also 
undertaken. 
The underpinning rationale for the heart failure review clinic was to provide a 
consistent approach to the optimisation of medications, and reduction of 
symptoms in patients with heart failure. The unique approach to the clinic 
aims to integrate specialist nursing, pharmacy and cardiology services to 
provide high quality evidence based care for patients with heart failure. 
Patients can be referred to the clinic by the GP with a specialist interest, 
cardiologists or general physicians. 
4.4 Summary of services and referral pathways 
The Darlington Integrated Heart Failure Service is built around partnership 
working between primary care staff, secondary care staff, patients and carers, 
palliative care services, voluntary agencies and charitable organisations. 
Figure 4.2. The Darlington integrated heart failure service 
• GP Specialist in Cardiology 
• Cardiologist 
• HF Specialist Nurses 
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4.5 Facts and figures 
4.5.1 Referrals 
55 (98%) Darlington GPs referred at least one patient to the diagnostic clinic 
within the first 14 months. 6 GPs from adjoining PCTs (Dales, Sedgefield and 
North Yorkshire) also referred patients to the clinic. The Darlington PCT area 
covers a population of around 100,000 with a hospital catchment population of 
around 150,000. 
4.5.2 Diagnoses 
In the first 14 months, 217 consecutive patients were seen in the one-stop 
diagnostic clinic. The age range of patients was 34-93 years, with a mean of 
72.9, and 61.3% were female. 82 (37.8%) had LVSD. Of these 33 (40.2%) 
were mild, 17 (20.8%) moderate and 32 (39%) severe LVSD. This diagnosis 
was based on a semi-quantitative eyeball assessment of L VSD rather than 
NYHA clasasification. However, these would correspond to NYHA I, 11 and Ill 
respectively. A further 82 (37.8%) had other significant cardiac abnormalities 
that could have accounted for symptoms and/or signs suggestive of heart 
failure. There were also non-cardiac conditions that led to patient referral. 
Many patients have multiple pathologies. Table 4.1 lists these alternative 
diagnoses. These alternative results are similar to other studies and should 
be rigorously sought and mamaged accordingly137• 
Table 4.1: Diagnosis in patients without LVSD 2002/3 
Diagnosis Number of Diagnosis Number of 
patients patients 
LVH 43 (19.8%) Mitral 29 (13.4%) 
Regurgitation 
Atrial Fibrillation 20 (9.2%) Diastolic 20 (9.2%) 
dysfunction 
PHT 9 (4.1%) COPD 6 (2.8%) 
Cor Pulmonale 3 (1.4%) Aortic 4 (1.8%) 
regurgitation 
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Diagnosis Number of Diagnosis Number of 
patients patients 
Left ventricular 4 (1.8%) Tricuspid 4 (1.8%) 
aneurysm regurgitation 
Aortic stenosis 4 (1.8%) Atrial flutter 2 (0.9%) 
Right ventricular 3 (1.4%) Lung cancer 2 (0.9%) 
hypertrophy 
SLE 1 (0.5%) Cardiac amyloid 1 (0.5%) 
Paraproteinaemia 1 (0.5%) Waldenstroms' 1 (0.5%) 
macroglobuline 
mia 
4.5.3 Initiation of evidence-based therapy 
All patients with a diagnosis of LVSD had a detailed explanation of the illness 
given by the GP and HF nurse. Evidence based therapy was initiated and 
titrated to target doses. In the majority of patients this titration was supervised 
by the specialist heart failure nurses and GPSI. Some patients were titrated by 
their GP, especially in those patients from rural communities. These GPs had 
received educational sessions on use of beta-blockers in heart failure. We did 
not document the number of visits patients had to make to reach target doses 
but estimate this to be between 6 to 8 visits if achieving maximal doses of 
ACE inhibitor and beta-blocker. In terms of medication prescribed at the clinic, 
there was a high level of use of ACE inhibitors211 and beta-blockers235 (see 
Table 4.2) 
Table 4.2. One-stop clinic medication for patients with LVSD 2002/3 
Drug Proportion of patients receiving 
Diuretics 89% 
ACE inhibitor 87.8% (intolerant 3. 7%; 
contraindicated 1.2%) 
Angiotensin 11 receptor antagonist 7.3% 
ACE inhibitor or angiotensin 11 receptor 95.1% 
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Drug Proportion of patients receiving 
antagonist 
Beta-blocker 69.5% (intolerant 8.5%; 
contraindicated 20.7%) 
Digoxin 11% 
Spironolactone 8.5% 
Nitrate 8.5% 
Statin 43.9% 
ACE inhibitor at target dose 73.6% 
Beta-blocker at target dose 63.2% 
95.1% of patients were taking an ACE inhibitor or angiotensin 11 recaptor 
antagonisf65, and 69.5% were taking a beta-blocker (29.2% had 
contraindications or were intolerant). Target doses were achieved in 73.6% of 
patients taking ACE inhibitors and in 63.2% of those taking beta-blockers. 
Spironolactone 19 has been more difficult: many patients have experienced 
side effects and have had to discontinue treatment with this drug. 
4.5.4 Admission data 
Table 4.3. DMH admissions with a primary diagnosis of heart failure 
Congestive Heart Left Heart Failure Total 
Failure ventricular unspecified 
failure 
2000 168 (57.5%) 117 (40.1%) 7 (2.4%) 292 
2001 156 (60.7%) 97 (37.7%) 4 (1.6%) 257 
2002 178 (65%) 82 (29.9%) 14 (5.1%) 274 
2003 166 (59.9%) 102 (36.8%) 9 (3.3%) 277 
2004 149 (69.6%) 54 (25.2%) 11 (5.2%) 214 
2005 124 (59.9%) 64 (30.9%) 19 (9.2%) 207 
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Table 4.4. DMH admissions with a secondary diagnosis of heart failure 
Congestive Heart Left Heart Failure Total 
Failure ventricular unspecified 
failure 
2000 85 (42%) 109 (54%) 8 (4%) 202 
2001 101 (52.3%) 75 (38.9%) 17 (8.8%) 193 
2002 103 (60.2%) 51 (29.8% 17 (10%) 171 
2003 147 (59.5%) 88 (35.6%) 12 (4.9%) 247 
2004 114 (50.4%) 83 (36.7%) 29 (12.9%) 226 
2005 109 (60.6%) 53 (29.4%) 18 (10%) 180 
The heart failure diagnostic clinic and the heart failure nursing services were 
introduced in January 2002. Using primary diagnosis data it appears that 
admissions increased in the first two years and now are showing a downward 
trend (see Table 4.3). The initial increase could have been due to increased 
awareness and knowledge about heart failure by local GPs attended in 
practice educational sessions on diagnosis and management of heart failure. 
This may have led to increased referrals for confirmation of a diagnosis. lt 
may be that thereafter admissions fell as a result of patients being established 
on evidence-based therapies; patients being managed more in the community 
by specialist heart failure nurses and GPs referring patients as emergencies 
into the clinics and home based service rather than admitting. Obviously this 
is retrospective audit data which is open to confounding factors such as 
coding errors, privatisation and availability of nursing and residential homes, 
social services, GP and district nursing workload. lt will be interesting to 
observe the continuing trend over the next few years. Admissions to DMH with 
a secondary diagnosis of heart failure are variable from year to year and most 
probably reflect difficulty in coding such admissions (see Table 4.4). 
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Table 4.5. Average length of stay for heart failure patients DMH 2003-
2005 
alendar year 
12.86 
11.67 
10.40 
Average 11.80 
The average length of hospital stay for patients with heart failure exceeds that 
of all other condition apart from stroke, averaging 14 days in 200224. 
The figures for DMH show a decline of 2.46 days between 2003 and 2005 
(see Table 4.5). Whilst this may not be as substantial as one would hope it 
represents a move in the right direction that has cost savings implications for 
the NHS. Furthermore it compares favourably with average lengths of 
inpatient stay of 14 and 16.5 days in studies from Scotland61 and the 
Netherlands62 respectively. lt cannot be said that the local heart failure 
services have directly lead to this decline in length of stay but may certainly 
have contributed by specialist nurse involvement in discharge planning, follow 
up at home and quicker access to echocardiography. 
4.5.5 Patient follow-up 
The integration of the one-stop diagnostic clinic into the Darlington heart 
failure service is shown in Figure 4.2. The clinic takes referrals from different 
outpatient and inpatient specialties. Once a diagnosis has been reached, the 
patient either returns to primary care, or attends the heart failure clinic or other 
specialties as appropriate. Ongoing L VSD management is carried out in both 
primary and secondary care. After receiving further education, many GPs are 
now confident in up titrating the doses of beta-blockers and other drugs. In 
secondary care, ongoing management is carried out by a specialist nurse and 
a pharmacist. A project to assess the effectiveness of heart failure 
rehabilitation and exercise training is planned. 
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4.6 Service evaluation 
Service evaluation has been carried out with feedback from GPs and patients 
(see section 4.8.2). 
These will be reported elsewhere. In brief the results indicated that; 
• A majority of GPs preferred the one stop clinic model to open access 
echocardiography or traditional cardiology outpatient clinics 
• Whilst GPs were happy to initiate diuretics and ACE inhibitors, only a 
minority felt confident in using beta-blockers in HF 
• Over 95% of patients were satisfied with the service they received at 
the one stop clinic 
The results were used to improve and further optimise the service offered to 
NHS patients. 
4. 7 Changing GP contractual obligations 
4. 7.1 The new GMS contract 
The new GMS contrace81 should further increase the uptake of evidence-
based therapies. The contract enables separate agreements to be negotiated 
for each practice. lt rewards quality, with a system in which all work is 
converted into points. For 2004/5, one point is worth £75 and for 2005/6 one 
point will be worth £120. The four main domains of quality are clinical, 
organisational, patient experience, and additional services (including child 
health surveillance, childhood immunisation, cervical screening). There are 
also 50 bonus points for achieving access targets. Clinical issues account for 
the highest number of points and 346 of the 550 clinical quality points are 
broadly based around cardiovascular disease. 20 of those points are 
specifically to meet indicators for left ventricular dysfunction (LVD). See table 
4.6 below: 
Table 4.6 New GMS Quality Indicators for Left Ventricular Dysfunction 
(LVD) 
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Indicator Points Payment stages 
LVD 1. Practice can produce register 4 
of patients with CHD and LVD 
L VD 2. Percentage of patients with 6 25-90% 
CHD and LVD (Diagnosis after 
1/4/03) confirmed by echo 
LVD 3. Percentage of patients with 10 25-70% 
CHD and LVD currently treated with 
ACEi orARB 
4.7.1.1 New GMS contract LVD data 
The first new GMS/QMAS381 data was collected in March 2005 and all 11 
Darlington practices achieved 1 00% for L VD 2, suggesting that the one stop 
clinic is enabling GPs to have all their patients investigated. Only one practice 
did not achieve maximum payment for LVD 3 by achieving 68% ACEi/ARB 
use. The other ten all met targets with a range from 70-100% achievement. 
(See table 4. 7 below) 
Table 4. 7 Summary of Quality Outcome Framework data for Darlington 
practices - March 2005 
Practice 1 2 3 4 5 6 7 8 9 10 
number 
Indicator Denominator 25 26 105 14 43 97 96 42 52 58 
Target 
LVD1 100% 100 100 100 100 100 100 100 100 100 100 
LVD2 90% 100 100 100 100 100 100 100 100 100 100 
LVD3 70% 100 89 68 100 75 89 81 97 76 98 
Total 121 121 121 120.3 121 121 121 121 121 121 121 
points 
4.7.2 Potential hospital influences on new GMS contract 
11 
22 
100 
100 
90 
121 
There are several ways in which secondary care colleagues can help GPs 
meet the targets in the GMS contract. Good communication and interaction 
with primary care is essential. lt is important to agree local management 
guidelines, and to have rapid, clear and accurate correspondence, perhaps 
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using a template for clinic letters to highlight the data that are required (as we 
do from the one stop clinic). In the Darlington area, pharmacists now indicate 
on discharge letters why a drug has been stopped or started and this 
information is very useful to GPs. There is a need for education of hospital 
medical staff about the contract. 
4.7.2.2 Myocardial Infarct National Audit Program (MINAP) data 
M I NAP data for the Darlington Memorial Hospital show that the NSF target for 
prescribing of ACE inhibitors and beta-blockers to eligible patients on 
discharge after Ml is being met in 86% and 83% of patients, respectively. As 
many patients develop LVSD after an Ml this will help GPs achieve targets. 
4.8 Discussion 
4.8.1 Strengths of the service 
Whilst HF care varies substantially across the country this project shows that 
good HF care can be delivered in the NHS and has been singled out as a 
model of excellence by a recent Royal College of Physicians report383. 
Although many new referrals to the clinic did not in fact have HF, a reliably 
accurate diagnosis can be achieved which is important for correct 
management. Particular strengths of the service are emphasis on patient 
involvement and education, improving patient compliance with treatment and 
improving communication between health care professionals and patients as 
well as between primary, secondary and tertiary care. Local palliative care 
access is a great strength of our service model. 
The candesatran on mortality and morbidity in patients with chronic heart 
failure (CHARM) screening programme13 and the Euro-Heart survey148 
showed the UK to have lower use of beta-blockers and spironolactone than 
other European countries. Our clinic experience demonstrates that beta-
blocker usage can be improved. We experienced difficulty establishing elderly 
patients on spironolactone, largely due to side effects of renal impairment, 
postural hypotension and gynaecomastia. The recent introduction of 
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eplerenone, an aldosterone antagonist with mortality benefits and fewer side 
effects is a welcome developmenf64 . 
The service meets all of the 8 key recommendations of NICE guidance for HF 
management105 : 
• The basis for historical diagnoses of HF should be reviewed, and only 
patients whose diagnosis is confirmed should be managed according 
to the guideline (Our data show that of primary care referrals, only two 
in every five patients had the diagnosis confirmed -thus three out of 
every five could have been treated inappropriately) 
• Doppler 20 echocardiographic examination should be performed to 
exclude important valve disease, assess the systolic (and diastolic) 
function of the (left) ventricle and detect intracardiac shunts (We would 
argue that just providing an echocardiogram does not equate to making 
a diagnosis of heart failure, and that the more broadly based service 
provides diagnosis and management planning) 
• All patients with heart failure due to left ventricular systolic dysfunction 
should be considered for treatment with an ACE inhibitor 
• Beta-blockers licensed for use in heart failure should be initiated in 
patients with heart failure due to LVSD after diuretic and ACE inhibitor 
therapy (regardless of whether or not symptoms persist) (Our service 
demonstrated high uptake of both Ace inhibitors and beta-blockers at 
evidence based target doses) 
• Patients should generally be discharged from hospital only when their 
clinical condition is stable and the management plan is optimised 
(Involvement of specialist heart failure nurse and pharmacists in 
identification of HF patients for referral into the service contributes to 
appropriate discharge of these vulnerable patients) 
• The primary care team, patient and carer must be aware of the 
management plan (Our letters back to GPs are structured and 
educational in their content with a clearly outlined management plan) 
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• Management of heart failure should be seen as a shared responsibility 
between patient and health care professional (Our service is based on 
shared responsibility, patient and carer education and empowerment. 
Interventions are individualised and tailored for each patient as it is 
clearly not feasible for all patients with HF to be asymptomatic, even on 
optimal therapy ) 
• All patients with chronic heart failure require monitoring. This 
monitoring should include: 
a clinical assessment of functional capacity, fluid status, cardiac 
rhythm, cognitive and nutritional status 
a review of medication, including need for changes and possible 
side effects 
serum urea, electrolytes and creatinine 
(All patients are closely monitored in the clinics and GPs advised on 
future monitoring on discharge from the clinic. GP specialist and 
pharmacist review all medication) 
4.8.2 GP and patient satisfaction surveys 
The diagnosis of heart failure due to left ventricular systolic dysfunction 
cannot be made by clinical assessment alone or by electrocardiography or 
chest X-ray in isolation or combination 139. Echocardiography is the optimal 
way of confirming left ventricular systolic dysfunction 127•233• Yet, five general 
practitioners (11.6%) from a survey of forty three respondents (response rate 
77%), felt that they could diagnose left ventricular systolic dysfunction by 
clinical assessment alone. 62.8% of general practitioners felt chest X-ray 
could be used to diagnose heart failure. Only a third (32.5%) felt an 
electrocardiogram and the majority (83.7%) felt echocardiography was useful. 
Three general practitioners (7%) felt an echocardiogram was not useful in 
making a diagnosis. This suggests that there is still lack of awareness of the 
need for echocardiography in accurately diagnosing left ventricular systolic 
dysfunction. 
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When asked about treatment of heart failure, all general practitioners were 
happy to initiate diuretics and ACE inhibitors. However, almost three quarters 
(74.4%) were not happy to use beta-blockers. A third (32.6%) were unhappy 
using spironolactone and 37.2% did not feel they could use digoxin. This 
would seem at odds with evidence-based guidelines recommending 
consideration of beta-blockers for patients with stable heart failure and 
spironolactone and digoxin in selected patients 127•233. Guidelines do suggest 
that beta-blockers should be initiated and titrated by a clinician skilled in the 
management of heart failure 127•233. Recent reports from outpatient and 
primary care settings advise that beta-blockers can be initiated safely using 
simple protocols258•384• However, until all general practitioners are confident in 
the use of beta-blockers, spironolactone and digoxin in heart failure, a GP 
service that is able to initiate these agents and to contribute to better 
understanding is one way of addressing these shortcomings. 
The majority of general practitioners (58.1 %) preferred the 'one stop heart 
failure clinic' run by a general practitioner with a specialist interest. Around a 
quarter (25.6%) favoured an open access service. Four general practitioners 
(9.3%) liked all three options, and two (4.7%) preferred a combination of open 
access echocardiography and a one-stop clinic for more difficult patients. 
Only one (2.3%) would refer to a consultant for all cases. 
Notably five of the GPs who wanted OAE with a clinical report did not feel 
confident in prescribing beta-blockers or spironolactone and one did not feel 
confident in prescribing digoxin. This raised the question as to whether OAE 
alone would facilitate evidence-based treatments to patients with LVSD. 
Having an interested/trained general practitioner within a practice who is 
confident in the management of all aspects of heart failure may be a way of 
increasing the uptake of newer therapies. 91% of general practitioners were 
happy to refer to another colleague with heart failure expertise within the 
practice. lt would seem that identifying a general practitioner in each practice 
and training them up to the standard of a 'Heart Failure Certificate' may be a 
useful way of advancing and improving the management of heart failure in a 
locality. 
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The implications from this survey are that following the one-stop HF clinic GPs 
are not comfortable with the introduction of evidence-based therapies such as 
beta-blockers. Despite the risk of becoming de-skilled, over 90% of the 
doctors in this sample were happy to refer to a GP trained in HF from within 
the practice for long term management. 
Service design is often dictated by the availability of resources in secondary 
care. GPs expressed a strong preference for the one-stop HF clinic and only a 
minority wanted OAE. The traditional general cardiology clinic was not 
supported. 
A literature search and verbal contact with experts in the field of heart failure 
failed to identify a validated questionnaire for use in assessing patient 
satisfaction. A postal questionnaire was designed and sent to 47 of 51 
consecutive patients accessing the clinic. To ensure the questionnaire was 
appropriate and to minimise bias it was reviewed by Primary Care Trust 
clinical governance and changes made accordingly. Whilst being mainly 
yes/no answers we also provided space for subjective patient comment. 
Prior to the survey, a flyer was sent out giving patients the opportunity to 
refuse being a part of the survey. A total of 51 people were approached to 
take part in the survey. 47 agreed to receive a postal questionnaire. 
Patient satisfaction was assessed in 39 patients (83% response rate) 
• 95% felt they had enough information prior to attendance 
• 1 00% had enough information about tests received 
• 97% said results were clearly explained 
• 97% were made aware of the diagnosis at the clinic 
• 87% received enough advice at clinic 
• 95% said it was beneficial to have all tests and receive diagnosis at the 
same appointment- 2 (5%) did not answer 
• 95% said the waiting time for initial appointment was acceptable - 2 
(5%) did not answer 
• 95% said they were treated with courtesy and respect and the same 
number felt there was adequate privacy- 2 (5%) did not answer 
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The questionnaire showed that the open stop clinic was popular and well 
received by a large majority of patients. Undertaking the patient satisfaction 
survey has proved a useful tool in making changes to the clinic. The changes 
that have been made include: 
•:• Patients may have a robe should they request it. 
•!• Summing up after the tests has become more structured and in words 
that patients and carers can understand. Patients (and carers) are 
offered the opportunity to discuss their diagnosis with medical and 
nursing staff at the clinic. Patients with concerns or educational needs 
may be followed up at home, and will be given a Helpline number to 
contact the specialist heart failure nurse if a visit is required. 
•!• Patient information sheet sent with appointment time and date has 
been adapted to give more clarity about the length of time in different 
diagnostic areas, having to undress more than once and general clinic 
procedures, including potential invitations to participate in research 
projects 
•!• Patients from outside of the Darlington PCT area are referred to their 
local CHD Nurse or Heart Failure Nurse at the point of discharge from 
the clinic to ensure continuity of care. Letters will be copied to the 
appropriate nurse. 
•!• Option to refer to dietician for obesity and cardiac cachexia has been 
formalised with the dietetic department 
One patient expressed a desire to be reviewed by myself and the specialist 
nurse after their cardioversion for atrial fibrillation. We need to explain follow 
up arrangements to patients, but if they do not have LVSD they tend to be 
reviewed at the general cardiology clinic, hence maintaining capacity in our 
clinic for new patients and those with LVSD. 
Potential changes which could be made to improve the patients experience 
include copying patients into communication about them made between 
clinicians. This has been recommended by two patients at the clinic and is 
suggested by the Department of Health. The initiative to copy clinician's letters 
to patients is part of the government's policy to increase patient involvement 
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in their care and treatment and to keep patients up to date about these 
matters. Both the NHS plan and the Kennedy Report of the Public Inquiry into 
children's heart surgery at the Bristol Royal Infirmary refer to copying to 
patients letters that are written between clinicians about them. There is wide 
spread support that the partnership between doctors and their patients should 
be improved and strengthened, and that providing better and timely 
information to patients is an essential element of a modern and effective 
health service. lt is one strand in the many different ways needed to improve 
and enhance communications between patients and professionals in the NHS 
4.8.3 Weaknesses of the service 
The service concentrates on patients with systolic dysfunction due to the 
benefits these patients derive from evidence-based therapy. As diastolic heart 
failure is harder to diagnose and we know little about effective therapies these 
patients were excluded from the heart failure nursing service and follow up. 
However, patients with diastolic heart failure are often admitted and also have 
a poor quality of life and may stand to benefit from nursing interventions 138. 
We plan to study the impact of such interventions in this group of patients in 
future service developments and research projects. 
lt is easy to presume that simply measuring the process of prescribing more 
will reduce morbidity and mortality. This assumption is based on the premise 
that the process of prescribing ACE inhibitors211 and beta-blockers259 is a 
reasonable proxy for outcome improvement extrapolated from the clinical trial 
data to real life practice. Unfortunately it is difficult to show that reduction of 
mortality and hospital re-admissions, and improvements in quality of life are 
as a direct result of interventions implemented in the heart failure clinic. 
However, measurements of mortality, hospital re-admissions and quality of life 
parameters are required by politicians, PCT audit and clinical governance 
managers, and may persuade commissioners of care to continue investing in 
a service. 
Reliance on a single GP specialist means that clinic waiting times can 
increase with sickness or holiday absence of the GP specialist. We have been 
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unable to attract a second GP specialist but have arranged for a consultant 
cardiologist or staff grade cardiologist to cover the clinic if waiting times 
become unacceptable (over 4 weeks). 
Hospital IT databases are cumbersome and have hindered the process of 
data collection. Improvements in hospital IT and its interface with primary care 
are urgently needed. 
4.9 Future service developments 
A number of key developments to the service are underway. These include a 
secondary care integrated pathway, establishment of a heart failure 
rehabilitation/exercise training programme, and development of a common IT 
database. These developments should lead to a comprehensive heart failure 
service that delivers seamless care to patients across primary, secondary and 
tertiary care. 
4.10 Conclusions 
A GP specialist led diagnostic clinic facilitated accurate diagnosis of LVSD in 
a single clinic visit rather than after repeated visits for further diagnostic tests, 
and was well received by GPs and patients. The majority of patients received 
evidence based therapy and attained target doses of ACE inhibitors and beta-
blockers. Contrary to perceived anxieties regarding use of BBs in outpatients 
we achieved a high level of use (70%), even in patients with severe LVSD, 
without observation of clinical parameters at initiation of therapy. The heart 
failure nursing and review clinic component and other elements of this 
integrated service deliver high quality care 189• Similar models of care should 
offer expedient care for patients with suspected LVSD, deliver NSF targets, 
compliment secondary care services and in my opinion urgently need to be 
developed across other NHS sites. 
Despite the success of our model and other heart failure clinics21 "23, the 
importance of accurate diagnosis of heart failure9-12 and the continuing debate 
around optimal service delivery15• 16 with some areas in the NHS still offering 
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traditional cardiology clinic referral or open access echocardiography there 
are no comparative studies of traditional outpatient care (usual care), open 
access echocardiography or heart failure diagnostic clinics. Further research 
is needed to determine the optimal service delivery model. Outcomes that 
would need to be considered would need to include uptake rates of ACE 
inhibitors and beta blockers for patients with LVSD; quality of control of heart 
failure symptoms; rates of referral to hospital and numbers of patients 
requiring emergency admission for heart failure; health economics outcomes; 
quality-of-life analyses; rates of inappropriate use of ACE inhibitors and beta 
blockers in patients with non-L VSD heart failure; proportions of patients 
achieving target doses of ACE inhibitors and beta blockers and rates of 
diagnosis of LVSD between the two groups. Furthermore, the practical 
management of patients with left ventricular diastolic dysfunction or heart 
failure with PLVEF needs further study. 
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